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The development of nanomaterials as medical diagnostic and therapeutic agents 
is a rapidly expanding field.  A brief search of the literature revealed that roughly half of 
all articles related to nanoparticle-based drug delivery were published after the onset of 
this thesis research, over the past 4 years.  A few nano-based formulations have entered 
into clinical use, including liposomal drug formulations, protein-linked drugs, and 
nanoparticle-based MRI contrast agents.  The chemistry that enables conjugation of a 
functional cargo, whether a drug, a targeting element, or a radionucleotide, to a 
nanocarrier is thus a critical component for development.  Oximation is one of the 
simplest and most efficient chemical conjugation methods.  It entails condensation of an 
aminooxy group with an aldehyde or ketone carbonyl yielding an oxime ether.  The 
versatility of oximation is highlighted and exploited in this thesis. 
v 
 
Chapter 1 provides an overview of the application of iron oxide nanoparticles in 
medicine, and more specifically, to nanoparticles as delivery agents for the anticancer 
drug doxorubicin.   
Chapter 2 describes an oximation methodology for cellular metabolite 
derivatization to enhance the detection of carbonyl analytes using mass spectrometry 
(MS).  Integration of carbonyl-selective aminooxy functionality with a quaternary 
ammonium moiety for MS electrospray enhancement and a hydrophobic domain for 
sample cleanup led us to design reagent QDA (quaternary dodecyl aminooxy) and its 
13CD3 isotopologue *QDA.  Analysis of QDA/*QDA-treated lung adenocarcinoma A549 
cells established a profile of carbonyl metabolites spanning multiple structural classes 
showing capability for global carbonyl profiling. 
In Chapter 4, hydroxylated cationic oxime ether lipids are described for coating 
core-shell Fe3O4-SiO2 nanoparticles.  Formulation of the nanoparticles produced lipid-
coated, highly ζ–potential–positive assemblies: a new form of cationic magnetoliposomes 
(CML).  The CMLs were evaluated as potential drug carriers by integrating into the bilayer 
a hydrophobically modified analog of doxorubicin.  On treatment of MCF-7 breast cancer 
cells with the drug-loaded CMLs, the assemblies were rapidly internalized and exhibited 
higher toxicity than treatments with doxorubicin alone.  In a separate assessment of the 
oxime ether lipids, complexation with nucleic acids to form cationic lipoplexes similarly 
showed high cellular uptake and marked them as viable candidates for siRNA delivery.   
Chapter 5 provides all experimental procedures for the aforementioned science.  
vi 
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1.1. Aminooxy functionality and oximation 
Oximation, the condensation of an aminooxy moiety with an aldehyde or ketone 
(Figure 1.1), is one of a select few that meet the criteria for the term “click chemistry” 
established by K. Barry Sharpless.1  Click chemistry reactions have high atom and reaction 
efficiency, innocuous byproducts, easy purification, and are insensitive to air and 
moisture.  They take their cue from nature, forming covalent links between discrete 
molecules via carbon-heteroatom bonds.  Oximation is a model click reaction in that it 
usually occurs spontaneously, at room temperature, in numerous solvents, requires no 
heat, and produces robust chemical bonds with water as its only byproduct.  It is an 
elegant reaction that can link independently functionalized components thus enabling 
convergent synthesis, and because of its high chemoselectivity, it is suitable for a broad 
range of tethering reactions.  The great versatility of oximation chemistry is reflected in 
this thesis — my investigations have applied aminooxy reagents to such diverse 
applications as metabolite derivatization, nanomaterial functionalization, drug delivery, 
and gene transfer. 
 
Figure 1.1. Representative oximation reaction: an aminooxy condenses 
with an aldehyde or ketone to form an oxime ether. 
 
The high stability of the products of oximation, oxime ethers, comes from the 
unique electronic structure of the functionality.  In comparison to analogous functional 
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groups, hydrazones and acyl hydrazones, oxime ethers have much slower rates of 
hydrolysis.  Jeet Kalia and Ronald Raines compared the rates of hydrolysis for these 
linkages and determined, as depicted in Figure 1.2, that oxime ether 1 had hydrolytic rates 
approximately 600 fold and 300 fold slower than hydrazones 2 and 3, respectively.  This 
effect is likely due to greater inductive electron donation from oxygen into the pi system 
as compared to nitrogen.2   
 
 
Figure 1.2. Compounds examined in a comparative hydrolysis study2 of 
oxime ethers, hydrazones, and acyl hydrazones 
 
Whereas the carbonyl carbon of most functional groups is electropositive, in the 
case of the sp2 carbon of oxime ethers, electron donation from the attached heteroatoms 
weakens the polarity of the bond.  An indicator of this phenomenon can be found in 
comparisons of the alpha hydrogen pKa’s for oxime ethers versus ketones.  The acidity of 
alpha hydrogens is heavily influenced by the capacity of the adjacent pi system to 
delocalize electron density through resonance.  It is thus an indirect indicator of the 
electrophilicity of the carbonyl carbon.  James Ciula and Andrew Streitwieser have 
examined the alpha hydrogen pKa’s for diphenylacetone and an oxime ether analog 
(Figure 1.3).3  A tenfold higher pKa for the oxime ether species was reported; this is 
evidence of a dramatic reduction in electrophilicity for oxime ether carbonyl carbons.  
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Given that hydrolysis proceeds through nucleophilic attack of water on this carbon, the 
reduction in its electrophilicity can be understood to promote a high degree of stability 




Figure 1.3. Comparison of alpha hydrogen pKa for ketone versus oxime 
ether 
 
1.2. Quaternary ammonium salts 
The major focus of this work is the synthesis and application of novel compounds 
that combine aminooxy functionality with quaternary ammonium moieties.  Such 
quaternary aminooxys (QAOs), exemplified in Figure 1.4, are adapted both for oximation 
chemistry and the aqueous environment of biological applications. 
 
Figure 1.4. Representative quaternary aminooxy (QAO) 
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Quaternary ammonium salts are a useful class of reagents.  The four substituents 
of the quaternary nitrogen provide opportunity for functional variety.  Depending upon 
the hydrophobicity of the attached substituents, amphiphilic species can be prepared 
with solubility in aqueous and organic solvents.  For this reason, such amphiphiles are 
used commercially as phase transfer catalysts and surfactants.  They are also relatively 
inexpensive, so their use in industry is more common than other phase transfer catalysts, 
such as  phosphonium salts and crown ethers.4  Another variant of this type of amphiphile, 
dual-chain cationic lipids, are often used in gene delivery owing to their ability to 
condense DNA and transport it across cell membranes;5 this activity will be discussed in 
detail in Chapter 4. 
The preparation of ammonium salts is generally straightforward.  The protecting 
group chemistry for nitrogen is well established and the products of quaternization, being 
salts, can often be isolated by recrystallization, thereby avoiding more costly 
chromatographic purification. 
The custom QAOs we describe in this work were utilized in several different 
applications.  Chapter 2 details the way in which a QAO reagent was used to capture 
cellular aldehydes and ketones from biological samples, as well as the how the permanent 
positive charge of the quaternary nitrogen was exploited to maximize the signal intensity 
of the conjugated metabolites in mass spectral detection.  In chapters 3 and 4, oximation 
allowed the linking of QAOs to fluorophores and drugs; in this case, the cationic 
ammonium group facilitated electrostatic attraction to negatively charged iron oxide and 
silica-coated nanoparticles.  Finally, as disclosed at the end of chapter 4, cationic oxime 
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ether lipids with quaternary ammonium headgroups were studied for their gene transfer 
activity.  In subsequent sections of this introductory chapter, I give the background for 
traditional carbonyl derivatization strategies for mass spectrometry (MS), and iron oxide 
nanoparticle functionalization for drug delivery. 
 
1.3. Derivatization reagents for mass spectrometry 
The analysis of cellular aldehydes and ketones is of considerable importance in the 
field of metabolomics since carbonyl species are pervasive intermediates of normal 
metabolism as well as common products of oxidative stress,6-7 which has been implicated 
in the pathogenesis of many diseases including cancer.8  The detection and identification 
of oxidized cellular species, in general, has become an important focus of research efforts 
in metabolomics where potential early markers of disease are sought.9-10  The 
identification of polar aldehyde and ketone metabolites from aqueous cell extracts is 
particularly challenging owing to their low-abundance, high reactivity, and the difficulties 
associated with their extraction from the cell matrix. Mass spectrometry (MS) has the 
sensitivity required for observing these low-abundant species, but due to insufficient 
mass accuracy and resolution, most MS methods are coupled with chromatography to 
distinguish analytes with similar m/z.  Fourier-transform ion-cyclotron resonance MS (FT-
ICR-MS), however, does not suffer these limitations and can provide unique molecular 
formulae of most metabolites. In addition, FT-ICR-MS can achieve simultaneous 
resolution of 13C isotopologues and distinguish them from other elemental isotopologues 
(such as 15N or 2H).11  However, direct infusion FT-ICR-MS is often compromised by 
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unstable sample introduction (e.g., electrospray) and low ion yields due to interference 
from cellular salts and/or interaction with matrix ions in aqueous biological extracts. 
Consequently, metabolite derivatization is a strategy that can be employed to overcome 
these challenges. 
In the case of aldehyde and ketone metabolites, derivatization is commonly 
performed to facilitate liquid chromatography with optical or MS detection (LC–MS) or 
gas chromatography coupled to mass spectrometry (GC–MS).  Such derivatization 
reagents either have distinct absorbances (for optical detection), preserve or increase 
volatility (GC), or have easily ionizable groups for MS detection, such as those exemplified 
in Figure 1.5.6, 12-17  These reagents react with carbonyls via their amine,12 hydrazine,14 
hydrazide,18-20 or aminooxy21-22 moieties to form corresponding imine, hydrazone, acyl 
hydrazone, or oxime ether adducts, respectively. For example, dinitrophenylhydrazine 
(DNPH) reacts with aldehydes and ketones to form hydrazone derivatives that can be 
more readily detected due to characteristic UV absorbances.6, 14  Similarly, O-2,3,4,5,6-
(pentafluorobenzyl)hydroxylamine (PFBHA) has been used to form stable, and readily 
ionizable oxime ether derivatives from aldehydes and ketones.21-22  The silylation of α,β-
unsaturated ketones, using a catalyst to facilitate ketone to enol tautomerization and thus 
enol silylation, also has been performed to improve the GC-MS analysis of this compound 
class.23  Some of these reagents also employ a permanent positive charge to enhance 
electrospray MS sensitivity.16-18, 20, 24-26  While still suitable for analysis by LC-MS, this 
approach precludes the use of GC since the resultant charged adducts have lower 
volatility.  The added charge enhances MS sensitivity and, more importantly, enables 
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direct MS analysis under milder, non-ionizing conditions.  For example, the hydrazide-
based derivatization agent 4-hydrazino-4-oxobutyl-[tris(2,4,6-trimethoxyphenyl)-
phosphonium bromide (TMPP-PrG) reacts with aldehydes and ketones and contains a 
quaternary phosphorous to impart a permanent positive charge on its adducts.27   
Additionally, Girard reagents,17, 26 such as Girard-P, also contain hydrazide functionality 
for reaction with carbonyl substrates and a quaternary ammonium moiety to enhance 
water solubility.  Such reagents have been used to enhance detection in secondary ion 
MS (e.g. Xe+),26 LC-MS,28 and electrospray ionization MS (ESI-MS).29  More recently, an 
aminooxy-based reagent for carbonyl capture was developed by Yuan et al.30 in which a 
biotinylated region of the reagent was used to separate conjugated carbonyls from other 
cellular species on streptavidin beads.  In this case, release of the derivatized metabolites 
was achieved through activation of a photo-cleavable linker. 
 
 
Figure 1.5.  Agents for the derivatization of carbonyl compounds. 
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The disadvantages in these reported approaches include multistep procedures for 
metabolite derivatization, potentially damaging UV light exposure, and/or lengthy 
chromatographic separation of the resultant metabolite adducts.  Chapter 2 will relate 
our strategy for using direct infusion FT-ICR-MS to analyze crude biological extracts using 
a QAO reagent.  Like several of the reagents described above, the reagent we designed 
bears a permanent positive charge for ready conversion of carbonyl metabolites into 
stable, non-volatile, charged adducts.  It was also designed for compatibility with aqueous 
medium.  Where it departs from traditional reagents is in the addition of a hydrophobic 
domain optimized for partitioning of charged adducts into an organic solvent for 
enhanced electrospray stability.  We apply this new cationic amphiphile to the global 
profiling of carbonyl metabolites directly from crude aqueous extracts of cancer cells. 
 
1.4. Iron oxide nanoparticles in nanomedicine 
The introduction of nanoparticles into clinical applications is at the cutting edge of 
medical science.  The scale of nanoparticles, typically 10-100 nm, makes them perfectly 
suited for operating in biological systems.  The standard tools of medicine inhabit vastly 
different size domains; molecular drugs are on the order of a nanometer, and a scalpel, 
at the other extreme, is roughly 50 million times larger.  With the emergence of 
nanomedicine, there is another tool for medical science, one that is much closer to the 
micrometer scale of cells.  Although the application of nanoparticles in clinical practice 
has been limited, it is a rapidly expanding field with a promising future. 
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Iron oxide, Fe3O4/Fe2O3, nanoparticles (NPs) are a particularly attractive class of 
nanomaterial.  They possess intrinsic magnetic properties that enable both diagnostic and 
therapeutic procedures, such as magnetic resonance imaging (MRI) through contrast 
enhancement,31 magnetic targeting,32 and thermotherapy through inductive heating 
using an alternating magnetic field.33  Moreover, the attachment of targeting ligands34 
and drugs demonstrates their potential for achieving the ultimate goal of directed, 
minimal-dose chemotherapy.  This versatility makes magnetic nanoparticles appealing 
candidates as multifunctional drug delivery systems. 
1.4.1. Nanoparticle preparation methods 
Iron oxide nanoparticles of Fe3O4 (magnetite) or γ-Fe2O3 (maghemite) can be 
prepared by a variety of methods.35  Among the common chemical syntheses are 
coprecipitation, thermal decomposition and hydrothermal reactions.  In coprecipitation, 
NPs form from an aqueous mixture of iron II and III chloride salts in the presence of base 
(Equation 1.1).  The method was known as far back as 1852, but was not well studied until 
the work of René Massart in the 1980s.36  It is the simplest technique as it is a wet 
chemistry approach that does not require special equipment.  However, coprecipitation 
has a drawback in that the control of particle size and shape is somewhat limited, and NPs 
made in this way will have a wider size distribution than in more rigorous syntheses.37  In 
thermal decomposition, NPs are formed from the decomposition and oxidation of 
organometallic precursors, such as iron acetylacetonate, at high temperature in organic 
solvents and in the presence of surfactants, typically fatty acids.38  The NPs generated by 
this method are hydrophobic and must be modified to confer aqueous solubility.39    In 
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hydrothermal reactions, NPs are generated using ferric nitrate under aqueous conditions 
at high temperatures and pressures.40  A number of physical preparations of NPs are also 
known including gas-phase deposition, electron beam lithography and laser pyrolysis.40  
In perhaps the most inventive methodology, NPs can also be harvested from bacteria; 
termed the microbial method, Fe(III)-reducing bacteria incubated with a β-FeOOH 
precursor synthesize Fe3O4 NPs under anaerobic conditions.35 
 
Fe2+ + 2Fe3+ + 8OH-   Fe3O4 + 4H2O 
Equation 1.1. Precipitation of iron salts to form Fe3O4 NPs 
 
1.4.2. Crystal phase and magnetic properties 
The magnetic iron oxides, Fe3O4 and γ-Fe2O3, both have inverted spinel crystal 
structure in which the metal ions are located in the tetrahedral and octahedral interstices 
of a tight packed face-centered-cubic oxygen lattice.  In the case of Fe3O4 (Figure 1.6),41 
Fe3+ occupies the tetrahedral coordination sites and Fe2+ and Fe3+, in equal parts, occupy 
the octahedral sites.  Below 851 K magnetite is ferrimagnetic; the different coordination 
sites have antiparallel alignment of magnetic moments, but electron hopping between 
the Fe2+ and Fe3+ ions in the octahedral sites produces a net magnetism.39, 42  γ-Fe2O3 
differs from magnetite in that iron is present in only the +3 oxidation state.  For 
maghemite, a somewhat weaker ferrimagnetism (60–80 emu/g compared to 92–96 
emu/g for magnetite)43 is still present due to an uneven distribution of the metal ions 
among the coordination sites, i.e. the presence of vacancies.  The aligned magnetic 
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moments of iron ions in very small NPs combine to create a single large magnetic moment 
for each individual particle.  These small NPs are said to exhibit superparamagnetism44 
where in the absence of a magnetic field thermal energy causes particle magnetic 
moments to orient randomly, thus creating a zero net magnetism.  In the presence of a 
field, however, the magnetic moments of the particles align with the external field.  This 
lack of remnant magnetism allows NPs to amass when a magnetic field is present, but 
redisperse into colloidal form when released from the field, making them ideal for 
biological applications.39  
 
 
Figure 1.6. Crystal structure of Fe3O4: green balls (Fe2+), brown balls (Fe3+), 
white balls (O).  Reprinted from Chem. Commun. (Cambridge, U. K.) 2011, 
47, 5130-5141 with permission from the Royal Society of Chemistry. 
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1.4.3. Magnetic targeting and imaging 
The magnetic properties of NPs enable magnetic targeting through external 
magnetic field application.  In a survey of the literature, several in vivo targeting studies 
are reported.32, 45-46  Ma and coworkers, for example, injected alginate-coated NPs into a 
rat femoral artery and were able to demonstrate retention of the NPs at a target site by 
magnetic field application.47  Similarly, Pisciotti et al. showed accumulation of 
intravenously injected polyethylene glycol (PEG)-coated NPs in a mouse tumor where an 
external field was applied.45  Although promising, magnetic targeting to this point has 
been applied only to superficial tumors; deep tissue targeting poses a challenge because 
the strength of a magnetic field rapidly weakens (r-3) with distance from the source 
magnet. 
NPs have also been applied in magnetic resonance imaging (MRI) where they 
provide negative contrast enhancement in NP-bearing tissues.  The proton signal intensity 
in MRI in tissue is influenced by proximity to NPs.  Both T1 and T2 relaxation processes are 
affected; however, because the NPs produce local field inhomogeneity, faster T2 
relaxation (decoherence of the transverse nuclear spins) dominates.  Thus NPs are used 
in T2-weighted pulse sequences.39  There are a few ferrofluids approved by the FDA for 
MRI use in humans including ferumoxsil and ferrumoxide, siloxane-coated and dextran-
coated NPs, respectively.  The biocompatibility of such formulations have been 
investigated.  Radiotracer evidence suggests that clinically administered NPs are 
biodegraded and incorporated into erythrocyte heme iron48 or bound to transferrin and 
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eliminated through defecation.35  Although organic coatings, particularly polymers, can 
carry their own intrinsic toxicity, ferrofluids are generally regarded as biocompatible.35 
There is presently a thrust in nanomedicine toward theranostics, the practice of 
combining therapy and diagnostics.  Along those lines, MRI contrast enhancement from 
NPs could be combined with other therapies enabled by the ferrofluid.  One such therapy 
that has the potential to excel in this capacity is thermotherapy, as described below. 
 
1.4.4. Heating by alternating magnetic field 
In the presence of an alternating magnetic field, the magnetic properties of NPs 
cause heat to be generated in a process called induction heating.  This can take place 
through a few different mechanisms depending upon the size of the particles as 
illustrated in Figure 1.7.49  In the case of small superparamagnetic NPs (<20 nm diameter), 
Néel relaxation is the primary mechanism of heating.  In this process the magnetic 
moment of a NP will reorient to align with the shifting external field direction, and 
resistance to this change in dipole orientation generates heat.  For larger particles (>20 
nm diameter), Brownian motion relaxation is the primary heating mechanism; the particle 
itself rotates to align its magnetic dipole with the external field, and the friction between 
the NP surface and the surrounding medium induces heating.  The third mechanism of 
heating, hysteresis losses, similarly occurs in larger particles.  Here, the particles are not 
superparamagnetic but instead are multi-domain particles where regions of the NPs have 
net magnetic moments oriented randomly with respect to one another.  Hysteresis 
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heating is a consequence of the growth of the domain best aligned with the magnetic 
field at the expense of neighboring domains.   
 
Figure 1.7. Illustration of NP heating mechanisms: (a) Néel relaxation; (b) 
Brownian motion relaxation; (c) Hysteresis losses 
 
Although this discussion has focused on the mechanisms of NP heating, it is 
important to note that the increase in temperature of the bulk solution of a ferrofluid is 
not necessarily indicative of the local environment at the NP surface.  There is 
considerable evidence to suggest that the energy transfer from AMF-induced NPs to 
attached ligands/polymers has exaggerated effects at the particle interface.50  Riedinger 
et al., for example, used a thermally sensitive azo molecule to probe NP surface 
temperature at subnanometer distances and found that a local temperature increase up 
to 44 °C during one hour of AMF exposure (17 mT, 334.5 kHz) could be found within 0.5 
nm of the NP surface.51  
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The heat-generating ability of NPs exposed to AMF is used clinically in magnetic 
fluid hyperthermia where ferrofluids are injected into tumor sites and heated by AMF 
induction.  The tumor tissue is heated to between 40 and 45 °C to achieve hyperthermia, 
as heating above 45 °C, termed thermoablation, causes tissue necrosis.52  Surrounding 
tissues, absent NPs, are unharmed by a well-directed oscillating field.  Hyperthermic 
temperatures can contribute directly to tumor regression, but they also boost the efficacy 
of traditional therapies (chemotherapy, radiation) through a process of tumor 
sensitization.53  The established use of hyperthermia therapy has led to the development 
of instrumentation designed for AMF administration in humans.  MagForce 
Nanotechnologies (AG, Berlin), for example, manufactures units for AMF application to 
human patients.  AMF is also used in NP applications as an external trigger for the release 
of bound substrates (drugs/fluorophores), as will be discussed shortly.   
 
1.4.5. Surface modifications 
Surface coating of NPs is typically employed to improve their aqueous solubility, 
prevent aggregation, and neutralize surface reactivity.  There are several classes of 
coating agents; iron chelators are common, including catechols43, 54 and carboxylates, 
both single molecule (oleic acid,55 citrate56) and polymeric species (alginate,32 
carboxymethyl dextran57).  These species bind to the iron at the surface of the NP.  
Hydrogen bond donors for NP surface oxyanions/hydroxyls are frequently used as well, 
including polymeric amines (polyethylenimine58), alcohols (polysaccharides,59 polyvinyl 
alcohol58), and ethers (polyethylene glycol).60  Creating composite core-shell 
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nanostructures with inorganic material surrounding iron oxide cores is also frequently 
employed, as these shells can contribute additional functionality to the NPs.  Gold-coated 
NPs,61 for example, can be imaged by surface plasmon resonance.  Silica coating of iron 
oxide is also common and will be discussed in detail in Chapter 4.  
 
1.5. Nanoparticle-mediated drug delivery 
To date, the clinical use of NPs has largely been confined to imaging and 
hyperthermia therapy, but the greater potential for NPs in nanomedicine is in multimodal 
therapies that augment the techniques enabled by NP magnetism with attachment of 
functional molecules, like pharmaceutical agents or targeting ligands.  Perfecting the 
technology of functionalized NPs carries big implications for human health.  The following 
excerpt62 from Amy Pope-Harman concerns progress in the field of cancer treatment and 
sums up the challenges and the motivations for nanotechnology in medicine quite 
poignantly.  
 
Clinical medicine has seen tremendous improvements in the past several 
decades.  Despite the progress . . . patients still are called on to endure toxic 
and uncomfortable whole-body chemotherapy and other treatments with 
the hope that their cancers will succumb.  There is expectation, however, 
that all of this will change radically with the use of nanotechnology . . . 
allowing improvements in mortality and prevention of suffering from 
cancer and other devastating diseases . . . By working on a nanometer, 
molecular scale, there is the potential to simultaneously assess and 
intervene, with accuracy in space and time, which is an ability that has 
never before been available.   
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In subsequent sections of this chapter, I will outline some of the recent 
innovations in adapting NPs to function as drug carriers.  Specifically, this overview will 
focus on the NP-mediated delivery of the anticancer agent doxorubicin.  
 
1.5.1. Doxorubicin 
Doxorubicin (Dox, Figure 1.8), is an anthracycline antibiotic known for its potent 
activity against a broad spectrum of cancers.63  Several modes of action for Dox have been 
detailed in the literature including DNA intercalation, helicase inhibition, free radical 
generation, and topoisomerase II interaction leading to apoptosis.64  In the case of MCF-
7, the breast cancer cell line used in the in vitro studies described in Chapters 3 and 4, the 
antiproliferative action of Dox may be related to interference with DNA unwinding.65  In 
the absence of a NP carrier, targeting agent, or liposomal formulation, Dox has 
nonspecific toxicity and is known to damage kidney tissue and bone marrow, but its most 
troubling side-effect is cardiotoxicity.66-68 
 
 
Figure 1.8. Doxorubicin hydrochloride 
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1.5.2. Progress in nanoparticle-mediated doxorubicin delivery 
Dox is frequently the model drug of choice for demonstrating targeted delivery 
using NP platforms.  Such platforms have incorporated Dox in a variety of ways using 
different methods of attachment.  Covalent attachment is a strategy that is occasionally 
used offering the benefit of good retention of Dox on the particle.  The drawback of 
covalent linkage is that release of the drug often requires cleavage of covalent bonds in 
the absence of an activator.  For example, Hua and coworkers formed an amide linkage 
between Dox and an activated carboxylic acid at the surface of acidic polymer-coated NPs 
to demonstrate MRI contrast enhancement and magnetic retention in a mouse 
hypodermic tumor (Figure 1.9).69  Similarly, Li et al.70 used silica-coated iron oxide NPs to 
covalently bind Dox via a urea linkage that tethered the Dox amine to an isocyanate group 
on the silane monomer used for constructing the silica shell.   
 
 
Figure 1.9.  Dox covalently linked to superhigh-magnetization nanocarriers 
(SHMNCs).  Adapted from Biomaterials 2011, 32 (34), 8999-9010 with 
permission from Elsevier. 
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Tumor sites are known to be more acidic than healthy tissue,71 and for this reason 
pH-triggered release is sometimes planned into the design for NPs with covalently bound 
Dox.  In this vein, a few investigators have covalently attached Dox to NPs via acid-
cleavable hydrazone bonds formed from hydrazine/hydrazide-functionalized NPs 
reacting with the Dox C-13 carbonyl.72-74  Patra and coinvestigators, for example, used 
hydrazide functionalized poly(styrene)-b-poly(acrylic acid) block copolymer to bind Dox 
on folate-conjugated NPs for targeted delivery to breast and colon cancer cells.73  In an 
alternate approach, that likewise used a pH-based cleavage strategy, Gautier and 
coauthors installed an Fe2+ ion bridging the oxygens of the Dox quinone system in order 
to bind Dox directly to NPs.75  PEG chains were added to stabilize the linkage and release 
profiles showed a pH dependence, as protons gradually displaced Fe2+ and freed the Dox 
from the NP surface.  This formulation was found to be effective against MCF-7 cells.   
Hydrophobic interactions have also been used as a means to reversibly attach Dox 
to NPs.  Jain et al.55 incorporated free base Dox, prepared by bubbling gaseous ammonia 
into an organic suspension of Dox HCl,76 into the hydrophobic shell of oleic acid coated 
iron oxide NPs. A capping polymer, Pluronic (similar to PEG), was then added to retain the 
Dox and confer aqueous solubility to the complex.  Drug release was achieved slowly over 
several hours by passive diffusion (Figure 1.10).  Chen and coworkers similarly utilized 
hydrophobic interactions to entrap Dox into the hydrophobic interior of a NP-containing 
micelle.77  Figure 1.11 illustrates this novel formulation in which a reduction sensitive 
copolymer generates the layered nanostructure pictured.  Release of Dox was designed 
to be mediated by the reducing environment of circulation and cytoplasm.  In vitro real-
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time fluorescent monitoring and in vivo tumor growth studies were used to demonstrate 
the efficacy of the formulation. 
 
Figure 1.10.  Left: charge neutral Dox (red dots) incorporated into an oleic 
acid hydrophobic layer surrounding a NP; right: confocal laser scanning 
microscopic images of MCF-7 cells incubated for 2, 24, and 48 h with the 
Dox-NPs. Adapted from Molecular pharmaceutics 2005, 2 (3), 194-205 
with permission from American Chemical Society.  Copyright (2005) 
American Chemical Society. 
 
 
Figure 1.11. Hydrophobic oleic acid nanoparticles coincorporated with Dox 
into a reducing-polymer/PEG-capped nanoassembly.  Adapted from 
Biomaterials 2014, 35 (4), 1240-1248 with from permission from Elsevier. 
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Noncovalent interactions such as electrostatic interactions and hydrogen bonding 
are likewise frequently used for Dox conjugation to NPs.  For example, Lübbe and 
coworkers in a phase I clinical trial, exploited noncovalent interactions by chemisorbing a 
Dox analog, epirubicin, to anhydroglucose polymer coated NPs.78  The magnetic targeting 
ability of the drug-loaded NPs were tested in vivo in 14 patients with solid tumors, and 
targeting was found to be successful in half of the patients.  In another noncovalent 
approach from Lee and coauthors,79 mesoporous silica particles were loaded with Dox, 
then magnetite nanocrystals and PEG chains were attached at the silica surface (Figure 
1.12). Dox was administered in this formulation to a mouse tumor model where 
accumulation of the particles in tumor tissue as well as cell death were observed.  Li et 
al.80 used amphiphilic gelatin to incorporate NPs and to electrostatically bind Dox to the 
carboxylated surface of the gelatin.  Calcium phosphate was then used as a capping agent 
to facilitate acidic pH-mediated degradation of the complex.  An in vitro study with HeLa 
cells verified the release of Dox by confocal laser scanning microscopy. Finally, Fan and 
colleagues used a lipid to electrostatically bind Dox in a novel construct illustrated in 
Figure 1.13.81  Here, gas bubbles of perfluoropropane were prepared in a lipid sphere that 
contained embedded NPs in addition to the adsorbed Dox.  Next, focused ultrasound was 
used to rupture the bubbles and simultaneously generating blood-brain barrier openings 
in an in vivo study with a rat glioma model.  The microbubbles were targeted with an 
external magnet and tracked by MRI. 
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Figure 1.12. TEM image of NP loaded onto the surface of mesoporous silica 
spheres.  Adapted with permission from J. Am. Chem. Soc. 2010, 132 (2), 
552-557.  Copyright (2010) American Chemical Society. 
 
Figure 1.13. Microbubble with lipid embedded NPs (labeled SPIO-C4) 





AMF application has also been applied to NPs to effect Dox release, most often in 
the context of heat-sensitive polymers or gels.  For example, Brulé et al.82 incorporated 
NPs and Dox into alginate gel beads and used AMF to induce Dox diffusion from the 
heated gel.  They observed no leakage of Dox at 4 °C, moderate release at 37 °C, and 
significant release from AMF heating at 53 °C.  Peiris and coworkers used the mechanical 
effect of AMF application, rather than heat generation, to trigger release of Dox from 
liposomes.83  In this creative approach, a string of NPs were tethered by crosslinking 
chains to a liposome containing encapsulated Dox (Figure 1.14).  The authors were able 
to demonstrate superior tumor distribution of Dox in an in vivo model by the AMF-




Figure 1.14. Depiction of AMF-triggered release of Dox from nanochain-
bound liposome.  Adapted with permission from ACS Nano 2012, 6 (5), 
4157-4168.  Copyright (2012) American Chemical Society. 
 
The above reports reflect the most recent advances in nanocarrier-mediated 
delivery of doxorubicin.  Several of these innovations were reported after the onset of 
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our own investigations and informed the evolution of our strategies.  In Chapters 3 and 4 
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2.1. Limitations of current derivatization methods 
Chapter 1 introduced derivatization as a technique for improving the detection by 
mass spectrometry (MS) of volatile, charge-neutral, or low molecular weight metabolites. 
The shortcomings of traditional ketone/aldehyde derivatization reagents highlighted 
earlier included the requirements of harsh reaction conditions (acidic pH and/or high 
temperature), and chromatographic separation of derivatives prior to MS detection.  We, 
along with our collaborators, Dr. Teresa Fan, Dr. Richard Higashi, and Mr. Tao Xu, set out 
to design a derivatization reagent and accompanying methodology that would overcome 
the drawbacks of the more common approaches to enable an aqueous phase, low-temp 
conjugation to carbonyl metabolites.  We aimed for a minimal processing method suitable 
for analysis of crude biological extracts using direct infusion Fourier-transform ion-
cyclotron resonance mass spectrometry (FT-ICR-MS).  
 
2.2.  Reagent design 
There were four key components of our reagent design.  We saw in the mild and 
aqueous-friendly reaction conditions of oximation chemistry an opportunity for facile 
derivatization of carbonyl metabolites in cell extracts.  The formation of oxime ether 
bonds from an aminooxy reagent to a bioanalyte carbonyl would stabilize the resultant 
adduct (recall from Chapter 1 the comparison of α-proton acidity for 1,3 diphenyl 
acetone, pKa ≈ 18, versus its corresponding methyl oxime ether, pKa ≈ 28).3  The second 
critical feature of the reagent was the incorporation of a permanent positive charge to 
maximize MS sensitivity, increase the aqueous solubility of the probe, and generate 
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nonvolatile adducts.  For this purpose, a quaternary ammonium cation seemed ideal.  
Third, to overcome the interference of cellular salts and cell matrix ions in the 
establishment of a stable electrospray, we sought a reagent that, when conjugated to an 
analyte, could be extracted into an organic solvent.  Lastly, we desired a reagent that 
could easily be labeled with a stable isotope both for the purpose of verification of 
adducts as carbonyl derivatives, as well as for quantitative MS analysis. 
Figure 2.1 is a representative structure of our initial design.  Present are an 
aminooxy moiety for chemoselective carbonyl capture, a cationic ammonium headgroup 
for MS sensitivity, an aliphatic tail to facilitate organic phase partition, and methyl groups 
for stable-isotope labeling through quaternization with commercially available and 
inexpensive iodomethane. 
 
Figure 2.1.  Representative structure of derivatizing agent 
 
2.3. Results and discussion 
2.3.1.  Chain length variations 
To examine the effect of aliphatic chain length on the efficiency of metabolite 
extraction, dodecyl and octyl versions of the reagent were prepared as depicted in 
Schemes 2.1 and 2.2 with designations QOA (quaternary octyl aminooxy) and QDA 
(quaternary dodecyl aminooxy).  These preliminary syntheses were three step reactions 
beginning with quaternization of a tertiary amine with an alkyl halide of the desired chain 
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length.  A modified Mitsunobu reaction84 generated the phthalimide-capped alcohol, and, 
in the final step, hydrazinolysis of the phthalimide revealed the aminooxy functionality.   
 
 
Scheme 2.1. Preparation of QOA iodide.  Reagents and conditions: (a) 1-
iodooctane (1.1 eq), acetone, reflux, 15h, 92%  (b) N-hydroxyphthalimide 
(1.1 eq), PPh3 (1.1 eq), DIAD (1.1 eq), THF, 0 °C-rt, 12h, 87%  (c) N2H4 · H2O 
(5 eq), CH2Cl2, rt, 2 h, 92% 
 
 
Scheme 2.2. Preparation of QDA bromide.  Reagents and conditions: (a) 1-
bromododecane (1.1 eq), acetone, reflux, 10h, 49% (b) N-
hydroxyphthalimide (1.1 eq), PPh3 (1.1 eq), DIAD (1.1 eq), THF:CH2Cl2 2.5:1, 
0 °C-rt, 15h, 82%  (c) N2H4·H2O (4 eq), anhyd. EtOH, 50 °C, 5 h, 90% 
 
Figure 2.2 shows 1H NMR stacked plots of the alcohol precursor 2.3 (Scheme 2.2) 
and QDA∙Br that highlight the disappearance of the hydroxyl proton (t, δ 4.99) as well as 
downfield shifts in the methylene protons of the aminooxy arm of QDA∙Br.  Product 
formation was also confirmed by high resolution mass spectrometry. 
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Figure 2.2. Stacked 1H NMR spectra of alcohol 2.3 and QDA∙Br in CDCl3 
 
2.3.2.  Extraction solvent determination 
To compare the two analogs, QOA and QDA, and to determine the best solvent 
for extraction of adducts into an organic phase, each analog was reacted with a mixture 
of ketone and aldehyde standards (pyruvate, α-ketoglutarate, α-ketobutyrate, and 
glucose1) in ammonium acetate buffer and subjected to extraction with one of three 
solvents: chloroform, ethyl acetate, or n-butanol.  The ion intensities of the resultant 
conjugates, normalized to a standard of known concentration, were used to compare 
carbonyl capture efficiency between the two reagents (Figure 2.3).  In both cases, n-
                                                     
1 In the case of glucose, the aldehyde of the open-chain isomer is reactive with the reagent. 
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butanol was the most efficient extraction solvent.  In addition, QDA, the dodecyl reagent, 




Figure 2.3.  Comparison of normalized ion counts for adducts of QOA 
(upper) and QDA (lower) with standards pyruvate (Pyr), α-ketoglutarate (α-




















































2.3.3.  Stable isotope labeled analog 
To prepare a stable isotope labeled version of QDA, we redesigned the original 
synthesis to allow for quaternization with a doubly labeled iodomethane, 13CD3I (Scheme 
2.3) and designated this analog *QDA.  As the QDA previously synthesized (Scheme 2.2) 
had a bromide counterion, we prepared both unlabeled QDA iodide and *QDA iodide by 
this new route so that direct comparisons of the salts could be made.  The successful 
incorporation of the label is apparent in Figure 2.4 in a mass spectrum of a mixture of the 
two salts showing a mass difference corresponding to 1 13C + 3 2H. 
 
 
Scheme 2.3. Reagents and conditions: (a) 1-bromododecane (1.0 eq), 
anhydrous Na2CO3 (1.0 eq), EtOH, reflux, 20 h; 70%; (b) N-
hydroxyphthalimide (1.1 eq), PPh3 (1.1 eq), DIAD (1.1 eq), THF, rt, 12 h; 
98%; (c) CH3I or 13CD3I (2.5 eq), CH2Cl2, 50 °C, 12 h; (d) N2H4·H2O (5.0 eq), 
anhydrous ethanol, rt (for QDA) or 50 °C (for *QDA), 12 h; 65-75% (2 steps). 
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Figure 2.4. Mass spectrum of a 1:1 mixture of QDA∙I and *QDA∙I 
 
2.3.4  Counterion effects 
With analogs QDA bromide and *QDA iodide in hand, we examined the effect of 
the differing counterions by comparing MS signal intensity for derivatized mixtures of 
standards conjugated to each analog.  Equal volume aliquots of the standards mixture 
described above were combined with solutions containing excess QDA bromide or *QDA 
iodide.  The results, represented in Figure 2.5, indicated a slight advantage for the iodo 
salt adducts, presumably through better partition of the larger ion pair into the organic 
layer during extraction. 
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Figure 2.5. Comparison of QDA bromide and *QDA iodide salts on 
extraction of standards (single sample).    
 
The efficiency of the partitioning process was also examined; we repeatedly 
extracted the same standard adducts from buffer into n-butanol five times.  The 
comparison of normalized ion counts suggested that the majority of the adducts (ca. 
>98%) were recovered within the first two extractions (Table 2.1).  Therefore, in 
subsequent cellular extract studies we performed three solvent partitions of the 


































1 0.833 0.865 0.802 0.989 
2 0.155 0.118 0.196 0.011 
3 0.002 0.016 0.001 0.000 
4 0.009 0.000 0.000 0.000 
5 0.000 0.000 0.000 0.000 
Aqueous Layer 
(post extraction) 0.000 0.000 0.000 0.000 
Table 2.1. Fraction of total QDA-standard adducts partitioned per 
extraction into n-butanol from 5 mM, pH 6 ammonium acetate buffer 
based on normalized ion count.   
 
2.3.5.  Cell extract derivatization and analysis 
The partitioning of the constituents of lysed cells into a polar acetonitrile/water 
layer and a nonpolar chloroform layer is a common technique used for metabolite 
collection.  Freeze-drying of the aqueous phase produces a cell extract that can be stored 
frozen and reconstituted when desired for analysis.  These salty extracts are difficult to 
analyze by MS using traditional means; their high salt content can destabilize the 
electrospray, the size of the metabolites may fall below the more sensitive range of the 
MS (>150 m/z), and the ubiquity of anionic functionality (carboxylates, phosphates) often 
precludes detection by the more sensitive positive mode.  As our custom reagent was 
designed to address these challenges, we set out to test its efficacy using the aqueous 
extracts of human lung adenocarcinoma A549 cells.  
In a typical derivatization experiment, an aqueous solution of QDA was combined 
with a buffered solution of aqueous cell extract (pH 6 NH4OAc buffer).  Mildly acidic pH 
facilitates oximation as loss of water is rate determining under such conditions.85  The 
mixture was then vortexed, sonicated, and placed in a 40 °C dry bath for 23 hours.  This 
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reaction time was chosen because increased ion counts were observed at up to 23h of 
reaction time in 63% of the metabolites assigned, even though 85% of all assigned 
metabolites were observable after 30 minute of reaction time. In the case of reducing 
sugars, for example, the rate of ring opening will dictate the availability of the reactive 
aldehyde.  Following reaction, the aqueous mixture was extracted with n-butanol three 
times, and dried by vacuum centrifugation. The resultant residue was dissolved in 
methanol with 0.1% v/v formic acid and analyzed by FT-ICR-MS as a 1:1 mixture with an 
external standard.  Figure 2.6A and B show representative FT-ICR-MS spectra from such 
experiments.  Figure 2.6A represents a control condition, *QDA with a standards mixture; 
here, the adducts with the four standards are distinct.  Figure 2.6B reflects QDA-
derivatized A549 cell extracts, where the QDA adducts of endogenous pyruvate, α-
ketobutyrate, α-ketoglutarate, and glucose are readily observed, along with several other 
adducts. From the exact masses, the molecular formulae of additional observed adducts 






Figure 2.6. Derivatization of carbonyl standards and A549 cell extract.  a) 
FT-ICR-MS spectrum of *QDA adducts of four carbonyl standards after 
partitioning from ammonium acetate buffer into n-butanol: a’ = pyruvate, 
b’ = α-ketobutyrate, f’ = α-ketoglutarate, k’ = glucose.  b) FT-ICR-MS 
spectrum of QDA-derivatized A549 cell extract: a = pyruvate, b = α-
ketobutyrate, c = C7H14O, d = C8H16O, e = C6H10O3, f = α-ketoglutarate, g = 
C5H10O5, h = C10H20O, i = C11H22O, j = C9H16O3, k = glucose 
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N-butanol was selected as an appropriate extraction solvent both for its high 
polarity and for the reportedly low partition of salts such as NaCl and KCl into the solvent 
(0.02-0.1 wt % at 25 °C).86  In fact, the partitioning of QDA adducts into n-butanol did 
appear to minimize the contribution of non-volatile salts in the final assay solution as 
confirmed by our finding that the sodiated peaks of the adducts of spiked carbonyl 
standards extracted from A549 cell extract represented, on average, only 0.1% of the total 
ion count (H+ + Na+) for a given adduct.  
 
2.3.6. Metabolite identification 
As mentioned above, the value of the labeled analog, *QDA, is two-fold: first, 
derivatization using *QDA helps verify whether species observed in positive mode FT-ICR-
MS are genuine carbonyl adducts of QDA as opposed to other n-butanol-soluble cellular 
metabolites.  “Sister signals” will be apparent in the case of a genuine adduct as a given 
pair of adducts represents a carbonyl metabolite that has reacted with both derivatizing 
agents.29, 87  Second, isotopic labeling enables quantitative analysis of carbonyl 
metabolites in cell extracts, as will be demonstrated shortly for pyruvate, the product of 
glycolysis and the entry metabolite of the Krebs cycle.   
Figure 2.7 illustrates how *QDA made possible the global visualization of carbonyl 
metabolites in a crude A549 cell extract.  QDA and *QDA were added in equal amounts 
to an aqueous cell extract and carbonyl adducts were extracted as described above.  This 
resulted in many pairs of adduct signals with comparable ion counts separated by 4.02188 
m/z (1x13C + 3x2H).  Example QDA and *QDA adduct pairs are delineated in Figure 2.7, 
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where the full FT-ICR-MS spectrum (top inset) along with an expanded spectral region 
(bottom main panel) are shown.  This spectrum was further processed to assign many 
likely carbonyl metabolites based on the derived molecular formulae of adducts matched 
against a custom database that compiles the molecular formulae of many known carbonyl 
metabolites. The adducts identified include α-keto acids of the Krebs cycle (oxaloacetate 
and α-ketoglutarate), carbohydrates (erythrose), lipid peroxidation products (eicosanal), 
serotonin metabolites (hydroxykynurenamine), nucleotide metabolites (deoxyribose), co-
factors (pryidoxal-5-phosphate), and metabolites of glycolysis (pyruvate) and the pentose 
phosphate pathway (sedoheptulose).  Table 2.2 is an abridged list of the QDA adducts 
assigned.  Since structural isomers exist for many of these molecular formulae, the 
assignments shown here represent the most likely species based on known mammalian 
biochemistry. Further interrogation of these structural isomers by tandem MS and/or 







































































































































































Table 2.2.  Selected metabolites assigned based on Figure 2.7 spectral data 




m/z for QDA 
adducts 
Observed m/z Mass error Ion count 
Pyruvate C3H4O3 343.295519 343.295769 0.00025 905472.8 
DHAP/GAP a C3H7O6P 425.277501 425.277999 0.000498 36810.4 
Oxaloacetate C4H4O5 387.285349 387.285619 0.00027 2621.8 
D-Erythrose C4H8O4 375.321734 375.322089 0.000355 22845.9 
L-glutamate γ-semialdehyde C5H9NO3 386.337718 386.338069 0.000351 33337.8 
Deoxyribose C5H10O4 389.337384 389.337689 0.000305 8659.2 
α-Ketoglutarate C5H6O5 401.300999 401.301469 0.00047 193346.3 
5-Methylthio-D-ribose C6H12O4S 435.325104 435.325029 -7.5E-05 2982.9 
Hexose (ketose and aldose) C6H12O6 435.342864 435.343289 0.000425 3235226.3 
Hydroxykynurenamine C9H12N2O2 435.369352 435.370609 0.001257 1106.1 
Sedoheptulose C7H14O7 465.353429 465.353969 0.00054 10502.8 
Oxo-dodecanoic acid C12H22O3 469.436369 469.437049 0.00068 33371.2 
S-(3-oxo-3-carboxy-n-
propyl)cysteine 
C7H11NO5S 476.315268 476.316249 0.000981 1017.3 
N-Acetylhexosamine C8H15NO6 476.369413 476.370119 0.000706 291404.4 
5-isobutylthioribose C9H18O4S 477.372054 477.373469 0.001415 77115.6 
Pyridoxal 5-phosphate C8H10NO6P 502.30405 502.304809 0.000759 69620.1 
Muramic acid C9H17NO7 506.379978 506.380799 0.000821 3817.1 
Octadecenal C18H34O 521.540439 521.541639 0.0012 1657.1 
Eicosanal C20H40O 551.587389 551.588249 0.00086 26901.3 
a DHAP: dihydroxyacetone phosphate; GAP: glyceraldehyde-3-phosphate.  
 
2.3.7. Quantification of pyruvate 
An accurate quantification of carbonyl metabolites by the QDA method requires 
consideration of several factors. Among these are the linearity of instrumental response 
to concentration changes, the “ion suppression” (loss of signal intensity) due to the 
abundant charged species recovered from crude cell extracts, and the reaction and 
extraction efficiency of the derivatizing agent.   
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We first verified linear instrumental response using a *QDA-derivatized standards 
mixture.  Figure 2.8, a scatter plot of ion counts versus concentration, illustrates that the 
FT-ICR-MS instrument response was linear in the range from 0.025 to 25 μM for all four 
metabolite derivatives.  Linear regression parameters are listed in Table 2.3. 
 
Figure 2.8. Log-log scatter plot of concentration versus ion count for four 
*QDA standard adducts.  αKg = α-ketoglutarate; Pyr = pyruvate ; αKb = α-
ketobutyrate; Glc = glucose. 
 
 
 *QDA-Pyr *QDA-αKg *QDA-αKb *QDA-Glc 
Slope 536847 579435 470851 265815 
Intercept 813724 1523225 781273 488369 
RSQ 0.97 0.92 0.97 0.96 
Table 2.3. Slopes, intercepts, and r-squared values for the linear 
regressions of Figure 2.6. 
 
To correct for the effects of QDA reaction efficiency and adduct solvent 
partitioning efficiency, an internal standard of uniformly labeled 13C3-pyruvate was spiked 




















*QDA-Pyr *QDA-αKg *QDA-αKb *QDA-Glc
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estimate of the ion suppressing effects of the extract matrix, the ion counts of QDA-
pyruvate (endogenous pyruvate) and QDA-13C3-pyruvate (spiked) were normalized by 
dividing by the ion counts of an external standard, separately prepared *QDA-pyruvate, 
which was added at the same concentration to every sample.  Figure 2.9 summarizes the 
results.  As can be seen, the internal [13C3]-pyruvate standard produced ion counts 
significantly higher for the mixture in buffer than for the mixture in cell extracts.   
 
Figure 2.9. Uniformly 13C-labeled pyruvate spiked at three concentrations 
into either buffer (left bars) or cell extract (right bars) and derivatized in 
situ with excess QDA.  Ion counts were normalized against that of an 
external standard of 2.5 μM *QDA-pyruvate.  Labeled Pyr = QDA-13C3-
pyruvate; endogenous Pyr = QDA-pyruvate. Error bars represent one 
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The normalized ion counts of QDA-13C3-pyruvate were then plotted against the 
known concentrations of 2.5, 5, and 7.5 µM in buffer conditions and cell extract 
conditions, along with linear regressions (Figure 2.10).  The ratio of the two slopes of the 
linear regressions indicated that there was a cellular extract ion suppression factor of 
4.97.   
 
Figure 2.10. Scatter plot with linear regressions of the normalized ion 
counts of QDA-13C3-pyruvate from buffer sample and cell extract sample at 
three concentrations, averaged over three injections.  
 
Using these calibrations in a manner consistent with the stable isotope-based 
quantitation methodology commonly employed in quantitative proteomics,88 we 
estimated the pyruvate concentration to be 0.4 nanomoles in ca. 625,000 cells or 
approximately 106 nmol/g cell wet weight, when cell numbers were calibrated against 
cell wet weight.  This result is within the reported concentration range for pyruvate in 
serum (22-258 μM).89      
y = 0.3364x + 0.4802
R² = 0.9824
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2.4. Conclusions 
In summary, we developed a new cationic aminooxy reagent for the selective 
derivatization of carbonyl metabolites in aqueous cell extracts.  QDA is sufficiently 
hydrophobic that its oxime ether adducts can be extracted efficiently into n-butanol for 
rapid analysis by FT-ICR-MS.  Furthermore, we demonstrated a stable isotope labeling 
approach wherein *QDA and QDA were used to generate mass spectral ion pairs 
separated by 4.02188 m/z for global profiling of carbonyl metabolites in crude extracts.  
The reagent could be easily adapted for multiplex analysis as the presence of two methyl 
groups permits the synthesis of 9 isotopologues using variably 13C/D-labeled 
iodomethane.  When applied to human lung cancer A549 cell extracts, numerous carbonyl 
metabolites across multiple structural classes were assigned, including important 
metabolites of the central metabolic pathways.  Thus, this approach enables both high 
sample and information throughput analysis of key components of the overall cellular 
oxidation state.  Lastly, this approach can facilitate quantification of these often low-
abundant and labile metabolites, as exemplified by the analysis of cellular pyruvate.  As 
such, our chemoselective derivatization approach coupled with high resolution and 
sensitive FT-ICR-MS analysis can overcome the difficult challenge of mapping key carbonyl 
metabolites as well as cellular oxidation states which may be indicators for the onset of 
diseases. 
Since this work was disclosed in the journal Metabolomics in 2012, it has been 
expanded upon by other researchers in our group.  A similar reagent with iodoacetimide 
functionality was developed for capture and profiling of thiols, for example, by my 
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colleague Sadakatali Gori.  We also continue to supply two groups of collaborators with 
the reagents QDA and *QDA, for additional profiling of cell extracts, and also for 
derivatizing human fluid samples at the University of Louisville’s Diabetes and Obesity 
Center.  The methodology for the use of QDA has been further optimized in studies by Dr. 
Pawel Lorkiewicz who has looked at how changes in pH, temperature, and timing can 
achieve better reaction efficiency for specific classes of carbonyls. 
Our Metabolomics article was cited by the researchers who developed the photo-
cleavable linker for carbonyl capture described in Chapter 1.30  Their reagent incorporated 
an aminooxy group for carbonyl capture, but used biotin to sequester derivatives onto 
streptavidin beads for subsequent release by UV light.  The critique that Yuan and 
coworkers had for our work was that their methodology detected 1784 carbonyl 
metabolites, whereas we listed only 31.  In fact, the QDA/*QDA derivatization of cell 
extracts produced thousands of sister signals in the mass spectra.  However, there is a 
difference between detection and assignment.  We chose to only report those 
metabolites for which a specific chemical formula could be unequivocally assigned based 
on the detected exact mass.  Additionally, we chose a very conservative threshold (1000 
ion counts) to label a signal to be above the level of instrumental noise.  As the work that 
we disclosed was only the proof of principle for the methodology, we are confident that 
the work being done by our collaborators on optimizing the reaction conditions and using 
a more sophisticated method for determining signal significance will lead to a broader 
and more comprehensive profile of carbonyl metabolites in biological samples.  
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3.1. Externally triggered release of drugs by AMF 
 The magnetic properties of iron oxide NPs described in chapter 1 highlight their 
potential for use in biological applications.  Of particular interest to us was the 
phenomenon of inductive heating from exposure to an alternating magnetic field (AMF).  
Magnetic fluid hyperthermia, one of the most common medical application of ferrofluids, 
takes advantage of only the heating ability of NPs but fails to exploit their potential as 
carrier platforms for drugs, tracers, or targeting agents.  Our intention in working with 
magnetic NPs, was to contribute to recent efforts focused on expanding NP applications 
to multipurpose therapies, and, in particular, to combine inductive heating with externally 
triggered drug delivery.   
 Typical NP formulations designed for AMF-triggered release of bound substrates 
rely upon a thermally labile mediator.  For example, when NPs are associated with 
liposomes,90-91 lipid coatings,92 or solid lipid particles,93 temperature elevation triggers 
changes in lipid packing and permeability which become the basis for substrate release.  
Otherwise, thermosensitive polymers, gels,94 and macrocyclic “nanovalves”95 have also 
been used for heat-gated release of drugs from NP platforms.   
 In developing reagents for external triggering, we aimed for a more 
straightforward approach, one in which a drug could be directly bound through an 
optimized linker to a NP via electrostatic interactions or hydrogen bonding.  We pursued 
a binding motif that would be strong enough to stabilize the attachment of a drug onto 
the NP surface, but weak enough for AMF-mediated release.  To explore the concept, we 
prepared a panel of aminooxy functionalized quaternary ammonium salts for attachment 
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to a NP surface and, using a fluorophore, probed its AMF release properties.  This led us 
to do a more fundamental study of the influence of hydroxyl groups and counterions on 
the binding of organic molecules to NPs.  We then prepared a Dox analog for reversible 
attachment to NPs and looked at its release properties as well as its efficacy in vitro.  
Inconsistencies in the results led us to consider modifications to the NP surface to 
facilitate stronger binding of Dox analogs.  A brief exploration of sulfur modified NPs 
yielded data that were revealing of the complexity of the iron oxide surface and 
peculiarities at the nanoscale. 
 
3.2. Results and discussion 
3.2.1. Preparation of iron oxide NPs 
 To synthesize iron oxide NPs, we followed a well-established36, 96-97 wet chemistry 
approach based on the coprecipitation of iron II and III chloride salts in aqueous base as 
described by Mikhaylova et al.98  Transmission electron microscopy (TEM) imaging99 of 
particles prepared using this method revealed particle diameters of 5-10 nM.  Zeta 
potential measurements, which measure the electrophoretic mobility of charged colloidal 
suspensions, showed a surface charge of ≈ -32 mV.   
 Whereas the coprecipitation method intends to produce the magnetite phase of 
iron oxide crystal (Fe3O4), it is also well documented that exposure to air and moisture 
can lead to oxidation and conversion to γ-Fe2O3 particles.100-102  Washing of the freshly 
prepared nanoparticle precipitate with a dilute hydrochloric acid solution is 
recommended97 in order to peptize the particles and form a stable colloid and it is 
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documented that avoiding this step tends to prevent colloid formation in aqueous media 
unless a hydrophilic coating species is introduced in its place.36  We reasoned that rinsing 
of the freshly prepared nanoparticle precipitate was likely sufficient to cause substantial 
oxidation.  Moreover, we found that depending upon how the particles were handled 
after precipitation, there were batch-to-batch inconsistencies in the color, texture and 
magnetoviscocity of the resultant NPs.  Color changes can be indicative of crystal phase 
changes,100 so we examined the phase of magnetite generated by our synthetic and 
workup procedures.  Crystallography and Mössbauer spectroscopy are commonly 
employed to differentiate the two phases, however the data generated from these 
methods can be difficult to interpret as the crystal structures of the two phases are 
similar, and nanoscale properties may differ from those of the bulk crystal.103  This point 
is illustrated in Figure 3.1 which depicts a Mössbauer spectrum of a sample of our NPs 
acquired by Dr. Charles Johnson from the University of Tennessee Space Institute.  The 
black lines (experimental data) are overlayed with reference peaks (red and green lines) 




 Figure 3.1. Mössbauer spectrum of NPs prepared by coprecipitation 
 
 We quantified the relative proportions of the two crystal phases in our NPs 
through a spectrophotometric method104 developed by Amonette and Templeton105 that 
enables the quantification of Fe2+ present exclusively in the Fe3O4 phase.  During chemical 
analysis the synthesized NPs were dissolved in an acid matrix and complexed with iron II 
chelator 1,10-phenanthroline.  Absorbance at 510 nm of the digestate allowed 
quantification of Fe2+.  Further, reduction of Fe3+ in the NP sample using hydroxylamine 
allowed for a total Fe determination.  Our results for the assay indicated that during the 
surface acidification work-up phase dictated by the Mikhaylova procedure, the amount 
of Fe2+ decreased and the amount of Fe3+ increased indicating over-oxidation.  For 
comparison, particles that were washed with neutral water alone were closer in 
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composition to stoichiometric Fe3O4. (Table 3.1).  In either case, our characterization 
established the prepared products as a mixture of Fe2O3 and Fe3O4 phases.  And indeed 
many investigators acknowledge this phenomenon and choose to report their 
preparations as a combination of the two phases.101, 106   
 
 Fe2+(weight %) Fe3+ (weight %) 
Neutral rinse  14.8 55.6 
Acid rinse 7.7 64.8 
Ref. for stoichiometric Fe3O4 24.1 48.24 
Table 3.1. Effect of work-up conditions on Fe composition 
 
 We also observed a second effect when rinsing NPs, namely neutralization of 
surface charge.  Figure 3.2 shows that NPs exposed to a single neutral rinse remain 
anionic, whereas multiple rinses generate neutral particles, and acid rinses produce highly 
positive NPs.  Given the greater magnetic susceptibility of Fe3O4 as compared to Fe2O3, 
and the better charge pairing of anionic NPs with cationic ammonium salts, we chose to 




Figure 3.2. ζ-potential measurements of NPs under three work-up 
conditions   
  
3.2.2.  AMF heating properties 
 To test the potential of our NPs for heating in the presence of an AMF, several 
concentrations of uncoated NPs were prepared in water with 3% alginate.  The rationale 
for the use of alginate was twofold; first, the bare particles are poorly dispersible in water, 
so the alginate provides increased viscosity to maintain suspension, and secondly, 
electrolytes are necessary for effective NP-mediated heating of the bulk solution.  The 
aqueous NP solutions were exposed to AMF for up to 60 minutes while temperature 
measurements were made with a fiber optic probe.  As can be seen in Figure 3.3, solution 
heating was dependent upon NP concentration, and 5 mg NP/mL was sufficient to raise 
the temperature of the surrounding solution by 10 °C.  Hyperthermia therapy, by 






































Figure 3.3. Change in temperature of water with 3% alginate during AMF 
exposure of 201 A, 203 kHz   
 
3.2.3. Fundamental study on the influence of hydroxyl substituents 
Our rationale for preparing anionic NPs was ultimately to utilize their charge 
properties to noncovalently bind a pharmaceutical agent.  In light of this goal, we focused 
on developing agent-linkers based on positively charged ammonium salts (i.e., prodrug 
modifiers) to promote electrostatic interactions with the negatively charged NP surface.  
Secondly, given that the surface of iron oxide supports oxyanions,59 we also wanted to 
demonstrate that hydrogen bonding groups could promote binding of small molecules to 
NPs.  To systematically investigate the binding impact of hydroxyl substituents, we 
synthesized a panel of ammonium salts (and for comparison, a free amine) which varied 
by the number and arrangement of hydroxyethyl groups (Figure 3.4).  The salts were 






























Figure 3.4. Panel of variably hydroxylated ammonium salts 
 
 We also were interested to see the effect of varying the counterion on binding 
properties, so the chloride forms of each salt were prepared through ion exchange 
methodology.  Exchange of iodide for chloride produced little change in the NMR of the 
compounds, however exchange was verified in two other ways.  In the first method, silver 
nitrate was added to aqueous solutions of the ammonium salts and the color of the 
precipitated silver halide was observed; silver chloride forms white crystals, whereas 
silver iodide forms yellow crystals.  MS was also used to verify anion exchange by looking 
for a signal representing the mass of dimers of the salts (m = 2 ammonium cations + 1 
halide, net charge = +1).  For example, the mass of 1OH∙Cl was calculated at m/z 
243.18283 and observed at 243.18357, but no iodide dimer was detected.   
To quantify the amount of organic material bound to ammonium coated NPs, 
thermogravimetric analysis (TGA) was used.  The precise weight of the NP sample was 
monitored while the sample was heated to 700 °C.  Sample weight loss below 200 °C was 
attributed to adsorbed water108 and above 200 °C was assigned to the desorption of 




Figure 3.5. A representative TGA of ≈ 6 mg each of NPs coated with variably 
hydroxylated ammonium salts (iodide form) and free base amine 
 
 The results of the TGA study supported our hypothesis that an ammonium ion 
motif having hydroxyl substituents would enhance binding to anionic NPs through both 
electrostatic and hydrogen bonding interactions at the NP interface.  A representative 
TGA depicting the iodo salts can be seen in Figure 3.5; descending lines represent actual 
percent weight loss and, for clarity, the derivatives of those lines are overlaid.  Figure 3.6 
defines the number of bound organic molecules, calculated according to equations 
supplied by Galeotti et al.,109 on each of the coated NP formulations.  There was enhanced 
binding of ammonium salts when more hydroxyethyl substituents were present.  
Additionally, the chloride salts proved to be more efficient binders than the iodide salts.  
This may have resulted because ion pairs of quaternary ammonium cations with chloride 
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are weaker than their iodide counterparts;110 thus displacement of the counter-ion by NP 
surface anions may be more readily achieved for the chloride salts.   
 
 
Figure 3.6. TGA results of bound panel members (see Figure 3.4 for 
structures). 
 
3.2.4.  Fluorescein release 
From our fundamental study we understood that hydroxyl groups aid in the binding 
of small molecules to NPs.  As our ultimate goal was AMF mediated release of NP bound 
substrates, we needed to determine the degree of binding that would cause ammonium-
based linkers to adhere tightly to NPs under normal conditions, but release from the 
particles under AMF exposure.  A fluorescent probe was chosen for this purpose as it 
would enable spectroscopic monitoring of release as well as function in the capacity of a 
drug mimic.  To this end, fluorescein isothiocyante (FITC) was modified as shown in 
























Scheme 3.1. Reagents and conditions: (a) 4-aminobutyraldehyde 
diethylacetal (1.2 eq), dimethyl-formamide, rt, 4 h (b) 30% aq. acetic acid, 
3h, 55% (2 step) 
 
Next, three quaternary aminooxy (QAO) salts (Figure 3.7) were prepared for 
conjugation with the FITC aldehyde (FITC-CHO).  The first, designated QAO, was prepared 
by phthalimide protection of the alcohol dimethylethanolamine.  Methylation with 
iodomethane produced the quaternary amine and hydrazinolysis cleaved the phthalimide 
to an aminooxy.  QAO-2OH was prepared by first protecting two of the alcohols on 
triethanolamine with silyl groups, then proceeding with the phthalimide protection and 
methylation as before, and finally deprotecting the alcohols to achieve the final bis-
hydroxy product (Scheme 3.2).  A 1H NMR expansion showing the methylene protons of 
QAO-2OH reveals the 4:2 integrations anticipated for the difunctional molecule (Figure 











Scheme 3.2. Synthesis of QAO-2OH.  Reagents and conditions: (a) TBSCl, 
Et3N, CH2Cl2, 0 °C-rt, 8h, 13%; (b) N-hydroxyphthalimide, PPh3, DIAD, THF, 
0 °C-rt, 12h, 81%; (c) CH3I, CH2Cl2, 50 °C, 6h (d) H2NNH2 monohydrate, 





Figure 3.8. 1H NMR expansion of methylene region of QAO-2OH in D2O 
 
Using a stepwise approach, the three QAOs were first coated onto the NPs followed 
by addition of FITC-CHO.  The resultant oxime ether adducts, FITC-I, II, and III, are pictured 
in Figure 3.9.  As a negative control, FITC-CHO was added to bare NPs as well.  The coated 
NPs generated by this method were then magnetically separated, washed to remove 
loosely bound fluorophore, and exposed to AMF (201.4A, 203 kHz, 30 min) to induce 
QAO•FITC conjugate release.  After magnetic separation, the supernatant solutions were 
collected, and fluorophore release was detected by fluorescence HPLC.  Prior to this, 
excitation-emission spectra were acquired on the FITC adducts to verify that QAO linkers 
did not significantly alter the fluorescent properties of the probe: deviations in excitation 
maxima varied by less than the excitation beamwidth of the fluorescence detector, and 




Figure 3.9. Cationic aminooxy-based oxime ether conjugates of FITC-CHO 
 
The results of this initial screen revealed that the negative control showed 
negligible fluorescence after AMF exposure; thus, no retention of FITC-CHO on NPs in the 
absence of an aminooxy linker.  However, under identical conditions, the NP•FITC-II and 
NP•FITC-III formulations showed an increase in supernatant fluorescence after AMF 
exposure indicating release of the conjugates in response to the external stimulus (Figure 
3.10).  The FITC-I adduct peak, however, could not be resolved from unreacted FITC-CHO 
in the HPLC run.  These results suggested that the hydroxyl motif was important for 
retention of drug surrogates prior to AMF induction.    
 
 
Figure 3.10. Fluorescence intensity of sampled solutions of three 
























3.2.5.  Doxorubicin oxime ether analogs 
 The model fluorescence study of FITC analogs had supported the idea that AMF 
could be used to free noncovalently bound species from the surface of NPs.  
Consequently, we set out to prepare a NP platform with an attached anticancer drug, 
doxorubicin (Dox, Figure 3.11).  As mentioned in the introductory chapter, Dox is a potent 
chemotherapeutic agent that, in the absence of a targeting agent or nanocarrier, exhibits 
nonspecific toxicity.  The C-13 carbonyl is a convenient reactive partner for a QAO-based 
aminooxy linker.  Thus, we aimed to demonstrate in an in vitro model how iron oxide NPs 
could be used to deliver modified doxorubicin to cancer cells in response to AMF 
induction.  To simplify the strategy, we altered our methodology to a direct rather than 
stepwise loading route; we chose for the Dox studies to first generate, purify, and 
characterize Dox-QAO adducts and then attach the adducts directly onto NPs.  Two Dox 
analogs were prepared using QAO-OH and QAO-2OH (Figure 3.6).  Since chloride salts 
were found to bind more effectively than iodide salts in the fundamental study of 
hydroxylated QAOs, the QAO-Dox conjugates were converted to chloride salts for these 
studies.  The Dox analogs Dox-OH and Dox-2OH (Figure 3.11) were characterized by NMR 
and high resolution mass spectrometry (Figure 3.12) to confirm the formation of the 
desired oxime ether conjugates.   
Upon loading the Dox analogs onto NPs by stirring in DMSO, a color change in the 
solution from red (the color of Dox∙HCl) to purple was noted.  This may be the result of 
the formation of an Fe2+ 112 or Fe3+ complex113 as these species have been documented to 
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occur and are associated with purple colors.  After rinsing to separate unbound Dox 
analogs, TGA indicated 7.51 weight percent organic material for both species.    
  
 
Figure 3.11. Unmodified doxorubicin hydrochloride (Dox) and mono- or di-
hydroxylated oxime ether conjugates  
 
 
Figure 3.12. FTMS spectrum of Dox-2OH showing the calculated exact mass 
and the observed peak 
 
3.2.6.  AMF release profiles 
AMF induction of magnetic fluids in living tissue has limitations; nonspecific tissue 
heating can lead to tissue necrosis.  Pulsed AMF, however, has been employed in mouse 
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models to avoid this problem.114  We looked at the release profiles of Dox-OH and Dox-
2OH during pulsed AMF exposure over one hour.  In this study, an aqueous solution of 
Dox analog-coated NPs received AMF pulses (203 kHz, 350 A, rt) at five minute intervals 
with intervening five minute incubations at 30 °C.  The NPs were then magnetically 
sedimented and the solution phase absorbance was measured by UV-Vis spectroscopy at 
480 nm (the maximum absorbance for Dox) to measure drug-analog release.  The 
responsiveness of the Dox analogs to AMF induction can be seen in the time course in 
Figure 3.13 in which the yellow bars indicate AMF “on” time.  Although Dox-OH exhibited 
greater release overall, Dox-2OH release was more closely associated with AMF 
stimulation; absorbance for Dox-OH rose steadily during AMF pulses as well as during 
intervening incubation, whereas Dox-2OH showed an increase in absorbance primarily for 
AMF on times, and flat absorbance during the intervening incubation periods.  This 
increased AMF responsiveness for Dox-2OH may be attributable to a more proximal 
interaction with the NP surface (facilitating AMF-induced energy transfer), presumably 
due to the presence of an additional hydrogen bond donor.  By comparison with a 
calibration curve, the 60 minute endpoint corresponded to 15 µM Dox-OH and 11 µM 
Dox-2OH.  Comparison with TGA data suggested this represented only 4.5 or 5.9% of 
payload release for Dox-OH and Dox-2OH respectively, however absorbance declined 
after further incubation at 30 °C indicating reattachment of the linker to the NP (likely an 
equilibrium phenomenon); additionally, in our experience TGA can overestimate loading.  
The better test for release, we reasoned, would be a non-equilibrium system, one in 
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which released Dox analog could be removed from proximity to the NP before 
readsorbance could occur, specifically, a living system.  
 
 
Figure 3.13. UV-Vis detection of Dox analogs released from Dox-NPs by 
pulsed AMF (203 kHz, 350 A, rt) as indicated by absorbance at 480 nm of 
the solution after magnetic separation of the particles.  Error bars 
represent +/- 1 standard deviation for triplicate samples. 
 
3.2.7.  In vitro studies 
 A pilot study conducted by my colleague, Dr. Souvik Biswas, on MCF-7 breast 
cancer cells had generated promising results using NPs conjugated to the iodo form of 
Dox-OH. 99  The key findings of his study were an initial demonstration of low toxicity for 
bare NPs, and high toxicity for NP-Dox-OH formulations upon AMF exposure.  Most 
exciting was the finding that the drug analog displayed very low toxicity in its bound state, 
but high toxicity upon release, effectively functioning as an inactive pro-drug until 
external triggering with AMF—a promising scenario.  We hoped that the new analogs, 
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with chloride counterions and, in the case of Dox-2OH, an additional hydrogen bond 
donor, could surpass the efficacy of the first generation analog.  We also hoped to 
overcome a challenge encountered with the first generation Dox-OH of premature drug 
release upon incubation at body temperature (≈14 % payload loss).   
 To test the NP-Dox formulations in vitro, MCF-7 breast cancer cells were cultured 
and plated into either 35 mm dishes or a 96 well plate modified to fit within the AMF coil.  
NP-Dox formulations were typically administered by suspending the NPs in PBS and 
adding the solution to cells in medium.  Half of the cells would then be exposed to AMF 
(350A, 203 kHz, 3 min on, 3 min off pulses, 30 min total time) by placing the culture dish 
within the coil of the AMF generator.  During pulsed AMF application, cells were 
incubated at 37 °C between pulses.  Cells would then be incubated with treatments for 
24 hours after which toxicity would be assayed by trypan blue exclusion and counting of 
living cells using a hemocytometer.    
 The toxicity studies presented a number of challenges.  As the synthesis and 
loading of NPs involved a great deal of processing, reproducibility in the toxicity 
measurements was poor.  Small differences in loading concentrations or post-loading 
washes of the NPs could produce particles with differing amounts of bound drug.  
Formulations with a lower coating of Dox were more prone to aggregate in PBS buffer 
resulting in uneven application to cells.  As a result, the toxicity studies were highly 
variable.  In a representative toxicity study (Figure 3.14) some effects were consistent 
between the first generation drug trial and the latter one.  For example, AMF alone did 
not produce significant cell death, nor did bare NPs induced by AMF cause cell death.  In 
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addition, the NP-Dox-OH formulation did demonstrate a modest degree of toxicity 
exclusively when AMF was applied.  Unfortunately, the NP-Dox-2OH formulation gave an 
undesirable result showing minor toxicity with or without AMF.  
   
 
Figure 3.14. Toxicity of NP-Dox formulations and controls on MCF-7 breast 
cancer cells for cells grown in a 96 well plate to 40% confluence and treated 
with 12.3 µg/well NP-Dox formulations.  Error bars reflect standard error 
over biological triplicates.  NP-Dox-2OH data reflect the average of 
biological duplicates.  
 
 Reproducibility in trials of a NP-mediated drug carrier is crucial for establishing the 
practical utility of the system.  And given the multi-step preparations involved with NP 
formulations, the components of the system must be robust with predictable 
interactions.  Since our modifications to Dox in this approach led to disappointing results 
in regard to toxicity, we began to consider modifications to the NP side of the drug-
nanocarrier interface — how could the surface of the iron oxide NP be altered to actuate 
























3.3. Sulfur-modified NPs 
3.3.1.  Dextran sulfate NPs 
 A quaternary ammonium cation is a large, diffuse positive charge.  We reasoned 
that a size-matched large anion on the NP surface could elicit a stronger electrostatic 
interaction with a QAO than the Fe-O-/OH- of the bare particle.115  In our first effort to 
modify the NPs, we elected to change the anion at the Fe3O4 surface to a sulfate.  We 
selected dextran sulfate as a coating agent to modify our NPs because dextran, a sugar 
polymer, was already a common coating reagent for NPs.   
 After coating NPs with dextran sulfate, QAO-2OH conjugated to an anthracene 
fluorophore (Figure 3.15) was added.  The release properties under AMF of this 
chromophore were then measured by UV-Vis.  As is shown in Figure 3.16, unfortunately 
the formulation exhibited slow leakage of the anthracene analog both in the presence 
and absence of AMF exposure. 
 
 




Figure 3.16. AMF-mediated release of anthracene derivative (rt) versus 
incubation at 37 °C  
 
3.3.2.  CS2-modified NPs 
The next strategy we examined for modifying the NPs was to incorporate xanthate 
functionality (ROCS2-M+) at the iron oxide surface with an eventual aim to pair the 
constituent dithiocarboxylate anion with a QAO.  Xanthates are typically prepared from 
reaction of an alcohol with carbon disulfide in the presence of base, but we wondered if 
reaction of iron oxyanions with CS2 might generate an analogous ferric xanthate (Figure 
3.17).  Some precedent for this concept is found in the adsorption of carbon disulfide and 
carbonyl sulfide (O=C=S) onto iron oxide.116-117  In fact, hydrated iron oxides are employed 
industrially as scrubbers for volatile sulfurous compounds generated during coke fuel 
production.118  Though these triatomic species are known to bind to iron oxide, they have 































Figure 3.17. Traditional xanthate preparation and ferric xanthate variant.  
 
To ascertain what functional transformations could be made on the surface of the 
NP, we used the strategies summarized in Figure 3.18.  Carbon disulfide was reacted with 
bare NPs 1 to produce product 2.  The zeta potential of 2 remained negative (bare NPs: -
35.9; CS2-coated: -29.3), indicating either no reaction or the formation of a sulfanion.  
There were indications that some type of reaction had taken place because the color and 
texture of the NPs changed upon coating, and off-gassing was noted after CS2 addition 
and workup (rinsing and drying the NPs).  Further, an IR of the product in comparison with 
bare NPs 1 showed the emergence of two new peaks in the fingerprint region at 1231 and 




Figure 3.18.  Strategies for incorporating organics onto sulfur-modified 
NPs. 
 
The CS2-modified NPs 2, were then reacted with either deuterated iodomethane, 
to cap the sulfanion with a methyl group, or they were mixed with deuterated ammonium 
salt 3 to test their potential for electrostatically binding substrates.  Deuterated reagents 
were selected in the hopes that attenuated total reflectance IR (ATR-IR) of the NPs on a 
germanium crystal could detect the C-D stretching vibrations of the products, as this 
vibration occurs in an otherwise sparse region of the IR spectrum (2075 cm-1).   
C-D stretches for compounds 6 and 7 were not observed, however surface 
changes were evident using other characterization techniques.  Figure 3.19 shows the 
results of elemental analysis (EA) that gives the weight percent of carbon, hydrogen, and 
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sulfur for NPs 1, 2, 8, and a control prepared by addition of iodomethane to bare NPs 1.  
The values displayed in the graph represent the weight percent of each element divided 
by its molecular weight to give relative moles of each element.  Of course, the bulk of the 
weight of these NP formulations is iron and oxygen which are not represented in this 
graph.  EA revealed an increase in the sulfur content of NPs 2 as compared with bare NPs 
1, but surprisingly no increase in the carbon content.  EA of 8 showed an increase in 
carbon content, but not the 3:1 ratio of H to C that would be expected for methyl group 
addition.  Meanwhile the sulfur content decreased for compound 8.  Most surprisingly, 
the negative control showed an increase in carbon content implying retention of 
iodomethane (b.p. 40 °C) on bare NPs, despite 24-48 hours under vacuum.    
 
 






























TGA also demonstrated high electrostatic binding properties for the CS2-modified 
NPs.  TGA of NPs 6 showed a large amount of bound ammonium salt 3 compared to a 
control of bare NPs 1 with the same salt (Figure 3.20).  The weight loss curves were 
integrated above 200 °C to exclude weight loss due to adsorbed water from the 
calculation. 
 
Figure 3.20. TGA curves for select NPs from Figure 3.18 
 
Presuming formation of methyl xanthate 8, amines 2 and 3 were prepared in the 
hopes of forming more stable thiocarbamates (ROC(=S)NR2) 9 and 10 by displacing 
methane thiolate.  IR of 9 revealed aromatic C-C stretching vibrations, C-H stretching, and 
a peak at 1036 cm-1, close to the reference peak for C=S of 1050 cm-1.  And MALDI-TOF-
MS of 9 detected a peak at m/z 108, the mass of the protonated form of 3 (108.08).  
Compound 10 showed the greatest change in morphology with NPs turning from brown 
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to beige after coating.  TGA validated the heavy loading on NPs 10 indicating 28.6 weight 
percent of bound organic. 
 We wondered how the CS2-modified NPs would compare to unmodified NPs in 
affinity for hydroxylated ammonium salts. Using the earlier study as our model, we mixed 
CS2-modified NPs 2 with the variably hydroxylated ammonium salts from Figure 3.4.  As 
can be seen from Figure 3.21, we did not observe the same trend for greater binding with 
increased hydroxylation, nor did the counterion have the same effect.  Strangely, the 
chloride salts appeared to displace some of the bound CS2.   
 
Figure 3.21. Weight % of bound organics based on TGA of CS2-modified 
NPs with variably hydroxylated ammonium salts. 
 
Although we were intrigued by the properties of the CS2-modified NPs, there was 
























experiments, we had conceived of the NPs as passive platforms for adsorbing organics, 
but the unexpected results of the EA in particular indicated a surface reactivity or catalytic 
activity that we had failed to appreciate.  A deeper look into the literature on the 
interaction of iron oxide with species like CS2 confirmed this reactivity.  Wang et al., for 
example, identified oxidation of CS2 on iron oxide atmospheric particles to carbonyl 
sulfide (COS).119  In fact, this is something we had observed with our own NPs; GC-MS of 
the headspace during off-gassing of CS2-modified NPs had shown a mass corresponding 
to COS.  And neither is such catalysis exclusive to CS2.  Chen and coworkers found 
oxidation of COS to CO2 on hematite, another form of iron oxide.  The proposed 
mechanism is given in Figure 3.22.120  Dissociative chemisorption of carbon dioxide on iron 
oxide has also been proposed.121  Even room temperature water splitting has been 
observed on the surface of magnetite.122  These phenomena would eventually lead us to 
a rethinking of attachment of sensitive molecules to NP surfaces.  Rendering the surface 




Figure 3.22. Proposed mechanism for oxidation of COS to CO2 on 
hematite.  Reprinted with permission from Environ. Sci. Technol. 2007, 41 
(18), 6484-6490. Copyright 2007 American Chemical Society. 
 
In our final investigation into sulfur-modified NPs, we turned our attention to an 
entirely different route for putting sulfur on the surface, one that makes sulfur an intrinsic 
component of the NPs themselves. 
3.3.3. Greigite NPs 
  Iron sulfide, Fe3S4, or greigite, shares many properties with its cousin, Fe3O4.  Like 
magnetite, it has a spinel crystal structure and is magnetic.  Greigite NPs can be prepared 
from an acidified mixture of iron II sulfate and sodium sulfide as described by Chang and 
colleagues.123   
 To assess whether the presence of sulfur anions as opposed to oxyanions at the 
particle surface could enhance adsorbance of quaternary amines, akin to the CS2-
modified NPs, we prepared greigite NPs and coated them with the QAO-2OH anthracene 
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derivative pictured in Figure 3.15.  TGA of the isolated product (Figure 3.23) showed that 
iron sulfide, like iron oxide, could bind ammonium salts.   
 
Figure 3.23. TGA showing percent weight lost from bare Fe3S4 NPs or QAO-
2OH anthracene-loaded particles. 
 
AMF release properties of the anthracene adduct from the Fe3S4 NPs were then 
assessed by UV-Vis at 384 nm, however no increase in solution absorbance relative to 
incubation at 30 °C was observed.  When the heating properties of Fe3S4 NPs were 
examined it was discovered that the greigite NPs did not heat significantly upon exposure 
to AMF, likely the culprit for the absence of release.  
It was at this point that we decided to retool our strategy for binding organics to 
NPs.  Iron oxide had proven the more efficient material for the sake of AMF heating, so 
we would return to that architecture, but the surface reactivity would need to be 
neutralized by coating with a more inert material.  As discussed in the next chapter, we 
would turn to silica coating to serve this purpose.  
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4.1.  Composite NPs: silica on iron oxide  
Modifications to the surface of iron oxide NPs are often required to generate 
stable aqueous colloids and to render the catalytically active119, 121 surface inert for the 
sake of ligand/drug stability.  Silica coating also allows for functional group 
interconversion to a variety of other functionalities including alkyne, azide, carboxyl, 
nitrile, phosphate, and thiol.124  To this end, coating NPs with silicon dioxide is commonly 
employed, particularly for multi-component nanosystems.125  Creating a core-shell Fe3O4-
SiO2 structure is desirable because the silica shell enhances the hydrophilicity of the 
particles and reduces cellular toxicity,126 while largely preserving their magnetic 
properties.127  Moreover, as silicon is a metalloid, rather than a metal, the composite 
structure has a less reactive surface than iron oxide. 
The surface of silica-coated NPs (SNPs) is inherently negatively charged due to the 
presence of silanol groups, but positively charged particles may be more desirable for 
oncological applications considering the favorable pairing of cationic particles with the 
negative exterior of many cells, including cancer cells.128-129  Further, a self-assembly 
process for formation of a therapeutic nanosystem is desirable since ultimate broad 




4.2.  Cationic magnetoliposomes 
 Dual-chain lipids, typically zwitterionic phospholipids, have been used to coat NPs 
and have been shown to self-assemble into bilayers surrounding anionic NPs forming 
what are termed classical magnetoliposomes.130  In that the lipid is directly bound to the 
particle surface, these constructs differ from extruded magnetoliposomes that are 
composed of NPs entrapped within the aqueous core of a lipid vesicle.131  Direct 
attachment of lipids at a NP surface offers the advantage of size control.  Namely, the size 
of the magnetopliposome is dictated by the dimensions of the NP, a tunable property.  
Thus classical magnetoliposomes are usually smaller (<100nm) than their extruded 
counterparts.131  In addition, the preparation of extruded liposomes generally requires 
more involved techniques, such as sonication or freeze-thaw cycling.  Positively charged 
magnetoliposomes, termed “cationic magnetoliposomes” (CMLs), are typically formed 
from a mixture of zwitterionic phospholipids, cationic aminium lipids, and neutral lipids.  
Marcel De Cuyper and Stefaan Soenen have studied such cationic magnetoliposomes132 
extensively, elucidating their cellular interactions, toxicity, and cell-labeling potential.133-
140   
 Cationic lipids containing a quaternary ammonium headgroup, and thus a 
permanent positive charge, are known in the context of gene transfection to promote 
rapid cellular uptake when complexed with nucleic acids in a “lipoplex”.  Their high charge 
density encourages association with cell membranes and facilitates endocytosis.141-142  
This capacity has also been exploited in concert with NPs in the practice of 
magnetofection where cationic lipid-coated NPs have been explored as magnetic gene 
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vectors.141, 143-144  As the surface of SNPs, like iron oxide, is anionic, we envisioned 
constructing a CML that could auto-assemble by simple mixing of a custom quaternary 
ammonium-based lipid and SNPs. 
 We aimed to prepare a self-assembling CML-SNP tailored for biological 
applications with suitable size and charge character for efficient cellular internalization.  
To demonstrate the potential of the system as a nanocarrier, we prepared an amphiphilic 
derivative of Doxorubicin (Dox) for incorporation into the CML bilayer. We envisioned 
that mixing of SNPs, our custom cationic lipid, and the Dox analog would produce a CML-
SNP drug carrier (Figure 4.1).  
 
Figure 4.1. Cationic magnetoliposome with a core-shell iron oxide-silica NP 
surrounded by a cationic lipid bilayer and a bilayer-embedded amphiphilic 
drug 
 
4.3.  Results and Discussion 
4.3.1.  Cationic oxime ether lipids 
 Traditionally, lipids are constructed with ester linkages that tether hydrophobic 
and polar domains.  In conceiving of a lipid to coat SNPs for Dox delivery applications, we 
turned to oximation for lipid construction.  By mixing an aminooxy headgroup with 
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aldehyde tails of the desired chain lengths and unsaturation, a wide variety of oxime ether 
lipids can be prepared. 141, 145   
 The panel of oxime ether-based cationic lipids we synthesized for loading onto 
SNPs were designed with quaternary ammonium headgroups as the permanent positive 
charge ensures that pH changes in the particle environment will not alter the electronic 
character of the lipid.  Building on our work with hydroxylated QAOs and Fe3O4 NPs, we 
also added hydroxyl functionality to the lipid headgroups to encourage association with 
the hydrophilic surface of the SNPs.  Hydroxyl groups have also been shown to enhance 
cell membrane interaction.146   
 Three lipids were prepared (Scheme 4.1 and Figure 4.2) with varying chain lengths 
(C12, C14, and C18) by reaction of aminooxy 4.1 with 2 equivalents of aldehyde-
functionalized alkyl chains.  The bis-oxime ether adducts (4.2-4.4) were formed as 
mixtures of E,E, and E,Z isomers and were not typically isolated as separate 
diastereomers.  In Figure 4.3 the 1H NMR triplets for the oximyl protons in E and Z 
configurations are shown for a representative lipid.  The dissymmetry provided by 
incorporation of the (E,Z)-containing lipid fraction likely will contribute to the formation 




Scheme 4.1. Conditions: a. N-hydroxyphthalimide, PPh3, DIAD, 0 °C to rt, 
12h; b. N2H4∙H2O, CH2Cl2, rt, 2.5h (16%, 2 steps); c. corresponding dodecyl, 
tetradecyl, or oleyl aldehyde, CH2Cl2, rt, 10h (47-71%); d. TFA, CH2Cl2, 0 °C 
to rt, 3h (91-100%); e. glycidol, EtOH, rt, 60h (38-41%); f. CH3I, CH2Cl2 
(sealed tube), 55 °C, 5h (63-64%).  
 
 





Figure 4.3. 1H NMR expansion showing oximyl proton shifts for E and Z 
configurations of lipid 2 
 
 To add hydroxyl functionality to the lipid headgroup we turned to nucleophilic 
addition of the amines generated from step d of Scheme 4.1 to the C-3 carbon of glycidol 
(Figure 4.4) as a strategy for installing a 1,2, diol functionality.147  Normally the reaction is 
performed at elevated temperatures, with an excess of amine, or catalysts such as lithium 
perchlorate.148-149  Kuwabe et al.,150 for example, reported addition of a secondary amine 
to glycidol after 48 hours refluxing in ethanol.  However, a recent report of room 
temperature reaction of secondary amines with glycidol in water148 piqued our interest.  
As our starting material was not soluble in water, we instead used ethanol.  Reaction of 
bis-oxime ether secondary amines with glycidol in ethanol (rt, 24h) was successful in 
yielding 1,2 diol substituted tertiary amines.  A representative FT-MS spectrum is depicted 









Figure 4.5. Calculated exact mass of 4.6 and FTMS spectrum of the 
observed mass 
 
4.3.2.  Preparation of Dox-AH 
Model drug, Dox, can be modified at the C-13 carbonyl group through 
condensation with a hydrazide, to from an acyl hydrazone.  In this way, the lipophilicity 
of an otherwise highly hydrophilic drug is increased, better suiting it for incorporation into 
a lipid bilayer.   
Several examples of Dox C-13 hydrazones have been documented in the literature.  
Effenberger et al.151-152 prepared Dox hydrazones using C17 and C18 fatty acids and 
menthyl/bornyl esters.  The cytotoxic efficacy of these analogs and mechanism of cell 
death were investigated in several cancer lines, and in many cases the derivatives were 
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more effective than the native form.  Particularly interesting was the efficacy against 
multidrug resistant cells, possibly a consequence of superior diffusion of the analogs 
through cellular membranes.153  Maleimide substituted acyl hydrazones of Dox have also 
been prepared and demonstrated to be practical derivatives, such as aldoxorubicin, 
currently in phase II clinical trials.154-155  Consequently, to adjust lipophilicity, we prepared 
a C-13-hydrazone (Scheme 4.2) by reaction of Dox with hexadecanoic acid hydrazide in 
the presence of an aniline activator156 to obtain Dox acyl hydrazone Dox-AH.  Hydrazone 
formation was verified by 13C NMR where the disappearance of the C-13 carbonyl peak at 
213.6 ppm was noted along with the appearance of a peak at 152.2 ppm (Figure 4.6).  This 
ppm shift is comparable to that reported for a similar Dox hydrazone.154 
 






Figure 4.6. Stacked 13C NMR of Dox (upper) and Dox-AH (lower), showing 
emergence of the C-13 hydrazone chemical shift 
 
4.3.3.  CML formation and stability 
To evaluate the formation and stability of CMLs, SNPs were stirred with cationic 
lipids 1, 2, or 3 in DMSO.  Particle size was monitored over 24 hours mixing time by 
measuring dynamic light scattering (DLS).  Lipids 2 and 3 with 14 and 18 carbon chains, 
respectively, did not form compact, stable CMLs (see appendix).  However, lipid 1 with 
saturated C12 chains, formed small, stable CMLs averaging 67 nm in hydrodynamic 
diameter (Figure 4.7) and positive surface charge as indicated by zeta-potential of 31.72 




Figure 4.7. Dynamic light scattering measurements of CML diameter.  The 
data represent direct measurements of a mixture of 13 µmols lipid 1 
(Figure 4.2) with 1 mg SNP in 2 mL DMSO taken over 24 hours mixing time.  
 
4.3.4.  Titration of SNP with cationic lipid 1 
To determine the amount of lipid sufficient to coat SNPs with a bilayer, an aqueous 
solution of SNPs was titrated with increasing amounts of lipid 1 and the change in surface 
charge, as indicated by zeta-potential, was measured to determine a saturation point.  A 
log-log plot of the data generated a sigmoidal curve with a plateau indicative of saturation 
of the particle (Figure 4.8).  This zeta potential plateau represents approximately 2800-
5700 lipid molecules per SNP (see appendix for calculation).  In subsequent CML 
formulations, we aimed for a lipid amount just sufficient to reach the onset of the positive 
plateau of the charge titration curve to avoid using excess lipid.  In the case of extruded 
MLs, a ratio of 4-13 mmol lipid/gm NPs is required to reach NP encapsulation efficiencies 
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of >70%.157  By comparison, the charge titration curve for CML formation indicated that 
significantly less lipid is required, 0.2-0.5 mmol lipid 1/gm SNP.     
 
Figure 4.8. Zeta-potential of SNP titrated with lipid 1 in water. 
 
 
4.3.5.  Estimation of lipid: Dox-AH ratio 
To determine the amount of Dox-AH to add for co-loading with lipid 1 onto SNPs, 
we examined the DLS of liposomal formulations of varying molar ratios of the two 
amphiphiles.  We presumed that smaller liposomes would be indicative of tighter packing 
and greater stability.  Liposomes were prepared using thin film hydration with 
sonication.158  DLS measurements were taken for each solution in water.  Figure 4.9 shows 
the plot of the percent of Dox-AH added versus the diameter of the liposomes.  From the 
data it was estimated that a Dox-AH percent less than 30 should be used for the sake of 

























Figure 4.9. Diameter versus percent Dox-AH in a liposomal formulation 
with lipid 1. 
 
4.3.6.  Cytotoxicity study 
Having established effective conditions for CML formation, we next examined 
incorporation of Dox-AH into CMLs to assess in vitro efficacy against MCF-7 breast cancer 
cells.  Dr. Geoffrey Clark, a collaborator at the University of Louisville Medical School, 
kindly provided the use of his facilities, resources, and the assistance of his postdoctoral 
student, Dr. Katharine Hobbing, for this work.   
Dox-AH-loaded CML were prepared by making a thin film of a 3:1 mixture of lipid 
1 and Dox-AH.  An aqueous dispersion of SNPs then was added to the lipid/Dox-AH film 
and the mixture was stirred for 12 hours to form loaded CMLs.  Aliquots containing 50 μg 
CMLs were diluted by 10% with 10x PBS and the formulation was added directly to cells 
in growth medium (serum supplemented DMEM).  Control conditions using separate 





























control, aliquots of Dox and Dox-AH alone at 4 times the dose of the CML drug complexes.  
After 2h incubation with treatments at 37 °C, the medium was removed and replaced with 
fresh medium.  Cell viability (Figure 4.10) was assayed by trypan blue exclusion after 48 
hours incubation.  SNPs alone showed very low toxicity, as expected.  Lipid 1 was 
somewhat cytotoxic but much more so when delivered in the form of CMLs, presumably 
a consequence of higher intracellular incorporation when associated with a cationic 
particle that is rapidly internalized.  This carrier-mediated cytotoxicity, likely a result of 
cell membrane destabilization by intercalated cationic lipids, is undesirable, and future 
studies will examine how the effect can be mitigated.  Nevertheless, the most potent 
formulations were the drug-loaded CMLs (both Dox and Dox-AH analogs), killing over 90% 
of the cells.  It is noteworthy that the positive controls of Dox and Dox-AH alone displayed 
lower toxicity than the CML-drug complexes, despite being added at four times higher 
dose, again suggesting efficient CML internalization and thus intracellular accumulation 
of the cytotoxic cargo.  To our surprise there was no significant difference between the 
cytotoxicity of Dox-AH CMLs and Dox CMLs.  We had anticipated that the lipophilicity 
imparted by the added C16-acyl hydrazone would be necessary for CML-mediated 




Figure 4.10. Cytotoxicity of treatment formulations in MCF-7 cells as 
indicated by trypan blue exclusion.  Uncoated particles (SNP), Lipid 1 alone 
(Lipid 1), Lipid 1-coated SNP (CML), Dox-AH alone *administered at 4X 
higher drug dose than Dox-AH CML (Dox-AH), Dox alone *at 4X higher drug 
dose than Dox CML (Dox), Dox-AH-loaded CML (Dox-AH CML), and Dox-
loaded CML (Dox CML).  Error bars represent standard error over biological 
triplicates.   
 
To determine the degree to which the modification of Dox to acyl hydrazone Dox-
AH altered the drug-CML formulation as a whole, we turned to fluorescence imaging.  Dox 
has a strong emission at 580 nm, so fluorescence microscopy can be used to trace it within 
cells.  Two hours after incubating MCF-7 cells, as above, with CML formulations containing 
either Dox-AH or Dox, fluorescence images were taken.  The acquired images are paired 
with their bright-field counterparts in Figure 4.11.  The more intense fluorescence was 
seen for the Dox-AH CML, so although the two drug-loaded CML function nearly 
identically with respect to toxicity, there is an apparent difference in the nature of their 
internalization.  We hypothesize that Dox adsorbs to the SNP surface during CML 



























moiety and thus benefits from the uptake enhancement conferred by the CML, but suffers 
from greater fluorescence quenching due to its tighter association with the SNP. 
 
Figure 4.11. Stacked bright-field (lower) and fluorescence (upper) images 
of MCF-7 cells after two hours treatment with (left) Dox-AH-loaded CML, 
and (right) Dox-loaded CML.  Scale: 200 µm. 
 
Although unanticipated, we were gratified to find that CML formulations 
increased the efficacy of both hydrophilic and amphiphilic forms of our model drug.  Still, 
for the purpose of Dox delivery by CML, an acyl hydrazone modification may yet be 
advantageous since Dox hydrazones have been shown to be more effective against 
multidrug resistant cell lines. 
  
Dox●HCl CML Dox-AH CML 
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4.3.7.  AMF and bilayer disruption 
A few investigators have examined the application of AMF to lipid-coated NPs for 
achieving substrate release.  Hsu and coworkers, for example, prepared “solid lipid” 
nanostructures with embedded NP.  They were constructed with a lipid core of 
triglyceride and an encapsulating polymeric surfactant.  Embedded within the 
hydrophobic interior were NPs and a model drug.  Application of AMF at 25 kHz for 20 
minutes resulted in release of 35% of the embedded drug.93  Similarly, Bringas et al.92 
reported AMF-mediated release of a dye from a lipid-coated SNP system.  In this work, 
NPs were capped with mesoporous silica into which the dye methylene blue was 
incorporated.  The mesoporous silica was then coated with a lipid bilayer consisting of 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC).  They observed full release of the dye 
after AMF exposure at 50 Hz for 350 minutes.  These reports encouraged us to think that 
AMF application might be used to induce Dox release in our CML system.  However 
several toxicity trials failed to show a difference in cell survival for treatment conditions 
that incorporated AMF exposure.  The studies mentioned previously differ from our 
system in that the AMF frequency used was lower than our own, which is fixed by the size 
of the coil on our generator.  Additionally, both involve structures that contain multiple 
NPs.  We theorize that these factors may have lessened the impact of AMF exposure on 




4.4.  Gene transfection studies 
As noted in the opening of this chapter, cationic lipids are commonly utilized as 
synthetic gene vectors owing to their ability to condense nucleic acids and form cationic 
lipoplexes that are rapidly taken up by cells through endocytosis.  Given the similar but 
distinct structures of the oxime ether lipids prepared for the CML study as compared to 
those that had previously proven141 to be efficient transfection agents (Figure 4.12), we 
chose to examine these novel compounds for their potential for nucleic acid delivery.  We 
were especially interested to see the effect that the 1,2 diol component of lipids 2 and 3 
might have on transfection efficiency, as recent reviews of structure-activity relationships 
in cationic lipids had cited enhanced transfection for lipids with hydroxylated 
headgroups.146, 159   
 
 
Figure 4.12. First generation oxime ether lipids for gene transfection 
 
In work done by collaborators at the National Cancer Institute, lipids 2 and 3 were 






DNA/RNA binding efficiency, transfection efficiency, cell viability, and RNA release.  In this 
section, the results related to lipids 2 and 3 are featured.   
 
4.4.1.  Binding affinity 
Liposomes were formed from each lipid in combination with a zwitterionic co-lipid 
(DOPE) and the binding affinity of the liposomes for a fluorescently tagged hybrid 
DNA/RNA was studied by fluorescence anisotropy, a technique that measures changes in 
polarization/tumbling time.  In this assay, lipids 2 and 3 were shown to bind nucleic acids 
as efficiently as or more so than the first generation lipids (Figure 4.13).  
 
Figure 4.13. Binding affinity of liposomes at different concentrations (1-40 





4.4.2.  Transfection efficiency 
The transfection efficiency of the lipids was then assessed using the fluorescently 
labeled hybrid RNA/DNA in MDA-MB-231 breast cancer cells.  The results, depicted in 
Figure 4.14, show a concentration dependence, where lipid 2 showed the highest 
transfection efficiency at lower doses and lipid 3 showed the highest efficiency at higher 
doses.  In either case, the hydroxylated lipids performed well in comparison to their first 
generation analogs.   
 
 
Figure 4.14. Transfection efficiency of oxime ether lipids with Alexa 488-




4.4.3  Cell viability 
Cell viability was assessed 24 hours after treatment of MDA-MB-231 cells with 
liposomes of each lipid by fluorescence of CellTitre blue reagent, a dye (resazurin) which 
becomes fluorescent by enzymatic conversion to resorufin in live cells.  None of the lipids 
elicited significant reduction in viability as shown in Figure 4.15. 
 
 
Figure 4.15. Viablilty of MDA-MB-231 cells with liposome/RNA complexes 
by CellTitre blue assay 
 
4.4.4.  Gene expression 
Gene silencing was used to assess nucleic acid release and gene expression for 
cells transfected with lipoplexes of each lipid.  In this examination, MDA-MB-231 cells 
expressing green fluorescent protein (GFP) were prepared, along with lipoplexes of lipids 





























based upon the silencing of the fluorescent protein (Figure 4.16A).  Lipids 2 and 3 
demonstrated silencing of the GFP gene indicating release of dicer RNA.  In this regard, 
lipid 3 bested the other analogs.  Figure 4.16B shows the reduction in green fluorescence 
for the lipoplex of lipid 3. 
 
Figure 4.16. (a) Silencing of GFP by lipoplexes of lipids with DS RNA (b) 
Fluorescent microscope images of MDA-MB-231/GFP cells showing 









The results of the transfection studies indicated that the hydroxylated cationic 
oxime ether lipids are promising candidates for non-viral nucleic acid delivery.  In our 
examination of the relationship between lipid structure and siRNA transfer efficacy, some 
trends emerged.  Polar domain hydroxylation had the greatest influence on binding and 
release properties, where hydroxylated lipids 2 and 3 outperformed their non-
hydroxylated counterparts both in regard to tighter binding, based on fluorescence 
anisotropy measurements, as well as in nucleic acid release on cellular internalization, as 
indicated by GFP silencing.  Whereas tight lipid complexation with nucleic acids is 
desirable for protection against enzymatic degradation, the nucleic acid phosphate–lipid 
ammonium interactions160 in concert with hydrophobic domain packing and any polar 
domain hydrogen bonding interactions must be readily overcome for later stage lipoplex 
disassembly to occur. In this regard, the hydroxylated lipids appear well-structured for 
effective siRNA protection and release.  Hydrophobic domain dissymmetry has been 
suggested as a structural factor that is beneficial for nucleic acid release, thus ultimately 
enhancing transfection activity.161-162  All of the lipids in these studies were used as a 
mixture of (E,E)- and (E,Z)-oxime ether isomers, meaning a nontrivial amount of non-
symmetric (E,Z)-lipid was present.  Non-symmetric hydrophobic domains likely benefit 
transfection due to better DNA release through looser lipid packing in the lipoplex 
formulation.163-164  
Lipoplex uptake and activity also was facilitated by lipid hydroxylation, and this 
observation agrees well with the assessment of a recent review146 citing greater 
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transfection efficiencies for lipids possessing hydroxylated headgroups.  This effect is 
thought to be mediated by the decrease in headgroup hydration that results from the 
incorporation of functionality capable of hydrogen bonding.  Neighboring lipid-lipid 
interactions in the lipoplex bilayers lead to exclusion of interstitial water, and the resulting 
high positive charge/low hydration motif promotes electrostatic interactions not only 
with the polynucleotide but also with cell membranes.165   
Lipid 3 was arguably the frontrunner in these studies where the unsaturation in 
the hydrophobic domain appeared to enhance gene expression.  Recent findings may 
explain this behavior; unsaturated lipids are thought to fluidize endosomal bilayers, 
facilitating lipoplex escape and have also been correlated with better nuclear 
localization.159   
 
4.5.  Conclusions 
Novel oxime either lipids were synthesized with the aim of optimizing their ability 
to self-assemble into bilayers surrounding silica-coated magnetic NPs.  The resultant 
cationic magnetoliposomes were assessed for their ability to function in vitro as drug 
carriers in a preliminary study with Dox and a modified amphiphilic analog.  Association 
of the drugs with the CML increased the potency of the nanoassembly over that of the 
free drug.  The preparation of the CML-drug complex was accomplished by simple mixing 
of SNPs (room temp., H2O, neutral pH) with small quantities of lipid and drug: 0.3-0.4 mg 
lipid + .085-0.12 mg anthracycline per mg SNP.  The CML-drug formulations showed high 
toxicity to MCF-7 cancer cells after 2 hours exposure to doses of 50 µg SNP/>50,000 cells 
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(3.6 µM with respect to the anthracycline).  The CML-drug formulations functioned 
effectively in the presence of serum-supplemented cell growth medium.  These results 
point to the potential for cationic magnetoliposomes built on Fe3O4-SiO2 nanoparticles as 
magnetic drug delivery vehicles, thus providing opportunity for use of the tandem 
techniques of magnetic targeting, imaging, and inductive heating.  Further, in vitro 
assessment of the transfection activity of hydroxylated oxime ether lipids and a 
comparison with similar lipids of that class highlighted their distinctive efficacy as gene 
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5.1. General Procedures 
Reagents were typically purchased from Aldrich Chemical Company (Milwaukee, 
WI).  Reagent grade ACS dichloromethane, tetrahydrofuran (THF), acetone, hexanes, 
ethyl acetate (EtOAc), and diethyl ether were purchased from Pharmco-AAPER 
(Shelbyville, Ky).  THF and CH2Cl2 were purified, when indicated, using a SPBT-101 Bench 
Top Solvent Purification System (LC Technology Solutions, Inc., Salisbury, MA). CDCl3 
(99.8%) was purchased from Cambridge Isotope Laboratories (Andover, MA).   NMR 
spectra were acquired on a Varian Inova 500 MHz or Varian 400 MHz spectrometer, as 
indicated.  Spectra were referenced to the residual solvent peaks according to Gottlieb et 
al.166  FTIR spectra were acquired on a Perkin Elmer Spectrum 100 FT-IR Spectrometer 
(diamond crystal) with range: 4000-650 cm-1, resolution: 4 cm-1, interval: 1 cm-1, and 
scans: 4. Solid samples were scanned using an ATR attachment, liquid samples were 
scanned neat or after being dissolved in CH2Cl2, placing a droplet onto the crystal, and 
allowing the solvent to evaporate.  Alternatively, DRIFT IR spectra were acquired on a 
Mattson galaxy series 5000 DRIFT spectrometer using 64 scans, at a scan speed of 2.1 kHz 
and a resolution of 4ν.  DRIFT samples were prepared as a loose powder in KBr.  High 
resolution mass spectra were acquired on a Finnigan LTQ- FT spectrometer (Thermo 
Electron Corp).  MALDI-TOF-MS detection was done on a Voyager DE-Pro MALDI-TOF 
instrument (PE Biosystems) using 2,5-dihydroxybenzoic acid (2,5-DHB) matrix.  Melting 
points were determined using a Fisher-Johns melting point apparatus or an SRS Digimelt.  
Heating of cell extract samples was done on a Barnstead/Thermolyne Type 17600 Dri-
bath.  Centrifugation was performed on an Eppendorf Centrifuge type 5415R; vacuum 
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centrifugation was performed on an Eppendorf Vacufuge.  Reaction progress was 
monitored by thin layer chromatography (silica gel 60 Å F-254 plates) using UV 
visualization and staining with ninhydrin, phosphomolybdic acid, or p-anisaldehyde 
solutions.  Column chromatography was performed using silica gel (230-400 mesh) or by 
using a Teledyne Isco combiflash system.  Cell microscopy was done on an EVOS FL Cell 
Imaging System (Advanced Microscopy Group, WA).  Dynamic light scattering and ζ–
potential measurements were acquired on a Brookhaven ZetaPALS Zeta Potential 
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5.2 Experimental Procedures for Chapter 2 
5.2.1 Syntheses of reagents and intermediates 
 
N-Hydroxyethyl-N,N-dimethyl-octylammonium iodide (2.1)   
Following a previously reported protocol,167 a solution of N, N-
dimethylethanolamine (0.50 mL, 4.98 mmol) and iodooctane (0.099 mL, 5.47 mmol) in 
acetone (15 mL) were heated to reflux.  After 30h, the reaction was cooled to room 
temperature and dried by rotary evaporation.  To the resultant yellow solid, hexanes were 
added (6mL) and the solution was triturated with sonication until the solid dispersed.  
Buchner filtration of the suspension followed by vacuum drying of the collected solids 
yielded 2.1 (1.77 g, 92%) as white crystals; mp 76-78 °C; 1H-NMR (500 MHz, CDCl3) δ 0.82 
(t, J = 6.7 H, 3H); 1.24 (m, 10H); 1.73 (m, 2H); 3.32 (s, 6H); 3.52 (m, 2H); 3.71 (m, 2H); 4.08 
(m, 3H); 13C NMR (125 MHz, CDCl3) 11C δ 14.1, 22.5, 22.9, 26.2, 29.0, 29.1, 31.6, 52.4; 
55.5, 65.5, 66.2.  IR 3277, 2952, 2920, 2853, 1483, 1464, 1410, 1104, 1073, 1006, 968, 





N-Aminooxyethyl-N,N-dimethyl-octylammonium iodide (QOA) 
To a solution of alcohol 2.1 (1.50 g, 4.55 mmol), N-hydroxyphthalimide ( 0.817g, 
5.01 mmol) triphenylphosphine (1.31 g, 5.00 mmol) in THF (15 mL) at rt was added 
diisopropyl azodicarboxylate (DIAD) (0.993 mL, 5.01 mmol).  After stirring 12h at room 
temperature, the solvents were removed by rotary evaporation.  To the crude yellow 
residue was added ethyl acetate (7.0 mL).  The resultant suspension of white solids was 
filtered, and the retentate (phthalimide intermediate) was used directly in the next step. 
1H NMR (500 MHz, CDCl3) δ 0.85 (t, J = 6.5 Hz, 3H); 1.32 (m, 10H); 1.85 (m, 2H); 3.57 (s, 
6H); 3.78 (m, 2H); 4.37 (m, 2H); 4.74 (m, 2H); 7.80 (m, 2H); 7.85 (m, 2H). 
To the phthalimide protected salt (1.88 g, 3.96 mmol) in CH2Cl2 was added 
hydrazine monohydrate (0.59 g, 11.9 mmol) and the mixture was stirred at rt for 2h.  
Collection of the CH2Cl2 filtrate followed by drying yielded QOA·I (1.26 gm, 93%) as a white 
powder;  mp 55.5-58.6 °C. 1H NMR (500 MHz, CDCl3) δ 0.80 (t, J = 6.5 Hz, 3H); 1.24 (m, 
10H); 1.69 (m, 2H); 3.33 (s, 6H); 3.51(m, 2H); 3.84 (m, 2H); 4.12 (m, 2H); 4.95 (bs, 2H -NH2-
).  Key 1H-1H COSI correlations: δ 4.12-3.84 (C(1’)H2-C(2’)H2 ); 3.51-1.69 (C(1)H2 – C(2)H2). 
13C NMR (125 MHz, CDCl3) 11C δ 14.0, 52.2; 22.5, 22.9, 26.2, 28.9, 29.1, 31.6, 62.5, 65.8, 
69.0.  IR: 3273, 3029, 2927, 2855, 1472, 1172, 954 ν(O-N), 858, 495 cm-1.  HRMS m/z calcd 





Dodecyl(2-hydroxyethyl)dimethylazanium bromide (2.3) 
A solution of N,N-dimethylethanolamine (0.5 mL, 4.97 mmol) and 1-
bromododecane (1.31 mL, 5.47 mmol) in acetone (25 mL) were heated to reflux,  After 
24h, the reaction was cooled to rt and the precipitated solids were collected by filtration, 
washed with chilled acetone and dried under vacuum.  The reaction filtrate was dried 
under rotary evaporation and to the resulting yellow residue hexane was added.  
Trituration with sonication of the hexane produced a white precipitate which was 
collected by filtration and combined with the precipitate from acetone to afford 2.3 
(0.977 gm, 58 %) as white crystals; mp (decomp) 190 °C.  1H NMR (500 MHz, CDCl3), δ 0.87 
(t, J = 6.75 Hz, 3H);1.25 (m, 18H); 1.75 (m, 2H); 3.37 (s, 6H); 3.54 (m, 2H); 3.75 (m, 2H); 
4.15 (m, 2H); 4.99 (t, J = 5.5 Hz, 1H).  13C-NMR (125 MHz, CDCl3) δ 15C δ 14.1; 22.6; 22.9; 
26.2; 29.2; 29.3; 29.4; 29.5; 29.6 (2 signals); 31.8; 52.0, 55.9, 65.4, 66.1.  IR: 3248, 3006, 
2952, 2917, 2850, 1475, 1421, 1375, 1078, 1073, 1055, 1016, 965, 918, 900, 730, 718, 





N-Aminooxyethyl-N,N-dimethyl-dodecylammonium bromide (QDA·Br) 
To a solution of alcohol 2.3 (0.699 g, 2.06 mmol), N-hydroxyphthalimide (0.371 g 
2.27 mmol), triphenylphosphine (0.596 g, 2.27 mmol) in CH2Cl2 (10 mL) at rt was added 
DIAD (0.45 mL, 2.27 mmol).  After stirring for 15h at rt, the solvents were removed by 
rotary evaporation.  To the crude yellow residue was added ethyl acetate (20 mL).  The 
resultant suspension of white solids was filtered, and the retentate (phthalimide 
intermediate) was used directly in the next step.  1H-NMR (500 MHz, CDCl3) δ 0.86 (t, J = 
6.7 Hz, 3H); 1.30 (m, 18H); 1.83 (m, 2H); 3.56 (s, 6H -N(Me)2-); 3.76 (m, 2H); 4.41 (m, 2H); 
4.74 (m, 2H); 7.82 (m, 2H); 7.84 (m, 2H). 
To the phthalimide protected salt (1.93 g, 3.98 mmol) in anhydrous ethanol was 
added hydrazine monohydrate (1.24 g, 24.7 mmol).  The reaction was stirred for 6hr at 
50°C.  The ethanol was then removed by rotary evaporation and CH2Cl2 was added (17 
mL).  The resulting white precipitate was filtered over a Buchner funnel and washed with 
CH2Cl2.  The CH2Cl2 filtrate was dried by rotary evaporation.  To the resultant off-white 
residue toluene was added (30 mL), heating and sonication yielded a suspension of fine 
white particles which were collected over a glass Buchner funnel.  This afforded QDA∙Br 
as a white powder; mp (decomp) 187 °C.  1H-NMR (500 MHz, CDCl3) δ 0.84 (t (J = 6.7 Hz), 
3H); 1.27 (m, 18H); 1.70 (m 2H); 3.36 (s, 6H); 3.54 (m, 2H); 3.94 (m, 2H); 4.17 (m, 2H); 5.30 
(bs, 2H).  13C-NMR (125 MHz, CDCl3) 15C δ 14.1; 22.1 (2 signals); 22.7; 22.9; 26.3; 29.2; 
29.3; 29.5; 29.6; 31.9; 51.8, 62.2, 65.6. IR: 3280, 2921, 2848, 1653, 1576, 1472, 1173, 
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A solution of 2-(methylamino)ethanol (1.37 mL, 17.0 mmol), 1-bromododecane 
(4.08 mL, 17.0 mmol), and anhydrous sodium carbonate (1.93 g, 17.0 mmol) in anhydrous 
ethanol (34 mL) was heated to reflux.  After 20h, the reaction suspension was cooled to 
room temperature and the precipitated solids were removed by filtration.  The filtrate 
was concentrated to one-third volume by rotary evaporation and then transferred to a 
centrifuge vial and centrifuged to pellet precipitated solids.  The supernatant was 
collected and evaporated by rotary evaporation.  Bulb-to-bulb distillation (Kugelrohr, 190 
°C, ca. -0.986 atm) of the crude residue afforded 2.6 (2.91 g, 70%) as a clear liquid.  
Spectral characterization of 2.6 gave values identical to those reported.168 1H NMR (500 
MHz, CDCl3) δ 0.88 (t, J = 6.0 Hz, 3H); 1.25 (m, 18H); 1.45 (m, 2H), 2.22 (s, 3H); 2.38 (t, J = 






To a solution of 2.6 (2.91 g, 11.9 mmol) in THF (50 mL) at 0 °C were added N-
hydroxyphthalamide (2.14 g, 13.1 mmol), PPh3 (3.44 g, 13.1 mmol) and DIAD (2.6 mL, 13.1 
mmol).  The reaction mixture was warmed to rt and stirred 12h before removing the 
solvents by rotary evaporation.  To the yellow residue was added hexane (60 mL) and the 
resultant suspension was triturated and sonicated (rt bath, 30 sec intervals).  The 
resultant fine solids were removed by filtration, and the filtrate was removed by rotary 
evaporation to afford crude 2.7 as an orange solid.  The crude product was dissolved in 
ethyl acetate (50 mL) and the solution was washed with saturated NaHCO3 (3X).  The 
organic layer was dried (Na2SO4) and then evaporated by rotary evaporation to yield 2.7 
(4.53 g, 98%) as a yellow, low melting semi-solid (38.7-40.1 °C); 1H NMR (500 MHz, CDCl3) 
δ 0.87 (t, J = 7.0 Hz, 3H); 1.24 (m, 18H); 1.41 (m, 2H); 2.29 (s, 3H); 2.39 (t, J = 7.8 Hz, 2H); 
2.83 (t, J = 5.5 Hz, 2H); 4.32 (t, J = 5.5 Hz, 2H); 7.74 (m, 2H); 7.83 (m, 2H).  13C-NMR (125 
MHz, CDCl3) δ 14.1; 21.9; 22.6; 26.9; 27.4; 29.3; 29.5-29.6 (m); 31.9; 42.1; 55.4; 57.8; 75.6; 





N-[2-(Aminooxy)ethyl]-N, N-dimethyl-1-dodecylammonium iodide (QDA) 
A glass pressure tube was charged with 2.7 (0.10 g, 1.79 mmol), dry CH2Cl2 (5 mL) 
and iodomethane (1.53 g, 10.8 mmol).  The tube was sealed and then immersed in an oil 
bath heated to 50 °C.  After 12h, the reaction was cooled to rt.  The tube was opened and 
the solvent was evaporated in a fume hood using a steady nitrogen stream.  The resulting 
off-white solid 2.8 was used directly in the next step.  1H NMR (500 MHz, CDCl3) δ 0.85 (t, 
J = 7.0 Hz, 3H); 1.24 (m, 16H); 1.36 (m, 2H); 1.84 (m, 2H); 3.56 (s, 6H); 3.77 (m, 2H); 4.37 
(t, J = 4.3 Hz, 2H); 4.75 (t, J = 4.0 Hz, 2H); 7.80 (m, 2H); 7.85 (m, 2H). 
To a solution of 2.8 (0.90 g, 1.70 mmol) in anhydrous ethanol (9 mL) was added 
hydrazine monohydrate (0.43 g 8.49 mmol).  The reaction mixture was stirred at rt for 
12h whereupon the solvent was removed by rotary evaporation.  To the residue was 
added CH2Cl2 (20 mL) and the resultant suspension was filtered.  The filtrate was 
concentrated by rotary evaporation and toluene (15 mL) was added.  The mixture was 
triturated with sonication (rt bath, 30 sec intervals) and the solids were collected and 
dried (vacuum) to afford QDA (0.45 g, 65%); mp 85.9-88.9 °C; 1H-NMR (500 MHz, CDCl3) 
δ 0.87 (t, J = 7.0 Hz, 3H); 1.20-1.43 (m, 18H); 1.75 (m, 2H); 3.42 (s, 6H); 3.58 (m, 2H); 3.96 
(t, J = 4.5 Hz, 2H); 4.16 (m, 2H); 6.85 (br. s, 2H); 13C NMR (125 MHz, CDCl3) δ 14.1; 22.6; 
22.9; 26.2; 29.2; 29.3; 29.35; 29.4; 29.6 (2 signals); 31.9; 52.1; 62.4; 66.0; 68.9; IR (DRIFT, 
KBr powder) 3270, 2917, 2848, 1468, 1172, 956, 900 cm-1; HRMS  m/z calcd [C16H37N2O]+ 






Using the procedure described for synthesis of QDA, amine 2.7 (0.50 g, 1.29 mmol) 
was reacted with 13CD3I (0.47 g, 3.21 mmol) and hydrazine monohydrate (0.302g, 
6.02mmol) to give *QDA (0.37 g, 75%) as a white powder; mp 86.6-87.5 °C; 1H NMR (500 
MHz, CDCl3) δ 0.86 (t, J = 7.0 Hz, 3H); 1.14-1.43 (m, 16H); 1.74 (m, 2H); 3.41 (d, J = 3.5 Hz, 
3H); 3.58 (m, 2H); 3.92 (m, 2H); 4.16 (m, 2H); 5.91 (br s); 13C NMR (125 MHz, CDCl3) δ 14.3; 
22.8; 23.1; 26.4; 29.4; 29.5; 29.6; 29.7; 29.8 (2 signals); 32.1; 51.6 (m); 52.2; 62.6; 66.0; 
69.2; IR (DRIFT, KBr powder) 3278, 2913, 2850, 1468, 1173, 1048, 947 ν(O-N), 720, 482, 




5.2.2 Mass spectrometry methods 
Samples were analyzed on a hybrid linear ion trap (LIT) FT-ICR mass spectrometer 
(LTQ-FT, Thermo Electron, Bremen, Germany) equipped with a TriVersa NanoMate ion 
source (Advion BioSciences, Ithaca, NY) with an “A” electrospray chip (nozzle inner 
diameter 5.5 µm). The TriVersa NanoMate was operated in positive ion mode by applying 
1.85 kV with 0.1 psi head pressure. MS runs were recorded over a mass range from 150 
to 1200 Da. Initially, low resolution LIT-MS scans were acquired for 0.75 minute to track 
the stability of the ion spray, after which high mass accuracy data were collected using 
the FT-ICR analyzer where MS scans were acquired for 8 min.  The AGC (automatic gain 
control) maximum ion time was set to 10 ms and 500 ms for the LIT and ICR operations, 
respectively, using default ion count targets for both and 5 “microscans” (ICR transients) 
were accumulated before Fourier transformation to produce each saved spectrum; thus 
the cycle time for each transformed, saved spectrum was about 5 s, the exact timing of 
which varied slightly with the AGC operations for each. The LTQ-FT was tuned and 
calibrated according to the manufacturer’s default standard recommendations, which 
typically achieved better than 0.2 ppm mass accuracy at 400,000 resolving power (m/z = 
400). 
FT-ICR mass spectra were exported as exact mass lists into a spreadsheet file using 
QualBrowser 2.0 SR2 (Thermo Electron, “Bremen” version for the LTQ-FT) by exporting all 
of the recorded peaks so that s/n decisions can be made in downstream data processing.  
QDA/*QDA adducts were assigned based on their accurate mass by using an in-house 
software tool PREMISE (PRecaculated Exact Mass Isotopologue Search Engine)11 which 
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was also manually validated. PREMISE is a simple algorithm that corrects small mass 
errors based on a selectable known peak (such as internal standard, or a known analyte), 
then matches observed with theoretical m/z values within a selectable window that is 
typically set to 0.0008 Da or smaller.  The theoretical m/z values of a large number of 
QDA-metabolite adducts were calculated and compiled in a reference table for the 
PREMISE assignment. 
 
5.2.3 Extraction solvent determination, counterion comparison, and partition efficiency 
One of three aminooxy reagents (QOA, QDA or *QDA) 9 µM was added to a 
mixture of aldehyde/ketone standards (pyruvate, α-ketoglutarate, α-ketobutyrate, and 
glucose, 2 µM each) in 5 mmM pH 6 NH4OAc buffer in microcentrifuge tubes.  The 
mixtures were sonicated 2h at rt and placed in a dribath at 40 °C for 12h.  The aqueous 
mixtures were then subjected to 5 equal volume extractions with either CHCl3, EtOAc, or 
n-butanol; each extraction was separately retained.  The organic extractions were dried 
by vacuum centrifugation.  The resultant residues were dissolved in MeOH with 0.1% 
formic acid and were detected by FT-ICR-MS after addition of a 200 nM standard (QOA-
acetone-d6 adduct) for normalization purposes.  Ion counts were normalized to the 





5.2.4 Verification of linear instrument response 
As the automatic gain control of the FT-ICR-MS prevents the use of simple serial 
dilution of standards for signal intensity comparisons, the feature can be compensated 
for by adding a known standard at high concentration to all samples.  A mixture of *QDA 
standard adducts (pyruvate, α-ketoglutarate, α-ketobutyrate, and glucose) were 
prepared in methanol and diluted to concentrations ranging from 25 µM-25 pM.  QOA-
acetone-d6 adduct (100 µM) was added as a standard for normalization and for use as a 
compensation for automatic gain control. 
 
5.2.5 Cell culture and extract preparation 
Human lung adenocarcinoma A549 cells were grown in 10-cm plates with 8 mL 
RPMI 1640 medium (Sigma) supplemented with 2 mM glutamine, 0.2% glucose, 10% fetal 
bovine serum, 100 U/mL penicillin, and 0.1 mg/mL streptomycin at 37°C, 5% CO2 and 95% 
humidity. When cells became 70% confluent, the medium was removed, and the cells 
were washed three times on ice each with 5 ml cold 1X PBS (phosphate buffered saline) 
to remove medium components.  1 ml of cold acetonitrile (-20 °C) was added to quench 
metabolism. Then, 0.75 mL of nanopure water was added before cells were scraped and 
collected into a 15 mL polypropylene conical centrifuge tube (Sarstedt, Newton, NC) 
containing three 3 mm diameter glass beads. These steps were then repeated to collect 
any remaining cells. Next, 1 mL HPLC-grade chloroform (Fisher Scientific) was added to 
the centrifuge tube containing the cell lysate.  Extraction of polar metabolites via solvent 
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partitioning was performed as described previously.169  The aqueous extract was 
lyophilized and stored at -80 °C prior to analysis.  
 
5.2.6 Cell extract derivatization 
50 μL of a 1:1 mixture of 100 μM QDA and *QDA as solutions in nanopure water 
was added to a 1.5 mL microcentrifuge tube containing the aqueous extract of 
approximately one quarter of a 10 cm cell plate in 50 μL of 10 mM pH 6 NH4OAc buffer.  
The tube was briefly vortexed, sonicated for 1 hr and placed in a 40 °C dry bath for 23 
hours.  Following reaction, the aqueous layer was extracted with n-butanol three times, 
and dried by vacuum centrifugation.  The residue was dissolved in methanol with 0.1% 
v/v formic acid and analyzed by FT-ICR-MS as a 1:1 mixture with an external standard of 
2 μM QOA-acetone-d6 adduct.  For each experiment, three replicate samples were made.  
A buffer blank consisting of 50 μL 10 mM pH 6 NH4OAc buffer and 50 μL of the QDA/*QDA 




5.2.7 Data analysis and statistics 
Each sample was acquired for nine minutes on FT-ICR-MS and the resultant 
spectra were averaged over all saved scans.  Next, all peaks of a single (representative) 
acquisition were exported to excel.  Any peaks with ion counts less than 1000 were 
deleted in order to eliminate noise, which typically appeared to be values around 200 
counts or below.  A theoretical “+4” m/z list was created by adding 4.02188 to all of the 
parent peaks.  PREMISE software was then used to find matches between the original 
data and the +4 peak-list with an error range of 0.0009 m/z.  This simplified list was then 
crosschecked manually against the negative control peak-list and any duplicate masses 
were deleted, except in cases where the intensity was significantly higher in the sample 
than the negative control (>80%).  Where multiple +4 peaks were matched, the peaks 
with ion counts most closely matching the parent (n) peak were retained.  Finally, any 




5.2.8 Estimation of cellular suppression factor and quantification of pyruvate  
For an estimate of the “ion suppression” (loss of signal intensity) factor in cellular 
extracts, the ion counts of the parent ions (protonated) of QDA-pyruvate and QDA-13C3-
pyruvate were normalized by dividing by the ion counts of the external standard *QDA-
pyruvate which was added at the same concentration to every sample.  The normalized 
ion counts of QDA-13C3-pyruvate were then plotted against the known concentrations of 
2.5, 5, and 7.5 µM in buffer conditions, and cell extract conditions, along with linear 
regressions.  The quotient of the slopes of the two linear regressions gives a cellular 
extract ion suppression factor of 4.97.   
The concentration of endogenous pyruvate was calculated using the standard 
curve established by the internal standard QDA-13C3 pyruvate.  Specifically, the 
normalized ion counts for QDA-pyruvate were averaged across three nine-minute FT-ICR-
MS acquisitions, then over three replicate samples.  Normalized ion counts of QDA-
pyruvate from the blank (QDA added to buffer alone) were subtracted.  This value was 
then entered as the y value into the linear regression equation of Figure 2.10 and the μM 
concentration was calculated.  This concentration indicated the amount of pyruvate (plus 
mass isomers) partitioned into the aqueous extract of 1/8th of a 70% confluent 10 cm well 
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5.3 Experimental Procedures for Chapter 3 
5.3.1 Preparation of iron oxide NPs 
180 mL of 0.1 M NaOH (0.719 g, 18.0 mmol) in Millipore water was prepared and 
deoxygenated by bubbling with N2 for 1h.  5.29 mL of 0.4M iron III chloride (0.573 g, 2.12 
mmol) and 5 mL 0.2M iron II chloride (0.232 g, 1.17 mmol) were likewise prepared in 
deoxygenated Millipore water.  5ml each of the iron chloride solutions were combined 
and added dropwise to the aqueous base under rapid stirring.  After 30 min the NPs were 
magnetically sedimented and the supernatant was aspirated under positive N2 pressure.  
The precipitate was washed with 40 mL degassed Millipore water (“water wash 
condition”) and again magnetically separated for supernatant aspiration.  NPs were 
transferred in a minimal amount of Millipore water to vials and freeze dried (0.2417 g, 
89%). 
For “acid washed” condition, NPs were prepared as above with the addition of 4X 
40 mL washes with Millipore water followed by 1X 40 mL wash with 0.01M aqueous HCl.  
For “multiple water wash” condition, NPs were simply washed 4X with 40 mL Millipore 
water. 
 
5.3.2 Quantification of Fe2+ and total Fe for determination of NP composition 
As outlined by Amonette and Templeton,105 the assay of Fe II and total Fe in iron 
oxide nanoparticles samples was accomplished by dissolving 1) 25 mg of “water washed” 
particles or 2) 27mg of “acid washed” particles in a preheated acid matrix consisting of 
10% sulfuric acid (12 mL), hydrofluoric acid (1 mL), and 10% 1,10 phenanthroline in 95% 
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ethanol (2 mL).  After boiling for 30 minutes, boric acid solution (5%, 10 mL)) and 
deionized water (90 mL) were added.  An aliquot of each sample was reduced with 1% 
NH2OH in 1% Na3-citrate (10 mL) to convert remaining Fe III to Fe II for a total Fe assay.  
Solutions were diluted in 1% Na3-citrate and absorbances were detected on a Beckman 
Coulter DU 800 spectrophotometer.  Absorbance at 510 nm was used to calculate total 
Fe and Fe II concentrations for each samples using equation 5 (ibid).  Fe III was determined 
by the difference of Fe II from total Fe concentrations. 
 
5.3.3 AMF heating properties 
Solutions of NPs with concentrations of 0.2, 1, 5, 25 mg/mL in Millipore water 
were prepared along with a control without NPs.  Alginate (Tica-algin 613 sodium alginate: 
sodium phosphate, and calcium sulfate) was added such that each solution contained 3% 
w/v alginate.  Each sample was exposed to AMF for 1h at 201.4A, 203 kHz while 
temperature measurements were made at 15 minute intervals with a fiber optic 




5.3.4 Syntheses of variably hydroxylated ammonium salts 
 
(2-hydroxyethyl)trimethylazanium iodide (1OH) 
N,N-dimethylethanolamine 4.99 mmols was added to a pressure vial as a 0.2 M 
solution in CH2Cl2 and cooled to 0° C.  Iodomethane was added (14.97 mmols) and the 
reaction was allowed to come to room temperature.  After 12 hours at room temp, the 
solution was filtered of the white precipitated product.  The precipitate was dried using a 
vacuum desiccator (1.61g, quantitative, mp. >260).  1H NMR (500 MHz, D2O) δ 3.21 (s, 9H, 
N(CH3)3); 3.54 (t, 2H, J = 5.00 Hz, C(1)H2); 4.08 (m, 2H, C(2)H2).  13C NMR (100 MHz, D2O) 
3C δ 53.8; 55.5; 67.3.  m/z calcd [C5H14NO]+ 104.10699, observed 104.10693. 
 
(2,3-dihydroxypropyl)trimethylazanium iodide (1,2 diol) 
3-(dimethylamino)-1,2-propanediol (1.0 g, 8.4 mmols) was added to a pressure 
vial as a 1M solution in CH2Cl2.  The vial was cooled to 0 °C and iodomethane (3.6 g, 25.2 
mmols) was added.  The sealed tube was capped and the reaction ran at room 
temperature for 10 hours with stirring.  Post reaction, a white precipitate was filtered 
from solution.  This retentate was rinsed with CH2Cl2 and dried (vacuum) affording the 1,2 
diol (2.077 g, 95%) as a white, crystalline solid, mp. 130.6-132.1°C.  1H NMR (400 MHz, 
D2O) δ 3.29 (s, 9H, N(CH3)3); 3.50 (m, 2H C(1)H, C(1)H’); 3.64 (m, 2H, C(3)H2); 4.35 (m, 1H, 
127 
 
C(2)H).  13C NMR (125 MHz, D2O) 4C δ 54.29; 63.74; 66.49; 68.30.  m/z calcd [C6H16NO2]+ 
134.117555, observed 134.11748. 
 
 
bis(2-hydroxyethyl)dimethylazanium iodide (2OH)  
N-methyl diethanolamine (1.0 g, 8.4 mmols) was added to a pressure vial as a 1M 
solution in CH2Cl2.  Iodomethane (5.9 g, 42.0 mmol) was added and the sealed tube was 
heated in an oil bath at 50°C for 10 hours with magnetic stirring.  Post reaction, the upper 
clear solution was decanted and the yellow oil was washed with CH2Cl2 (15 mL).  
Acetonitrile was used to dissolve the yellow oil, the solvent was removed by rotary 
evaporation and drying (vacuum) afforded 2OH as a hygroscopic orange solid, mp. 76.4-
78.9°C (2.55 g, 119%).  1H NMR (500 MHz, D2O) δ 3.25 (s, 6H, N(CH3)2); 3.62 (t, 4H, J = 5.00 
Hz, C(1)H2); 4.09 (m, 4H, C(2)H2).  13C NMR (100 MHz, D2O) 3C δ 52.2; 55.3; 66.9.  m/z 






tris(2-hydroxyethyl)(methyl)azanium iodide (3OH) 
Triethanolamine (1.0 g, 6.7 mmols) was added to a pressure vial as a 1M solution 
in CH2Cl2.  Iodomethane (2.85 g, 20.1 mmol) was added and the sealed tube was heated 
in an oil bath at 50°C for 6 hours with magnetic stirring.  Post reaction, the upper clear 
solution was decanted and the amber oil was washed with CH2Cl2 (8 mL).  Acetonitrile 
was used to dissolve the oil, the solvent was removed by rotary evaporation and drying 
(vacuum) afforded 3OH as an orange semisolid (2.55 g, 119%).   1H NMR (400 MHz, D2O) 
δ 3.28 (s, 3H, N(CH3)); 3.70 (t, 6H, J = 5.00 Hz, C(1)H2); 4.09 (m, 6H, C(2)H2).  13C NMR (100 
MHz, D2O) 3C δ 50.0; 55.1; 64.4.  m/z calcd [C7H18NO3]+ 164.12812, observed 164.12804. 
 
 
(2-hydroxyethyl)trimethylazanium chloride (1OH) 
A Dowex ion exchange resin (10g, 200-400 mesh, chloride form) was hydrated and 
packed in water; the eluent was then gradually switched to methanol.  The iodide form 
of 1OH (0.21g, 0.89 mmols) was passed through the resin using gravity elution with 
methanol.  The product, a white solid (0.143g, 115%), was verified as the chloride salt 
using the silver nitrate method as well as by mass spectrometry.  1H NMR (500 MHz, D2O) 
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δ 3.21 (s, 9H, N(CH3)3); 3.53 (t, 2H, J = 5.00 Hz, C(1)H2); 4.07 (m, 2H, C(2)H2).  13C NMR (125 
MHz, D2O) 3C δ 54.0; 55.7; 67.5.  m/z calcd [C5H14NO]+ 104.10699, observed 104.10693.  




(2,3-dihydroxypropyl)trimethylazanium chloride (1,2 diol) 
The iodo form of the 1,2 diol (0.21g, 0.79 mmols) was passed through an ion 
exchange resin prepared as above using gravity elution with methanol.  The product, a 
pale yellow semi-solid (0.142g, 106%), was verified as the chloride salt using mass 
spectrometry.  1H NMR (500 MHz, D2O) δ 3.24 (s, 9H, N(CH3)3); 3.46 (m, 2H C(1)H, C(1)H’); 
3.60 (d, 2H, J = 5.00 Hz, C(3)H2); 4.30 (m, 1H, C(2)H). 13C NMR (125 MHz, D2O) 4C δ 68.3; 
66.5; 63.7, 54.3. m/z calcd [C6H16NO2]+ 134.117555, observed 134.11748.  Dimer (chloride 





bis(2-hydroxyethyl)dimethylazanium chloride (2OH)  
The iodo form of 2OH (0.21g, 0.82 mmols) was passed through an ion exchange 
column prepared as above using gravity elution with methanol.  The product, a 
transparent solid (0.146g, 105%, 104 °C (d)), was verified as the chloride salt using mass 
spectrometry.  1H NMR (500 MHz, D2O) δ 3.23 (s, 6H, N(CH3)2); 3.60 (t, 4H, J = 5.00 Hz, 
C(1)H2); 4.08 (m, 4H, C(2)H2).  13C NMR (100 MHz, D2O) 3C δ 52.3; 55.5; 66.3.  m/z calcd 
[C6H16NO2]+ 134.117555, observed 134.11748.  Dimer (chloride counterion) m/z calcd 
303.203963, observed 303.20479, no iodide dimer observed. 
 
 
tris(2-hydroxyethyl)(methyl)azanium chloride (3OH) 
 
The iodo form of 3OH (0.21g, 0.72 mmols) was passed through an ion exchange 
column prepared as above using gravity elution with methanol.  The product, a 
transparent hygroscopic solid (0.148g, 104%), was verified as the chloride salt using mass 
spectrometry.  1H NMR (500 MHz, D2O) δ 3.26 (s, 3H, N(CH3)); 3.69 (t, 6H, J = 5.25 Hz, 
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C(1)H2); 4.08 (m, 6H, C(2)H2).  13C NMR (125 MHz, D2O) 3C δ 50.1; 55.3; 64.5.  m/z calcd 
[C7H18NO3]+ 164.12812, observed 164.12818.  Dimer (chloride counterion) m/z calcd 
363.225093, observed 363.22728, no iodide dimer observed. 
 
5.3.5 NP coating with variably hydroxylated ammonium salts  
3M solutions in methanol of each ammonium salt (or amine free base) were 
prepared and added to microcentrifuge tubes containing ≈10 mg NPs such that there 
were 10 mmol ammonium salt per g NP.  The microcentrifuge tubes were briefly vortexed 
and sonicated (rt, 1h) followed by rotating on an inverter at rt for 3h.  NPs were pelleted 
by centrifugation (16000 rcf, 20 min) and the supernatant was removed.  The NPs were 
then washed with water (3X 0.5 mL) with intervening pelleting by centrifugation.  The 
pellets were then freeze dried. 
  
5.3.6 Thermogravimetric analysis of NP-bound ammonium salts 
TGA was performed on a TA Instruments Hi-Res 2950 Thermogravimetric 
Analyzer.  Approximately 6 mg of each lyophilyzed NP sample was loaded into a platinum 
sample pan for analysis.  After an initial equilibration phase at 35 °C, the temperature was 




5.3.7 Synthesis of FITC-CHO 
 
To a solution of fluorescein isothiocyanate (80% isomer 1, 1.28 g, 3.28 mmol) in 
DMF (10 mL) was added 4-aminobutyraldehyde diethyl acetal (0.771 g, 3.94 mmol) via 
syringe.  The mixture was stirred 4h at rt.  The reaction solvent was diluted with 100 mL 
dilute aq. HCl (pH4) and extracted with diethyl ether (8X 100 mL).  The organic phase was 
dried over sodium sulfate and evaporated by rotary evaporation.  The product was passed 
through a silica gel plug (CH2Cl2:MeOH, 1:0-9:1) and was used in the next step without 
further purification. 
To the acetal was added 30% v/v aqueous acetic acid (150 mL) and stirred 15h at 
rt.  The solvent was removed as an azeotrope with toluene to yield FITC-CHO as an orange 
solid (0.550 g, 55% 2 steps).  1H NMR (400 MHz, dmso) major isomer δ = 10.11 (br s, 2H); 
8.12 (s, 1H); 7.84 (m, 1H); 7.26-7.12 (m, 2H); 6.66 (s, 2H); 6.58 (m, 4H); 5.76 (br s, 1H); 
3.78 (m, 1H); 3.61 (m, 2H); 2.30 (s, 1H); 2.09 (br, 2H); 1.89 (br, 2H).  HRMS m/z calcd 




5.3.8 Syntheses of aminooxy linkers 
 
2-[2-(dimethylamino)ethoxy]-2,3-dihydro-1H-isoindole-1,3-dione 
To a solution of triphenylphosphine (5.3 g, 20.2 mmol) and N-hydroxyphthalimide 
(3.29 g, 20.2 mmol) in anhydrous THF (50 mL) at 0 °C was added N,N dimethyl 
ethanolamine (1.50 g, 16.80 mmol).  After stirring 20 min, DIAD (4.08 g, 20.18 mmol) was 
added dropwise.  The reaction mixture was then allowed to warm to room temperature.  
After 12 h, the solvent was removed by rotary evaporation.  EtOAc (300 mL) was added 
to dissolve the residue and the organic phase was washed with saturated aq. NaHCO3 (3 
X 200 mL), and brine (3X 200 mL).  The EtOAc was dried (Na2SO4), and concentrated by 
rotary evaporation.  The residue was redissolved in EtOAc (250 mL) and extracted 3X with 
50 mL portions of 5% v/v aqueous HCl and washed with Et2O.  Saturated NaHCO3 was 
then added until the pH registered slightly basic and the aqueous phase was extracted 
with CHCl3 (3X 100 mL).  The CHCl3 was evaporated to yield a yellow solid (1.56 g, 40%).  






O-[2-(trimethylazaniumyl)ethyl]hydroxylamine iodide (QAO) 
To the phthalimide protected amine shown above (0.78 g, 3.33 mmol) in CH2Cl2 
(10 mL) in a pressure vial was added iodomethane (11.4 g, 79.7 mmol).  The reaction was 
sealed and heated at 50 °C for 12h.  After cooling, the solvent and excess iodomethane 
were evaporated under N2 stream in a fume hood.  The isolated white solids were used 
directly in the next step. 1H NMR (400 MHz, DMSO-d6) δ 7.90 (s, 4H); 4.67 (s, 2H); 3.79 (s, 
2H); 3.23 (s, 9H). 
To the iodo salt (1.46 g, 5.77 mmol) in ethanol (20 mL) was added hydrazine 
monohydrate (0.92 g, 17.8 mmol).  The reaction was stirred 4h at rt and the solvent was 
removed by rotary evaporation.  The resultant residue was triturated in hot acetonitrile, 
filtered, and the filtrated was evaporated to yield a yellow amorphous solid (QAO).  1H 





   
[2-(aminooxy)ethyl](2-hydroxyethyl)dimethylazanium iodide (QAO-1OH) 
QAO-1OH was prepared by my colleague, Dr. Xuan Huang as reported in Tetrahedron 




Synthesis of 3.1 
To a solution of triethanolamine (56.7 g, 380.0 mmol) and triethylamine (38.4 g, 
380.0 mmol) at 0 °C, a solution of tert-butyldimethylsilyl chloride (68.7 g, 455.9 mmol) in 
CH2Cl2 (40 mL) was added via cannula. The reaction mixture was stirred 1h at 0 °C then 
was allowed to warm to rt. After 12h the reaction solvent was removed by rotary 
evaporation.  The crude residue was purified by flash chromatography using 2:1 
hexanes:ethyl acetate as eluant.  The product was a clear oil (12.7g, 13%).  1H NMR (CDcl3, 





Synthesis of 3.2 
To a solution of triphenylphosphine (3.055 g, 11.649 mmol) and N-
hydroxyphthalimide (1.90 g, 11.65 mmol) in anhydrous THF (50 mL) at 0 °C was added 
dropwise the bis- t-butylated amine 3.1 (4.0 g, 10.59 mmol).  After stirring 30 min, 
diisopropyl azodicarboxylate (DIAD) (2.3 g, 11.6 mmol) was added dropwise via syringe.  
The reaction mixture was then allowed to warm to room temperature.  After 12h, the 
solvent was removed by rotary evaporation.  Diethyl ether (150 mL) was added to dissolve 
the orange residue and the organic phase was washed with successive washings of 
saturated aq. NaHCO3 (3 X 100 mL), and brine (100 mL).  The ether was dried (Na2SO4), 
filtered, and concentrated to a viscous yellow-orange semisolid by rotary evaporation.  
The product was purified by silica gel chromatography eluting in 4:1 CH2Cl2/EtOAc.  Rf 
0.59 in 2:1 hexanes:EtOAc.  The product is a yellow oil (4.5 g, 81%).  1H NMR (CDCl3, 400 
MHz)  7.83 (m, 2H), 7.74 (m, 2H), 4.27 (t, J = 6.0 Hz, 2H), 3.67 (t, J = 6.4 Hz, 4H) 3.06 (t, J 





Synthesis of 3.3 
The phthalimide protected amine 3.2 (4.5 g, 8.5 mmol) was dissolved in anhydrous 
CH2Cl2 (20 mL) and placed in a pressure vial.  Iodomethane (6.1 g, 42.8 mmol) was added 
dropwise.  The vial was sealed and warmed to 50 °C.  After 5 h, the vial was cooled, 
opened, and the solvent was evaporated under reduced pressure in a fume hood to afford 
the crude ammonium iodide 3.3 as a light yellow solid (5.3 g, 92%) which was used directly 
in the next step.  1H NMR (CDcl3, 400 MHz)  7.82 (m, 4H), 4.73 (m, 2H), 4.41 (m, 2H), 4.15 
(m, 8H) 3.64 (s, 3H); 0.88 (s, 18H), 0.11 (s, 12H). 
The crude iodo salt 3.3 (15.2 g, 22.8 mmol) was dissolved in 95% EtOH (115 mL).  
Hydrazine monohydrate (4.6 g, 91.3 mmol) was added.  The reaction mixture was stirred 
24h at room temperature.  The solvent was removed by rotary evaporation and the 
residue was dissolved in CH2Cl2 (10 mL).  The white precipitate was filtered over a Buchner 
funnel and the CH2Cl2 filtrate was condensed by rotary evaporation.  A pale yellow solid 
was isolated (12.0 g, 98%, Rf 0.61in 9:1 MeOH/CH2Cl2).  1H NMR (CDCl3, 400 MHz) δ 5.90 
(bs, 2H), 4.17 (m, 2H), 4.09 (m, 4H), 4.02 (t, J = 4.2 Hz, 2H), 3.97 (m, 4H), 3.47 (s, 3H), 0.88 





[2-(aminooxy)ethyl]bis(2-hydroxyethyl)methylazanium iodide (QAO-2OH) 
The silylated aminooxy salt 3.3 (2.971g, 5.55 mmol) was stirred in anhydrous CH2Cl2 
at 0 °C for 5 minutes, tetrabutylammonium fluoride (11.1 mL of 1M in THF) was added 
dropwise to the reaction mixture.  The reaction was stirred at room temperature for 3h.  
The solvent was removed by rotary evaporation.  The resulting pale yellow solid was 
dissolved in water and purified by C18 reverse phase flash chromatography eluting in 97:3 
water:acetonitrile.  The aqueous solvents were removed by rotary evaporation and 
vacuum drying.  The product was isolated as colorless oil (0.61g, 36%).  1H NMR (D2O, 400 
MHz) δ 4.17 (m, 2H), 4.07 (m, 4H), 3.80 (t, J = 4.8 Hz 2H), 3.67 (t, J = 5.0 Hz, 4H), 3.25 (s, 




5.3.9 Fluorescence study of FITC-loaded NPs 
Aqueous solutions (0.1 M) of QAO, QAO-1OH, and QAO-2OH compound were 
added to suspensions of iron oxide nanoparticles (3 mg each) in vials (5 μmoles of 
aminooxy compound/mg of nanoparticles).  The vials were briefly sonicated (15 minutes) 
and then vortex mixed for 45 minutes at room temperature.  The resultant QAO-coated 
NPs were magnetically separated from the supernatant solution, washed with water to 
remove unbound QAO salts, and freeze dried.   
To a suspension of the QAO-NPs (3 mg) in methanol at room temperature was 
added a solution of FITC-CHO in methanol (0.01M, 50 μL/mg of NPs).  The reaction 
mixture was vortex mixed 2 hours at room temperature.  The particles then were 
magnetically separated, the supernatant was removed and analyzed.  The particles were 
washed twice with methanol (3X reaction volume) and the supernatants collected each 
time and analyzed.  Water was then added (50 μL/mg NPs), an aliquot was collected for 
analysis, and the aqueous suspensions then were placed in an Easy Heat LI alternating 
electromagnetic field at 201.4A and 203 kHz for 30 minutes.  After AMF exposure, the 
particles were removed by magnetic separation and an aliquot of the final supernatant 
was collected for analysis. 
The collected aliquots, both pre- and post-AMF exposure, were identically diluted 
and their fluorescence was measured during reverse phase HPLC using a Waters Atlantis 
C18 column (5μm, 3.9x150mm) on an Agilent 1100 series HPLC.  The total run-time was 
45 minutes with the following gradient: (% line B, elapsed time in minutes) 0,0; 0,3; 60,10; 
80,25; 100,30; 100,35; 0,45 where the A line was 5mM ammonium acetate (pH 6) and the 
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B line was 75% v/v aqueous acetonitrile.  Excitation-emission spectra (EES) of FITC-CHO, 
FITC-I, and FITC-II were acquired on a PerkinElmer LS55 fluorescence spectrometer in 
order to determine the excitation wavelengths that would yield maximum emission for 
each adduct.  The fluorescence excitation beam-width of the Agilent instrument was 
20nm. 
 
5.3.10 Syntheses of doxorubicin analogs 
 
Synthesis of Dox-2OH  
To a solution of doxorubicin•HCl (105.3 mg, 0.18 mmol) in anhydrous methanol (9 
mL) at room temperature was added QAO-2OH (162.3 mg, 0.54 mmol) and trifluoroacetic 
acid (9.0 μL).  After stirring the reaction mixture in the dark at room temperature for 110h, 
the solvent was removed by rotary evaporation.  The product was purified from the crude 
mixture by C18 reverse phase flash chromatography (C18Aq) with gradient elution in 
water/methanol with 0.1% TFA.  The product eluted at 55% water 45% methanol/TFA.  A 
hygroscopic red solid was isolated.  The residue was dissolved in methanol and gravity 
eluted through an ion exchange resin as previously described to yield a red solid (0.13 g, 
93%).  1H NMR (500 MHz, CD3OD) δ 1.28 (d, J = 5, 3H); 1.91 (m, 1H); 2.01 (m, 1H); 2.18 (d, 
J = 5.0 Hz, 1H); 2.45 (d, J = 15 Hz, 1H); 2.90, 3.01 (ABq, 2H, JAB = 17.5 Hz); 3.27 (m, 1H); 
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3.30 (s 3H); 3.60 (d, J = 15 Hz, 1H); 3.67-3.75 (m, 6H); 3.82 (bs, 3H); 3.91-4.05 (m, 9H); 4.23 
(m, 1H); 4.49, 4.53 (ABq, 2H, JAB = 15 Hz); 4.63 (m, 4H); 4.74 (splitting and integration 
obscured by water peak, presumed to be 1H on C7, according to ref);170 5.35 (bs, 1H), 7.23 
(d, J = 10 Hz, 1H); 7.43 (d, J = 10 Hz, 1H); 7.51 (t, J = 7.5 Hz, 1H). 13C NMR (125 MHz, CD3OD) 
δ 185.9, 185.63, 162.9, 160.7, 156.0, 154.5, 135.7, 134.8, 134.7, 134.3, 119.5, 118.8, 
118.7, 110.5, 110.3, 99.5, 71.6, 70.8, 67.7, 66.6, 66.4, 64.9, 62.2, 55.8, 55.4, 54.2, 49.9, 
37.7, 33.2, 28.1, 15.9.  m/z calcd [C34H46N3O13]+ 704.302518, observed 704.30269.   
 
Synthesis of Dox-OH  
To a solution of doxorubicin•HCl (103.0 mg, 0.178 mmol) in anhydrous methanol 
(9 mL) at room temperature was added QAO-1OH (146 mg, 0.533 mmol) and 
trifluoroacetic acid (9.0 μL).  After stirring the reaction mixture in the dark at room 
temperature for 72h, the solvent was removed by rotary evaporation.  The product was 
purified from the crude mixture by C18 reverse phase flash chromatography (C18Aq) with 
gradient elution in water/methanol with 0.1% TFA.  The product eluted at 55% water 45% 
methanol/TFA.  The hygroscopic red solid was then converted to a chloride salt by gravity 
eluting through an ion exchange resin prepared as described previously (0.1348 g, quant). 
1H NMR (500 MHz, CD3OD) δ 1.28 (d, J = 6, 3H); 1.91 (m, 1H); 2.01 (m, 1H); 2.23 (m, 1H); 
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2.50 (br d, J = 14 Hz, 1H); 3.03 (m, 2H); 3.26 (d, J = 3.5 Hz, 6H); 3.58 (m 3H); 3.72 (br s, 1H); 
3.88 (m, 5H); 3.99 (m, 2H);  4.25 (m, 1H); 4.49,4.55 (ABq, 2H, JAB = 13.3 Hz); 4.61 (m, 2H); 
5.37 (m, 1H), 7.33 (m, 1H); 7.59 (m, 2H).  One 1H signal was obscured by water 
contamination in methanol, but was verified in DMF-d7 at δ 5.15.  13C NMR (125 MHz, 
CD3OD) δ 15.8, 22.6, 23.5, 28.1, 28.7, 30.2, 33.2, 37.9, 38.7, 51.9, 54.3, 55.5, 55.8, 63.8, 
66.4, 66.6, 67.7, 67.8, 71.0, 71.7, 99.6, 110.5, 110.7, 118.9, 118.9, 119.8, 135.0, 135.8, 
154.7, 156.1, 160.9, 163.0, 186.0, 186.3.  m/z calcd [C33H44N3O12]+ 674.291953, observed 
674.29305.    
 
5.3.11 Preparation of NP formulations of Dox analogs 
To NPs (30.1 and 29.9 mg) was added 1.5 mL of either Dox-OH or Dox-2OH 
(respectively) as 0.1M solutions in anhydrous DMSO such that 5 μmols Dox analog per 1 
mg NP was added.  Vials were vortex mixed, then inverted (Labquake microcentrifuge 
tube shaker, Barnstead Thermolyne) at room temperature for 12 h.  The drug-loaded 
particles were then magnetically separated from the supernatant and washed with 
methanol (2X 1.5 mL) and water (2X 1.5 mL) to afford NP∙Dox-OH (30.9 mg) and NP∙Dox-




5.3.12 UV-Vis detection of Dox-OH and Dox-2OH release by pulsed AMF 
2.5 mg/mL solutions of either NP∙Dox-OH or NP∙Dox-2OH were prepared in 1X 
phosphate buffered saline and added to polystyrene cuvettes (Brookhaven Instruments).  
The cuvettes were placed, one per trial, in the center of an induction coil (Easy Heat LI 
AMF generator).  The solutions were exposed to AMF pulses lasting five minutes (203 kHz, 
350 A) at room temperature.  After each pulse, the NPs were magnetically sedimented 
and the cuvettes were placed in a 30 °C spectrophotometer (Beckman Coulter DU 800) 
where absorbance at 480 nm was detected.  Absorbance at 380 nm was used for baseline 
correction.  A total of 6 five-minute pulses were applied with intervening 5 minute periods 
of “off” time for a total time of 1h per experiment.  Trials were performed in triplicate.   
 
5.3.13 Toxicity of Dox-NPs in MCF-7 cells 
MCF-7 breast cancer cells were cultured in DMEM, 10% FBS, and 1% Pen strep and 
were plated into one of two 96 well plates which had been cut down to fit within the coil 
of the AMF generator.  NP∙Dox-OH, NP∙Dox-2OH, or bare NPs (control) were dispersed in 
PBS buffer (50 µL/well) and then diluted with supplemented medium (200 µL/well).  
When cells had grown to 40% confluence, the medium was removed and replaced with 
the NP formulations.  One 96 well plate was placed within the coil of the AMF generator 
and cells were exposed to 15 minutes pulsed AMF (350A, 203 kHz, 3 min on, 3 min off, 30 
min total time).  Between pulses cells were incubated at 37 °C.  After 48 hours, toxicity 
was assayed by trypan blue exclusion.  The medium was removed, wells were washed 2X 
with 200 µL PBS.  100 µL trypsin was added and the plates were incubated for 5 min.  100 
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µL medium was added to neutralize the trypsin and the contents of the wells were 
transferred to microcentrifuge tubes.  The cells were pelleted by centrifuge (1100 rpm, 5 
min), and the supernatant was aspirated.  Cell pellets were dispersed in 30 µL PBS buffer 
plus 10 µL trypan blue.  Live cells, which had excluded the blue dye, were counted using 
a hemocytometer.    
 




To aminooxy precursor QAO-2OH (0.405 g, 1.89 mmol) in 2:1 MeOH:CH2Cl2 (25 
mL) was added 9-anthracenecarboxaldehyde (0.582 g, 2.82 mmol).  The mixture was 
stirred at rt for 48h.  The solvent was removed by rotary evaporation.  The residue was 
passed through a thin silica gel plug eluting with CH2Cl2:MeOH (9:1).  The solvent was 
evaporated by rotary evaporation to yield the product as a viscous yellow liquid (0.263 g, 
35%).  1H NMR E isomer (400 MHz, CD3OD) δ 9.08 (s, 1H), 8.31 (d, J = 9.6 Hz, 2H), 7.87 (d, 
J = 8.4 Hz, 1H), 7.55 (t, J = 7.6 Hz, 2H), 7.53 (t, J = 7.4 Hz, 2H), 4.72 (br s, 2H), 4.04 (m, 4H), 
3.96 (m, 2H), 3.70 (m, 4H), 3.31 (s, 3H).  13C NMR E isomer (100 MHz, CD3OD) δ 150.8; 




5.3.15 Dextran sulfate coating of NPs 
49.5 mg NPs were dispersed in 100 mL DMSO.  100.3 mg dextran sulfate in DMSO 
(100 mL) was added to the NPs with rapid stirring slowly by addition funnel.  The mixture 
was stirred 14h at rt.  NPs were magnetically separated, the supernatant was removed by 
aspiration, the precipitated particles were washed 2X with Millipore water and freeze 
dried.    
 
5.3.16 Coating of dextran sulfate NPs with QAO-2OH anthracene derivative 
To 19.9 mg dextran sulfate-coated NPs in DMSO (30 mL) was added QAO-2OH 
anthracene derivative (0.040 g, 0.10 mmol).  The mixture was stirred at rt for 12h.  Coated 
NPs were magnetically separated, the supernatant was removed by aspiration, the 
precipitated particles were washed 2X with Millipore water and freeze dried. 
 
5.3.17 Release of QAO-2OH anthracene derivative from dextran sulfate NPs 
A 2.5 mg/mL aqueous solution of the QAO-2OH anthracene derivative-loaded 
dextran sulfate NPs was placed in a cuvette.  The solution was vortex mixed and the 
particles were magnetically sedimented.  Absorbance of the solution phase was measured 
at 382 nm UV-Vis.  This procedure was repeated every 5 minutes for 30 min at rt.  The 
solution was then exposed to pulsed AMF for 30 minutes (5 min on, 2.5 min off).  At 5 min 
intervals after each pulse the particles were again magnetically separated and absorbance 




5.3.18 CS2 and CS2/CH3I coating of NPs   
In a typical procedure for coating NPs with CS2, 20-60 mg NPs would be heated in 
a Kügelrohr distillation apparatus under vacuum at 125 °C for 4 hours to remove surface-
bound water.  A pre-heated stir bar and CS2 (2-3 mL) would then be added and the 
solution would be stirred for 4h at rt.  The particles would then be magnetically separated 
and dried under vacuum.  For methyl capping, iodomethane (1-2 mL) would be added to 
the particles and the solution would be stirred for 12h at rt.  Excess iodomethane would 
be evaporated under N2 stream in a fume hood and, following that, the coated NPs would 
be dried under vacuum for up to 48h.         
 
5.3.19 Synthesis of deuterated ammonium salt 3 
 
Following a modified procedure by Sommer et al.,171 to benzylamine (0.49 g, 4.57 
mmol) in DMF (2.3 mL) was added N,N-diisopropylethylamine (1.6 mL, 9.15 mmol).  The 
mixture was stirred for 15 minutes and cooled to 0 °C with an ice bath.  CD3I (2.99 g, 20.6 
mmol) was added dropwise and the mixture was allowed to come to rt and stirred 12h.  
After removal of excess CD3I in vaccuo, hot EtOAc was added and the reaction was filtered 
of a white precipitate.  The filtrate was concentrated by rotary evaporation and the DMF 
removed by azeotrope with toluene.  The product was isolated by reverse phase flash 
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column chromatography (RediSep Rf Gold C18Aq) as a white solid (1.07 g, 82%). 1H NMR 
(400 MHz, CD3OD) δ 7.79 (d, J = 8.4 Hz, 2H); 7.69-7.60 (m, 3H); 4.90 (s, 2H); 13C NMR (400 
MHz, CD3OD) δ 133.8; 131.7; 130.0; 128.6; 69.2, 52.2 (m); m/z calcd [C33H44N3O12]+ 
674.291953, observed 674.29305. 
 
5.3.20 Coating of CS2 NPs with 3 
20.8 mg NPs were heated at 125 °C under vacuum in a Kügelrohr.  0.7 mL CS2 was 
added and the solution was stirred at rt for several hours.  Excess CS2 was evaporated 
under N2 stream.  0.63 mL of a 0.1M solution in DMSO of the ammonium salt was added 
and the solution was stirred 19h.  The particles were then magnetically separated and the 
supernatant removed.  Particles were washed with 2X 1mL water and freeze dried.  As a 
control, NPs were treated as above without the addition of CS2.  TGA analysis was 




5.3.21 Synthesis of anthracen-9-ylmethanamine (4) 
 
Reagents and conditions: (a) NaBH4 (4.8 eq), THF/MeOH, rt 
2.5 h; (b) Phthalimide, PPh3, DIAD, THF, 0 °C-rt, 16h; (c) 




To 9-anthracene carboxaldehyde (2.51 g, 12.2 mmol) in 5:1 THF:MeOH (60 ml) was 
slowly added NaBH4.  The mixture was stirred 2.5h after which the reaction was quenched 
with aq. NH4Cl.  The precipitate was removed by filtration and the filtrate extracted with 
diethyl ether (3X, 50 mL).  The combined organic phases were washed with brine and 
dried over sodium sulfate.  The product was purified by column chromatography 
(EtOAc/CH2Cl3) to yield a yellow solid.  Rf 0.55 (1:20 EtOAc: CH2Cl2).  1H NMR (400 MHz, 
CDCl3) δ = 8.47 (m, 3H); 8.03 (d, J = 8.4 Hz, 2H); 7.57 (m, 2H); 7.49 (m, 2H) 5.68 (d, J = 5.2 




To a solution of triphenylphosphine (2.82 g, 10.77 mmol), phthalimide (1.58 g, 
10.77 mmol), and anthracene methanol in anhydrous THF (40 mL) at 0 °C was added 
dropwise DIAD (2.18 g, 10.77 mmol).  The mixture was stirred at rt for 16h.  THF was 
removed by rotary evaporation.  The yellow solid was triturated in 50 mL rt diethyl ether 
and the precipitated solids were collected over a Buchner funnel giving a yellow solid that 
was used directly in the next step.  1H NMR (400 MHz, CDCl3)  5.87 (s, 2H), 7.48 (t, J = 
7.4 Hz, 2H), 7.57-7.66 (m, 4H), 7.75-7.77 (m, 2H); 8.01 (d, J = 8.8 Hz, 2H), 8.48 (s, 1H); 8.66 
(d, J = 9.2 Hz, 2H). 
The anthryl phthalimide (0.667 g, 1.98 mmol) was dissolved in 2:1 CH2Cl2:EtOH (50 
mL).  Hydrazine monohydrate (0.495 g, 9.89 mmol) was added and the mixture was stirred 
for 14h at rt.  The product was purified by silica gel chromatography (9:1:0.1 CH2Cl2: 
MeOH: NH4OH) to yield an amber solid (16 %, 2 step).  1H NMR (400 MHz, CDCl3)  1.70 




5.3.22 Preparation of thiocarbamate NPs 10 
 
To xanthate ester NPs 8 (35.6 mg) in THF (2 mL) was added 20 mg of 4 in 0.3 mL.  
The mixture was magnetically stirred at rt for 6h.  The coated particles 10 (which had 
changed color from brown to beige) were magnetically sedimented.  The supernatant was 
removed and the particles were washed with THF.  With successive washing the particles 
lost their pale coloring. 
 
5.3.23 Elemental analysis 
Elemental analyses were performed on ≈50 mg of sample by Midwest Microlab, 
LLC. 
 
5.3.24 CS2-modified NPs with variably hydroxylated ammonium salts 
A stock solution of CS2 modified NPs in DMSO was aliquoted into 15 
microcentrifuge tubes such that each tube contained ≈10 mg particles.  0.15 mL of 0.66M 
solutions of each ammonium salt (Figure 3.3) were added to the particle solutions and 
the mixtures were vortex mixed, sonicated (5 min) and placed on inverter for mixing for 
20h.  The coated NPs were then magnetically separated, the supernatant was removed 
and the particles were washed with water (3X 0.5 mL) with intervening pelleting by 
centrifugation (13000 rpm, rt, 5 min) and supernatant removal.  The washed particles 
were freeze dried.  An unidentified orange solid was seen to pellet with the NPs.  
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5.3.25 Synthesis of greigite NPs 
Following a procedure describe by Chang et al.,123 6.5 mL water was deoxygenated 
with N2 bubbling for 45 min.  Iron II sulfate (1.82 g, 6.54 mmol) and Na2S∙ 9H2O (1.57 g, 
6.54 mmol) were added and a black precipitate formed immediately.  Glacial acetic acid 
was then added dropwise as the solution pH was monitored, until the pH reached 3.3.  
Greigite NPs were pelleted by centrifugation (5000 rpm, 5 min, rt).  After supernatant 
removal the particles were washed with deoxygenated water (40 mL) and again pelleted 
by centrifuge.  The supernatant was once again removed and the particles were freeze 
dried.  The particles were not immediately responsive to a magnet, however after sitting 
overnight at rt in a vial, they became magnetic. 
 
5.3.26 Greigite NP coating with QAO-2OH anthracene derivative 
 
To 1 mL of QAO-2OH anthracene derivative (25 mg/mL) in andhyd. DMSO was 
added 50.6 mg greigite NPs.  The mixture was stirred at rt for 48h.  Coated particles were 
pelleted by centrifugation (13000 rpm, 15 min, rt).  The supernatant was removed and 
the particles were washed with water (3X 1 mL) with intervening centrifugation and 
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5.4 Experimental Procedures for Chapter 4 
5.4.1 Syntheses of cationic oxime ether lipids and intermediates 
 
 
tert-butyl N,N-bis[2-(aminooxy)ethyl]carbamate (4.1). 
[Steps a, b]  To a solution of tert-butyl bis(2-hydroxyethyl)carbamate  (5.01 g,  24.4 
mmol), triphenylphosphine (14.1 g, 53.7 mmol) and N-hydroxyphthalimide (8.75 g, 53.6 
mmol) in THF (245 mL) at 0 °C was added dropwise diisopropyl azodicarboxylate (DIAD) 
(10.6  g, 52.4 mmol).  The resultant red mixture was allowed to warm to rt.  After stirring 
for 12 h, the solvent was removed by rotary evaporation.  Et2O (150 mL) was added and 
the mixture was cooled to 0 °C for 3 h.  The resultant suspension was decanted to remove 
an off-white precipitate.  The decanted solution was chilled to –20 °C for another 3 h and 
again decanted to remove a second crop of precipitated solids.  The solvent then was 
removed by rotary evaporation and a mixture of hexanes:EtOAc, 1:1 (60 mL) was added 
to the crude residue.  The precipitated solids were collected using a Buchner funnel, 
dissolved in a minimal volume of CH2Cl2, and passed through a plug of silica gel, eluting 
with a gradient of CH2Cl2: EtOAc, 1:0 to 0:1.  The isolated product containing minor 
impurities was recrystallized by first dissolving in a minimal volume of hot EtOAc and then 
adding hexanes (final ratio: 2:1 hexanes/EtOAc).  The bis-phthalimide, tert-butyl N,N-
bis({2-[1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)oxy]ethyl})carbamate, obtained as a white 
solid (2.07 g, 17%) was used directly in the next step; m.p. 139-141 °C; TLC, Rf  0.47 
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(hexanes/EtOAc, 1:1, UV/ninhydrin stain); FT-IR 2972, 2956, 1793, 1736, 1729, 1697, 1412 
cm-1;  1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H); 3.73 (m, 4H); 4.36 (m, 4H); 7.71 (m, 8H); 
13C NMR (125 MHz, CDCl3) δ 28.5; 47.7; 78.0, 80.5; 123.6; 129.1; 134.6; 155.4; 163.5.  
To a solution of the isolated bis phthalimide carbamate (3.10 g, 6.26 mmol) in 
CH2Cl2 (33 mL) at rt was added dropwise hydrazine monohydrate (1.57 g, 31.3 mmol).  
After stirring at rt for 2.5 h, the reaction mixture was filtered to remove the white 
precipitate, and the retentate was washed with small portions of CH2Cl2. The combined 
filtrate was evaporated by rotary evaporation to afford bis-aminooxy carbamate 4.1 as a 
clear oil (1.42 g, 96%); TLC, Rf  0.74 (CH2Cl2:MeOH, 9:1); FT-IR 3312, 2976, 2925, 2871, 
1677, 1590 cm-1;  1H NMR (400 MHz, CDCl3) δ 1.45 (s, 9H); 3.41 (br s, 2H),3.49 (br s, 2H); 
3.74 (t, J = 5.2 Hz, 4H); 5.46 (br s, 4H, -ONH2); 13C NMR (100 MHz, CDCl3) δ 28.4; 46.0; 46.2; 






(21E)-14,20-dioxa-13,17,21-triazatritriaconta-12,21-diene (4.2)  
Bis-aminooxy carbamate 4.1 (0.10 g, 4.21 mmol) was dissolved in CH2Cl2 (20 mL).  
To this solution was added dodecyl aldehdye (1.71 g, 9.26 mmol), prepared from dodecyl 
alcohol by Swern oxidation.172  After stirring the reaction for 10 h at rt, the solvent was 
removed by rotary evaporation and the crude product was purified by silica column 
chromatography (CH2Cl2: EtOAc, 1:0 to 9:1) to afford 4.2 (2.23 g, 93%) as a colorless oil.  
The mixture of (E,E):(E,Z) diastereomers was used directly in the next step without isomer 
separation; TLC, Rf  0.53, 0.42 (CH2Cl2/EtOAc, 9:1, p-anisaldehyde stain); 1H NMR (400 
MHz, CDCl3) (E,E)-isomer (major): δ 0.88 (t, J = 5.6 Hz, 6H); 1.25 (m, 34H), 1.45 (s, 9H); 1.62 
(m, 2H); 2.17 (q, J = 6.2 Hz, 4H); 3.47 (m, 4H); 4.11 (m, 4H); 7.37 (t, J = 6.0 Hz, 2H); 13C NMR 
(100 MHz, CDCl3) δ14.1, 22.6, 25.7, 26.2, 26.7, 28.4, 29.1, 29.3, 29.4, 29.5, 29.6, 29.8, 31.9, 
47.3, 71.7, 72.2, 79.5, 151.3, 152.3, 155.4. 
The bis-oxime ether 4.2 (1.57 g, 2.77 mmol) was dissolved in a chilled 1:1 mixture 
of trifluoro-acetic acid: CH2Cl2 (7.0 mL) and the mixture was stirred at rt for 3 hours.  The 
solvent was evaporated by rotary evaporation and Et2O (50 mL) was added to dissolve 
the residue.  The Et2O solution was washed with sat. NaHCO3 (50 mL).  The aqueous wash 
layer was extracted with Et2O (2 x 30 mL) and the combined Et2O phase was dried (NaSO4) 
and then evaporated by rotary evaporation to yield bis-oxime ether amine (1.25 g, 96%) 
as an amber liquid; 1H NMR (400 MHz, CDCl3) (E,E)-isomer: δ 0.88 (t, J = 7.0 Hz, 6H); 1.25 
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(m, 32H); 1.47 (m, 4H); 1.98 (br, 1H); 2.16 : (q,  J = 7.2, 4H); 2.96 (m, 4H); 4.14 (q, J = 5.3 
Hz, 4H); 7.39 (t, J = 6.5 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.1, 22.6, 25.7, 26.2, 26.7, 




dien-17-ium iodide (Lipid 1) 
Following a modified version of the procedure for glycidol epoxide opening 
described by Kuwabe et al.,173 to a solution of the amine generated in the previous step 
(1.09 g, 2.33 mmol) in 1:1 water/ethanol (12 mL) was added racemic glycidol (0.568 g, 
7.67 mmol) and acetic acid (0.073 g, 1.22 mmol).  The reaction flask was covered with foil 
and stirred in the dark at 55 °C for 48 h.  Note: reactions of this type were later performed 
without acid at 1M in ethanol (95%), with 1 eq. glycidol over 12h at rt.  The ethanol was 
removed by rotary evaporation and Et2O (50 mL) was added to dissolve the residue.  The 
Et2O solution was washed with sat. NaHCO3 (50 mL).  The aqueous wash layer was 
extracted with Et2O (2 x 50 mL) and the combined Et2O phase was dried (NaSO4) and then 
evaporated by rotary evaporation.  The residue was purified by silica column 
chromatography (CH2Cl2: CH3OH, 19:1 to 9:1) to afford 4.5 (1.01 g, 80%) as a yellow oil; 
TLC, Rf = 0.47 (CH2Cl2/MeOH, 9:1, p-anisaldehyde stain); 1H NMR (400 MHz, CDCl3) (E,E)-
isomer: δ 0.88 (t, J = 6.6 Hz, 6H); 1.26 (m, 32H); 1.46 (m,  4H); 2.17 (q, J = 7.1 Hz, 4H); 2.71 
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(m, 2H); 2.95 (br, 4H); 3.48 (m, 1H); 3.72 (dd, J = 4.0, 11.2 Hz, 2H); 3.88 (br, 1H); 4.15 (m, 
4H); 7.38 (t, J = 6.4 Hz, 2H); HRMS m/z calcd [C31H64N3O4] + [M + H]+: 542.48913, observed 
542.48952. 
A pressure tube was charged with a solution of 4.5 (0.85 g, 1.57 mmol) in CH2Cl2 
(3.5 mL).  To the solution was added iodomethane (2.23 g, 15.7 mmol).  The tube was 
sealed and then heated at 60 °C for 6 h.  On cooling, the tube was opened and the solvent 
and excess iodomethane were evaporated using a nitrogen stream in a closed fume hood.  
The residue was purified by silica column chromatography (CH2Cl2: CH3OH 1:0 to 9:1) to 
yield lipid 1 (0.941 g, 88%) as an amber oil; TLC, Rf = 0.68 (CH2Cl2/MeOH, 9:1, p-
anisaldehyde stain); 1H NMR (400 MHz, CDCl3) (E,E)-isomer: δ 0.85 (t, J = 7.2 Hz, 6H); 1.23 
(m, 30H); 1.44 (m, 4H); 2.15 (q,  J = 7.4 Hz, 4H); 3.37 (s, 3H); 3.68 (m, 3H); 3.85-4.01 (m, 
5H); 4.45 (m, 5H); 7.39 (t, J = 6.2 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 13.9, 16.8, 22.6, 
26.0, 26.1, 26.4, 29.1, 29.2, 29.3 (2 signals), 29.4, 29.5, 31.8, 51.6, 62.7, 62.9, 63.1, 64.1, 






Bis-aminooxy carbamate 4.1 (0.105 g, 0.446 mmol) was dissolved in CH2Cl2 (4.0 
mL).  To this solution was added tetradecanal (0.208 g, 0.982 mmol), prepared from 
tetradecanol by Swern oxidation.172  After stirring the reaction for 10 h at rt, the solvent 
was removed by rotary evaporation and the crude product was purified by silica column 
chromatography (CH2Cl2: EtOAc, 1:0 to 9:1) to afford tert-butyl N,N-bis({2-
[(tetradecylideneamino)oxy]ethyl})carbamate (4.3) (0.199 g, 71%) as a colorless oil.  The 
mixture of (E,E):(E,Z) diastereomers was used directly in the next step without isomer 
separation; TLC, Rf  0.50, 0.46 (hexanes/EtOAc, 4:1, ninhydrin stain); FT-IR 2954, 2923, 
2853, 1698, 1466, 1406, 1366 cm-1;  1H NMR (400 MHz, CDCl3) (E,E)-isomer (major): δ 0.88 
(t, J = 6.6 Hz, 6H); 1.26 (m, 44H), 1.45 (s, 9H); 2.16 (q, J = 6.9 Hz, 4H); 3.46 (m, 4H); 4.11 
(m, 4H); 7.37 (t, J = 6.0 Hz, 2H); 13C NMR (125 MHz, CDCl3) δ14.1, 22.7, 25.7, 26.2, 26.7, 
28.4, 29.1, 29.3, 29.4, 29.5 (2 signals), 29.6 (3 signals), 29.7, 31.9, 47.6, 47.3, 71.7, 72.2, 
79.5, 151.25, 152.2, 155.4. 
The bis-oxime ether 4.3 (0.467 g, 0.748 mmol) was dissolved in 1:1 mixture of 
trifluoro-acetic acid: CH2Cl2 (3.2 mL) and the mixture was stirred at rt for 3 hours.  The 
solvent was evaporated by rotary evaporation and Et2O (30 mL) was added to dissolve 
the residue.  The Et2O solution was washed with sat. NaHCO3 (30 mL).  The aqueous wash 
layer was extracted with Et2O (2 x 20 mL) and the combined Et2O phase was dried (NaSO4) 
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and then evaporated by rotary evaporation to yield the bis-oxime ether amine (0.36 g, 
91%) as an off-white solid; TLC, Rf  0.66 (CH2Cl2/MeOH, 9:1, ninhydrin stain); FT-IR 2955, 
2917, 2849, 1463 cm-1; 1H NMR (500 MHz, CDCl3) (E,E)-isomer: δ 0.88 (t, J = 6.7 Hz, 6H); 
1.25 (m, 40H),1.47 (m, 4H); 1.98 (br, 1H); 2.16 : (q,  J = 7.2, 4H); 2.96 (m, 4H); 4.14 (q, J = 
5.3 Hz, 4H); 7.39 (t, J = 6.5 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.3, 22.9, 25.9, 26.4, 
26.9, 29.4, 29.6 (2 signals), 29.7 (2 signals), 29.8, 29.9 (2 signals), 32.1, 48.8, 71.8, 152.0. 






Following a modified version of the procedure for glycidol epoxide opening 
described by Kuwabe et al.,173 to a solution of the amine prepared in the previous step 
(0.166 g, 0.317 mmol) in ethanol (0.28 mL) was added racemic glycidol (0.035 g, 0.476 
mmol).  The reaction flask was covered with foil and stirred in the dark at rt for 57 h.  The 
solvent then was removed by rotary evaporation and the residue was purified by silica 
column chromatography (CH2Cl2: CH3OH, 1:0 to 9:1) to afford bis-oxime ether 4.6 (0.078 
g, 41%) as a light yellow oil; TLC, Rf = 0.59 (CH2Cl2/MeOH, 9:1, p-anisaldehyde stain); FT-
IR 3380, 2921, 2854, 1465, 1380, 1041 cm-1; 1H NMR (400 MHz, CDCl3) (E,E)-isomer: δ 0.88 
(t, J = 6.6 Hz, 6H); 1.25 (m, 40H),1.45 (sex, J = 6.8 Hz,  4H); 2.17 (q, J = 7.1 Hz, 4H); 2.87 (m, 
2H); 3.11 (br, 4H); 3.52 (m, 1H); 3.72 (dd, J = 3.8, 11.4 Hz, 1H); 3.88 (br, 1H); 4.21 (m, 4H); 
7.39 (t, J = 6.4 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.3, 22.9, 26.0, 26.4, 26.9, 29.4, 29.6 
(3 signals), 29.7, 29.9 (2 signals), 32.1, 54.1, 54.2, 58.3, 64.6, 67.8, 70.2, 152.4.  HRMS m/z 






dien-19-ium iodide (Lipid 2) 
[Step f]  A pressure tube was charged with a solution of 4.6 (0.078 g, 0.131 mmol) 
in CH2Cl2 (2.0 mL).  To the solution was added iodomethane (0.372 g, 2.62 mmol).  The 
tube was sealed and then heated at 55 °C for 18 h.  On cooling, the tube was opened and 
the solvent and excess iodomethane were evaporated using a nitrogen stream in a closed 
fume hood.  The residue was purified by silica column chromatography (CH2Cl2: CH3OH 
9:1) to yield lipid 4 (0.062 g, 64%) as a hygroscopic yellow solid; TLC, Rf = 0.71 
(CH2Cl2/MeOH, 9:1, phosphomolybdic acid stain); FT-IR 3329, 2921, 2854, 1790, 1734, 
1702, 1466, 1368, 1271, 1186, 1056 cm-1; 1H NMR (400 MHz, CDCl3) (E,E)-isomer: δ 0.87 
(t, J = 6.8 Hz, 6H); 1.25 (m, 40H); 1.46 (m, 4H); 2.18 (q,  J = 7.1 Hz, 4H); 3.40 (s, 3H); 3.74 
(m, 3H); 3.94 (m, 6H); 4.50 (m, 5H); 4.65 (m, 1H); 7.42 (t, J = 6.2 Hz, 2H); 13C NMR (100 
MHz, CDCl3) δ 14.3, 22.9, 26.3 (2 signals), 26.7, 29.4, 29.6 (3 signals), 29.7, 29.9, 32.1, 51.9, 






Tert-butyl N,N-bis[2-({[(9Z)-octadec-9-en-1-ylidene]amino}oxy)ethyl]carbamate (4.4) 
Bis-aminooxy carbamate 4.1 (0.495 g, 2.10 mmol) was dissolved in CH2Cl2 (12 mL).  
To this solution was added oleyl aldehyde (1.966 g, 8.42 mmol), prepared from oleyl 
alcohol by Swern oxidation.172  After stirring the reaction for 12 h at rt, the solvent was 
removed by rotary evaporation and the crude product was purified by silica column 
chromatography (CH2Cl2: EtOAc, 1:0 to 19:1) to afford 4.4 (0.731 g, 47%) as a colorless oil.  
The mixture of (E,E):(E,Z) diastereomers was used directly in the next step without isomer 
separation; TLC, Rf  0.32, 0.25 (CH2Cl2, phosphomolybdic acid stain); FT-IR 3006, 2923, 
2855, 1700, 1462, 1407, 1366, 1150 cm-1; 1H NMR (400 MHz, CDCl3) (E,E)-isomer (major): 
δ 0.88 (t, J = 6.6 Hz, 6H); 1.30 (m, 48H), 1.45 (s, 9H); 1.99 (m, 8H); 2.16 (q, J = 7.2 Hz, 4H); 
3.47 (m, 4H); 4.12 (m, 4H); 5.35 (m, 4H);  7.37 (t, J = 6.0 Hz, 2H); 13C NMR (125 MHz, CDCl3) 
δ14.1, 22.7, 25.8, 26.3, 26.8, 27.2, 27.3, 28.5, 29.2, 29.2, 29.3, 29.4 (2 signals), 29.6, 29.7 
(2 signals), 29.8, 31.9, 32.6, 47.4, 71.8, 72.2, 79.5, 110.1, 129.7, 130.0,  151.2, 152.2, 155.4.  






The bis-oxime ether 4.4 (0.281 g, 0.383 mmol) was dissolved in a 1:1 mixture of 
trifluoro-acetic acid: CH2Cl2 (4 mL) and the mixture was stirred at rt for 1 h.  The solvent 
was evaporated by rotary evaporation and Et2O (60 mL) was added to dissolve the 
residue.  The Et2O solution was washed with sat. NaHCO3 (60 mL).  The aqueous wash 
layer was extracted with Et2O (2 x 40 mL) and the combined Et2O phase was dried (NaSO4) 
and then evaporated by rotary evaporation to yield the bis-oxime ether amine as an 
amber oil which was used without further purification; TLC, Rf  0.29 (CH2Cl2/MeOH, 19:1, 
phosphomolybdic acid stain); FT-IR 3006, 2923, 2855, 1462, 1068 cm-1; 1H NMR (400 MHz, 
CDCl3) (E,E)-isomer: δ 0.87 (t, J = 6.8 Hz, 6H); 1.28 (m, 44H),1.45(m, 4H); 2.01 (m, 8H); 2.16 
: (q,  J = 7.2, 4H); 2.49 (br, 1H); 3.02 (m, 4H); 4.16 (t, J = 5.4 Hz, 4H); 5.36 (m, 4H); 7.39 (t, 
J = 6.0 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.2, 22.8, 25.7, 26.3, 26.8, 27.2, 27.3, 29.2, 
29.3, 29.4, 29.8 (2 signals), 32.0, 32.7, 48.5, 48.7, 71.8, 72.2, 129.8, 130.1, 151.7, 152.6. 






Following a modified version of the procedure for glycidol epoxide opening 
described by Kuwabe et al.,173 to a solution of the amine produced in the previous step 
(0.154 g, 0.243 mmol) in ethanol (0.25 mL) was added racemic glycidol (0.020 g, 0.268 
mmol).  The reaction flask was covered with foil and stirred in the dark at rt for 16 h.  The 
solvent then was removed by rotary evaporation and the residue was purified by silica 
column chromatography (CH2Cl2: CH3OH, 1:0 to 9:1) to afford bis-oxime ether 4.7 (0.066 
g, 38%) as a light yellow oil; TLC, Rf = 0.66 (CH2Cl2/MeOH, 19:1, phosphomolybdic acid 
stain); FT-IR 3423, 2955, 2923, 2854, 1728, 1462, 1274, 1123, 1072, 738 cm-1; 1H NMR 
(400 MHz, CDCl3) (E,E)-isomer: δ 0.87 (t, J = 6.6 Hz, 6H); 1.27 (m, 44H),1.45 (m,  4H); 2.00 
(m, 8H); 2.16 (q, J = 7.1 Hz, 4H); 2.65 (m, 2H); 2.88 m, 4H); 3.03 (br, 2H); 3.47 (m, 1H); 3.71 
(m, 2H); 4.12 (m, 4H); 5.33 (m, 4H); 7.37 (t, J = 6.2 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 
14.2, 22.8, 25.9, 26.4, 26.9, 27.3 (2 signals), 29.3, 29.4 (3 signals), 29.5, 29.6, 29.8 (2 
signals), 29.9, 32.0, 32.7, 38.8, 54.0, 57.6, 64.5, 68.2, 68.3, 71.1, 71.6 (2 signals), 129.8, 






triazapentatetraconta-9,18,27,36-tetraen-23-ium iodide (Lipid 3) 
A pressure tube was charged with a solution of 4.7 (0.053 g, 0.075 mmol) in CH2Cl2 
(1.0 mL).  To the solution was added iodomethane (0.213 g, 1.50 mmol).  The tube was 
sealed and then heated at 50 °C for 6 h.  On cooling, the tube was opened and the solvent 
and excess iodomethane were evaporated using a nitrogen stream in a closed fume hood.  
The residue was purified by silica column chromatography (CH2Cl2: CH3OH 19:1 to 9:1) to 
yield lipid 3 (0.040 g, 63%) as a yellow semisolid; TLC, Rf  0.63 (CH2Cl2/MeOH, 9:1, 
phosphomolybdic acid stain); FT-IR 3459, 3336, 3001, 2969, 2955, 2923, 2855, 1736, 
1457, 1365, 1269, 1228, 1219, 1123, 1072, 958, 742 cm-1; 1H NMR (400 MHz, CDCl3) (E,E)-
isomer: δ 0.86 (t, J = 6.4 Hz, 6H); 1.26 (m, 44H); 1.45 (m, 4H); 1.99 (m, 8H); 2.16 (q,  J = 6.9 
Hz, 4H); 3.39 (s, 3H); 3.71 (m, 3H); 3.95 (m, 6H); 4.50 (m, 6H); 5.33 (m, 4H); 7.40 (t, J = 5.8 
Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.2, 22.8, 26.2 (2 signals), 26.6, 27.3 (2 signals), 
29.2, 29.3 (2 signals), 29.4 (2 signals), 29.6, 29.7, 29.8 (2 signals),  32.0, 32.7, 51.8, 62.7, 
62.8, 62.9, 63.1, 64.3, 66.0, 66.3, 66.9, 67.4, 129.8, 130.1, 153.8 154.5; HRMS m/z calcd 




5.4.2 Synthesis of doxorubicin hexadecanyl acyl hydrazone (Dox-AH) 
 
To doxorubicin hydrochloride (0.053 g, 0.092 mmol) in anhydr. CH3OH (10 mL) was 
added hexadecane hydrazide prepared as in Effenberger et al.152 (0.033g, 0.122 mmol), 
aniline (0.007 g, 0.077 mmol), and trifluoroacetic acid (0.008 g, 0.070 mmol).  The reaction 
was stirred at rt for 10h.  The CH3OH was removed by rotary evaporation and the product, 
a red solid, was recrystallized from CH3OH (0.065 g, 85%); 1H NMR (400 MHz, CD3OD) δ 
0.89 (t, J = 6.6 Hz); 1.10-1.38 (br m, 28H);  1.43 (t, J = 5.4 Hz, 2H); 1.67 (t, J = 6.8 Hz, 1H); 
1.84-1.98 (m, 1H); 1.99-2.12 (m, 1H); 2.26-2.45 (m, 3H); 2.55 (dd, J = 14.0, 6.5 Hz, 1H); 
2.90 (d, J = 17.6 Hz, 1H); 3.16 (br m, 1H); 3.35 (s, 3H); 3.45 (d, J = 17.2 Hz1H 3H); 3.58 (br 
d, J = 12.8 Hz 1H); 3.62-3.71 (m, 1H); 4.04 (s, 3H); 4.21 (dd, J = 8.4 Hz, 6.1 Hz, 1H); 4.62 (q,  
J = 14.8 Hz 2H);  5.07 (t, J = 6.2 Hz, 1H); 5.48 (br s, 1H); 7.59 (t, J = 9.6 Hz, 1H), 7.85 (t, J = 
8.1 Hz, 1H); 7.98 (t, J = 10.0 Hz, 2H).  13C NMR (175 MHz, DMSO-d6) δ 186.5 (2 signals), 
186.5, 174.0, 160.7, 156.5, 154.2, 152.2, 136.9, 136.3, 135.7, 134.8, 120.0, 119.7, 119.0, 
110.6, 110.5, 98.9, 72.4, 72.1, 66.31, 66.0, 56.6, 56.0, 46.6, 33.9, 31.3, 31.1, m 29.1-29.0, 
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28.9, 28.8 (2 signals), 28.7, 28.1, 24.1, 22.1, 16.8, 14.0; HRMS m/z calcd [C43H62N3O11]+ 
796.4379, observed 796.43916. 
 
5.4.3 Synthesis of core-shell Fe3O4-SiO2 NPs 
SiO2@Fe3O4 nanoparticles were prepared using a modified procedure by Pinho et 
al.127  Commercially available Fe3O4 ferrofluid (Ferrotec EMG 304, 0.25 mL, ca. 58 mg) 
dispersed in water  (25 mL) was added in 1 mL aliquots to a solution of EtOH (78 mL) and 
NH4OH (1.55 mL, 28-30%) under rapid mechanical stirring.  Tetraethyl orthosilicate (TEOS) 
(0.532 mL) was added to the colloidal suspension and was stirred for 12 h at rt.  The NPs 
were magnetically sedimented for 1h on a neodymium permanent magnet.  To collect 
additional particles, the colloidal supernatant was removed and centrifuged at 6000 rcf 
for 1h at rt.  The ethanolic supernatant was removed by aspiration and the combined NP 
pellets were washed with EtOH (2x 8mL) with intervening centrifugation (16100 rcf, 20 
min, rt) and supernatant removal.  After a final wash and centrifugation cycle in water (8 
mL) with supernatant removal, the NPs were dispersed in water (4 mL) and freeze-dried 





5.4.4 CML formation and stability 
Lipids 1, 2, and 3 (6.45 mM) in DMSO were each mixed with 1 mg SNP for up to 
24h.  Dynamic light scattering (DLS) measurements (0.5 mg SMP/mL) were made on the 
mixture at intervals.  3D plots over 24 hour time intervals of the histograms of relative 
number of particles versus diameter are given in the appendix.  In the case of lipids 2 and 
3, particles aggregated at mixing times approaching 24h to diameters outside a useful 
range.  The following table lists weighted average diameters from size histograms 
calculated for the DMSO suspension of CML with lipid 1 at 24h mixing time and for a water 
suspension of CML with lipid 1 (after magnetic separation, supernatant removal, and 
resuspension, 0.25 mg SNP/mL).   




DMSO 62.62 0.59 68.2 
 72.89 0.29  
 84.85 0.12  
Water 44.56 0.29 51.5 
 50.60 0.42  
 57.46 0.21  
 65.24 0.08  




5.4.5 ζ-potential of CML 
Lipid 1 (6.45 mM) in DMSO was mixed with 1 mg SNP for 5h.  CML were 
magnetically separated, the supernatant was removed, the particles were rinsed with 
water, and resuspended in water (0.25 mg SNP/mL) for  ζ-potential measurements (see 
appendix).  The mean ζ–potential was 31.72 +/- 2.9 mV. 
 
5.4.6 Calculation of lipid molecules per NP 
The mass of an SNP was calculated based on volume and density according to 
McCarthy et al.124 as 2.073*10^-17g.  Volume was estimated based on average SNP 
diameter from transmission electron microscope images.  A typical coating of SNP with 
lipid used a weight ratio of 0.3-0.4 mg lipid/mg SNP to achieve the plateau of ζ-potential 
shown in Figure 4.8 of the manuscript.  The number of lipid molecules per SNP that this 
ratio represents was calculated according to: (moles lipid/g SNP) (mass of 1 SNP) 
(Avogadro’s #).      
 
5.4.7 Titration of SNP with cationic lipid 1 
Multiple concentrations of lipid 1 were prepared by serial dilution with water in 
microcentrifuge tubes.  0.5 mL of a 0.6 mg/mL stock solution of SNP in water were added 
to each tube.  Solutions were agitated for several hours.  Zeta potentials of the solutions 




5.4.8 Estimation of lipid: Dox-AH ratio 
Thin films of lipid 1 and DOX-AH were made by dissolving varying ratios of the two 
species in CHCl3/CH3OH and removing the solvent in vacuo.  To the thin films was added 
water for a concentration of 2 mM (lipid 1 and DOX-AH combined) and the mixtures were 
vortex mixed and solicited 10 min, 50% duty, 1 min intervals.  DLS measurements were 
taken for each solution in water (2mL).  Figure 4.5 shows the plot of the percent of DOX-
AH added versus the diameter of the liposomes: the diameter with the highest relative 
number of particles from the size histogram.   
 
5.4.9 Cell toxicity study 
Lipid films were prepared by dissolving lipid, or lipid + DOX-analog mixtures (3:1 
molar ratio) in CH3OH in microcentrifuge tubes and removing the solvent in vacuo.  SNP 
were dispersed in molecular grade water (0.185 mg/mL) by briefly sonicating.  Aliquots of 
SNP suspensions were added to the thin films (lipid: 0.108 mM, lipid:DOX-analog mixture 
0.081:0.027 mM) and the mixtures were stirred at rt 12h.  The solutions were diluted 10% 
with 10x PBS prior to addition to cells.     
MCF-7 breast cancer cells were grown in supplemented media (DMEM, 10% FBS, 
1% Pen strep) in 35mm culture dishes.  Prior to treatment, cells were plated in 12-well 
dishes (50,000 cells/well) for biological triplicates and incubated for 24h.  Treatment 
formulations described above were added directly into cell growth media (2 mL): 0.05 mg 
SNP, 29.2 total nanomoles lipid or lipid + DOX-analog mixture per well in 0.3 mL volume.  
After 2h incubation at 37 °C the medium was removed and replaced with fresh medium.  
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Cell viability was assayed after 48h incubation by removing media, rinsing 2X with PBS, 
adding 0.25 % trypsin-EDTA 1X (0.2 mL), incubating for 5 minutes, neutralizing with 0.2 
mL DMEM, diluting 1:1 with trypan blue and counting live cells (in replicate for each 
condition) with a hemocytometer.  
 
5.4.10 Preparation of oxime-ether liposomes and nucleic acid complexes 
Lipids were solubilized in CHCl3 at a concentration of 10 mg/mL. Lipids (1 mg) were 
placed in glass vials and then mixed with equimolar amount of the co-lipid DOPE.  Lipid 
films were prepared using rotary evaporatoration  under reduced pressure, and kept 
overnight in a desiccator at room temperature.  Lipids films were hydrated with 3 mL of 
enzyme free water under vortexing and were probe sonicated for 10 minutes on ice bath 
with 1 min cycle of sonication and 1 min rest to obtain 0.33 mg/mL of lipid in the 
liposomes.  The resulting OEL liposome preparations were either used for further 
complexation with nucleic acids (described below), or alternatively, the OEL liposomes 
were stored at 4°C and used within two weeks of their preparation.   
To prepare oxime-ether lipid/nucleic acid complexes, the lipids at different 
concentrations were introduced to fixed concentration of nucleic acids at 500 nM (DS 
RNAs or RNA/DNA hybrids or DNA duplexes) and incubated for 30 min at room 
temperature. After incubation, the mixture was diluted 10 fold by using either enzyme 
free water/buffer or serum media at room temperature. The final concentration of 
nucleic acids was 50 nM and the lipid concentrations were typically in the range of 1-20 




5.4.11 Cell culture for gene transfection studies 
MDA-MB-231 (human breast cancer) cells either stably expressing enhanced 
green fluorescent protein (GFP) or  non-GFP cells were maintained in a Dulbecco’s 
modified Eagle’s medium (DMEM) 10% (v/v) heat-inactivated FBS (fetal bovine serum), 
100 i.u./mL penicillin and 100 μg/mL streptomycin under a humidified 5% CO2 incubator 
at 37°C. On the basis of the requirement of the experiments either GFP expressing or non-
GFP MDA-MB-231 cells were used. 
 
5.4.12 Binding affinity of oxime ether lipids with hybrid DNA/RNA 
Binding affinities of lipids 1-3 with nucleic acids were determined by conducting 
fluorescent anisotropy/polarization measurements using Tecan Infinite M1000 (Tecan, 
USA).  Fluorescent Alexa-488 labeled RNA/DNA hybrid duplexes (200 nM) were incubated 
with various concentrations of the lipids. Changes in fluorescent (anisotropy/polarization) 
values of hybrid duplexes upon binding to the lipids with respect to the hybrids alone was 




5.4.13 Cell viability for gene transfection studies 
Viability of the MDA-MB-231 human breast cancer cells was determined on 
treatment with lipids alone and in complexation with DS RNAs. 20,000 cells/well were 
seeded in 96 well plates in serum containing media 24 hours prior to experiments. Lipids 
at different concentrations with and without DS RNAs (50 nM final) were added to the 
cells in triplicate in serum containing media and incubated for 4 hours at 37° C. After 
incubation, the media was replaced with fresh serum-containing media. The cells were 
then incubated for another 24 h at 37° C. At the end of incubation, cell titer blue reagent 
was added to each well according to the manufacturer’s protocol and the cells were 
further incubated for 4 hours at 37° C. The fluorescence of the resofurin (converted from 
resazurin by viable cells) was measured at λex 560 nm and λem 590 nm with an auto cut-
off in a fluorescent ELISA plate reader (Spectra MAX, Molecular Devices, Sunnyvale, CA). 
 
5.4.14 Transfection and GFP silencing assay 
One day before the experiments 60,000 cells/well of MDA-MB-231 cells and 
30,000 cells/well of MDA-MB-231/GFP were plated in two separate 24 well plates for 
uptake and silencing experiments in serum containing media. On the day of transfection, 
liposomes complexed with either Alexa-488 RNA/DNA hybrid duplexes or dicer substrates 
of RNA duplexes (DS RNAs) were added to the cells in serum containing media. The cells 
were then incubated for 4h at 37° C. After 4h, the media was replaced with the fresh 
serum media. Uptake efficiency of RNA/DNA hybrid duplexes and silencing of GFP was 
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quantified using Cell Quest software after 1 day and 3 days of transfections respectively 
by fluorescence-activated cell sorting (FACS).  
Approximately 72 hours after the transfection, MDA-MB-231/GFP were imaged 
with a Nikon 200 TE inverted microscope (Melville, NJ) using Meta Morph software 
(Universal Imaging Co., Downingtown, PA) to determine the silencing efficiency of GFP by 
liposome/ DS RNAs complexes. PanFluor 20X, ELWD, NA=0.45 objective and a Nikon B-
2E/C, 465–495/505/515–555 cube (Chroma Technology Corp., Rockingham, VT) were 





1. Kolb, H. C.; Sharpless, K. B. The growing impact of click chemistry on drug discovery. 
Drug Discovery Today 2003, 8 (24), 1128-1137. 
2. Kalia, J.; Raines, R. Hydrolytic stability of hydrazones and oximes. Angewandte Chemie 
(International ed. in English) 2008, 47 (39), 7523-7526. 
3. Ciula, J. C.; Streitwieser, A. Carbon acidity. 79. Acidity of enolate equivalent compounds: 
oxime ethers. J. Org. Chem. 1991, 56, 1989-93. 
4. Selvi, R. S.; Nanthini, R.; Sukanyaa, G. The Basic Principle of Phase-Transfer Catalysis, 
Some Mechanistic Aspects and Important Applications. International Journal of Scientific and 
Technology Research 2012, 1 (3), 61-63. 
5. Tros de Ilarduya, C.; Sun, Y.; Düzgüneş, N. Gene delivery by lipoplexes and polyplexes. 
European journal of pharmaceutical sciences : official journal of the European Federation for 
Pharmaceutical Sciences 2010, 40 (3), 159-170. 
6. Zajdel, A.; Wilczok, A.; Slowinski, J.; Orchel, J.; Mazurek, U. Aldehydic lipid peroxidation 
products in human brain astrocytomas. J Neurooncol 2007, 84, 167-173. 
7. Noda, Y.; Berlett, B.; Stadtman, E.; Aponte, A.; Morgan, M.; Shen, R.-F. Identification of 
enzymes and regulatory proteins in Escherichia coli that are oxidized under nitrogen, carbon, or 
phosphate starvation. Proceedings of the National Academy of Sciences of the United States of 
America 2007, 104 (47), 18456-18460. 
8. Negre-Salvayre, A.; Auge, N.; Ayala, V.; Basaga, H.; Boada, J.; Brenke, R.; Chapple, S.; 
Cohen, G.; Feher, J.; Grune, T.; Lengyel, G.; Mann, G.; Pamplona, R.; Poli, G.; Portero-Otin, M.; 
Riahi, Y.; Salvayre, R.; Sasson, S.; Serrano, J.; Shamni, O.; Siems, W.; Siow, R.; Wiswedel, I.; 
Zarkovic, K.; Zarkovic, N. Pathological aspects of lipid peroxidation. Free Radical Research 2010, 
44 (10), 1125-1171. 
9. Griffiths, W.; Koal, T.; Wang, Y.; Kohl, M.; Enot, D.; Deigner, H.-P. Targeted 
metabolomics for biomarker discovery. Angewandte Chemie (International ed. in English) 2010, 
49 (32), 5426-5445. 
10. Wikoff, W.; Anfora, A.; Liu, J.; Schultz, P.; Lesley, S.; Peters, E.; Siuzdak, G. Metabolomics 
analysis reveals large effects of gut microflora on mammalian blood metabolites. Proceedings of 
the National Academy of Sciences of the United States of America 2009, 106 (10), 3698-3703. 
11. Lane, A.; Fan, T.; Xie, Z.; Moseley, H.; Higashi, R. Isotopomer analysis of lipid biosynthesis 
by high resolution mass spectrometry and NMR. Analytica Chimica Acta 2009, 651 (2), 201-208. 
12. Eggink, M.; Wijtmans, M.; Kretschmer, A.; Kool, J.; Lingeman, H.; Esch, I. J. P. d.; Niessen, 
W. M. A.; Irth, H. Targeted LC–MS derivatization for aldehydes and carboxylic acids with a new 
derivatization agent 4-APEBA. Anal Bioanal Chem 2010, 397, 665-675. 
13. Jacobo, I.; José Manuel, G.; Isabel, M. Determination of carbonyl compounds in fish 
species samples with solid-phase microextraction with on-fibre derivatization. Food Chemistry 
2010, 123. 
14. Maboudou, P.; Mathieu, D.; Bachelet, H.; Wiart, J. F.; Lhermitte, M. Detection of 
oxidative stress. Interest of GC-MS for malondialdehyde and formaldehyde monitoring. 
Biomedical Chromatography 2002, 16, 199-202. 
15. Sugaya, N.; Sakurai, K.; Nakagawa, T.; Onda, N.; Onodera, S.; Morita, M.; Tezuka, M. 
Development of a headspace GC/MS analysis for carbonyl compounds (aldehydes and ketones) 
in household products after derivatization with o-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine. 
Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 2004, 
20 (5), 865-870. 
176 
 
16. Barry, S. J.; Carr, R. M.; Lane, S. J.; Leavens, W. J.; Manning, C. O.; Monte, S.; 
Waterhouse, I. Use of S-pentafluorophenyl tris(2,4,6-trimethoxyphenyl) phosphonium acetate 
bromide and (4-hydrazino-4-oxobutyl) tris(2,4,6-trimethoxyphenyl)phosphonium bromide for 
the derivatization of alcohols, aldehydes and ketones for detection by liquid 
chromatography/electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 2003, 17 (5), 
484-497. 
17. Wheeler, O. H. The Girard Reagents. Journal of Chemical Education 1968, 45 (6), 435-
437. 
18. Griffiths, W.; Hornshaw, M.; Woffendin, G.; Baker, S.; Lockhart, A.; Heidelberger, S.; 
Gustafsson, M.; Sjövall, J.; Wang, Y. Discovering oxysterols in plasma: a window on the 
metabolome. Journal of Proteome Research 2008, 7 (8), 3602-3612. 
19. Hong, H.; Wang, Y. Derivatization with Girard reagent T combined with LC-MS/MS for 
the sensitive detection of 5-formyl-2'-deoxyuridine in cellular DNA. Analytical Chemistry 2007, 
79 (1), 322-326. 
20. Johnson, D. A modified Girard derivatizing reagent for universal profiling and trace 
analysis of aldehydes and ketones by electrospray ionization tandem mass spectrometry. Rapid 
communications in mass spectrometry : RCM 2007, 21 (18), 2926-2932. 
21. Iglesias, J.; Gallardo, J. M.; Medina, I. Determination of carbonyl compounds in fish 
species samples with solid-phase microextraction with on-fibre derivatization. Food Chemistry 
2010, 123, 771-778. 
22. Sugaya, N.; Sakurai, K.; Nakagawa, T.; Onda, N.; Onodera, S.; Morita, M.; Tezuka, M. 
Development of a Headspace GC/MS Analysis for Carbonyl Compounds (Aldehydes and Ketones) 
in Household Products after Derivatization with o-(2,3,4,5,6-Pentafluorobenzyl)-hydroxylamine. 
Analytical Sciences 2004, 20, 865-870. 
23. Fang, K.; Pan, X.; Huang, B.; Liu, J.; Wang, Y.; Gao, J. Simultaneous Derivatization of 
Hydroxyl and Ketone Groups for the Analysis of Steroid Hormones by GC–MS. Chromatographia 
2010, 72, 949-956. 
24. Eggink, M.; Wijtmans, M.; Kretschmer, A.; Kool, J.; Lingeman, H.; de Esch, I.; Niessen, W.; 
Irth, H. Targeted LC-MS derivatization for aldehydes and carboxylic acids with a new 
derivatization agent 4-APEBA. Analytical and bioanalytical chemistry 2010, 397 (2), 665-675. 
25. Hong, H.; Wang, Y. Derivatization with Girard Reagent T Combined with LC-MS/MS for 
the Sensitive Detection of 5-Formyl-2'-deoxyuridine in Cellular DNA. Anal. Chem. 2007, 79, 322-
326. 
26. Ross, M. M.; Kidwell, D. A.; Colton, R. J. Selective detection of aldehydes and ketones by 
derivatization/secondary ion mass spectrometry International Journal of Mass Spectrometry and 
Ion Processes 1985, 63, 141-148. 
27. Barry, S. J.; Carr, R. M.; Lane, S. J.; Leavens, W. J.; Manning, C. O.; Monté, S.; 
Waterhouse, I. Use of S-pentafluorophenyl tris(2,4,6-trimethoxyphenyl)phosphonium acetate 
bromide and (4-hydrazino-4-oxobutyl) [tris(2,4,6-trimethoxyphenyl)phosphonium bromide for 
the derivatization of alcohols, aldehydes and ketones for detection by liquid 
chromatography/electrospray mass spectrometry. Rapid Communications in Mass Spectrometry 
2003, 17, 484-497. 
28. Griffiths, W. J.; Hornshaw, M.; Woffendin, G.; Baker, S. F.; Lockhart, A.; Heidelberger, S.; 
Gustafsson, M.; Sjövall, J.; Wang, Y. Discovering Oxysterols in Plasma: A Window on the 
Metabolome. Journal of Proteome Research 2008, 7, 3602-3612. 
29. Johnson, D. W. A modified Girard derivatizing reagent for universal profiling and trace 
analysis of aldehydes and ketones by electrospray ionization tandem mass spectrometry. Rapid 
Communications in Mass Spectrometry 2007, 21, 2926-2932. 
177 
 
30. Yuan, W.; Edwards, J. L.; Li, S. Global profiling of carbonyl metabolites with a photo-
cleavable isobaric labeling affinity tag. Chem. Commun. (Cambridge, U. K.) 2013, 49 (94), 11080-
11082. 
31. Bulte, J. W. M.; Kraitchman, D. L. Iron oxide MR contrast agents for molecular and 
cellular imaging. NMR in Biomedicine 2004, 17, 484-499. 
32. Ma, H.-L.; Qi, X.-R.; Ding, W.-X.; Maitani, Y.; Nagai, T. Magnetic targeting after femoral 
artery administration and biocompatibility assessment of superparamagnetic iron oxide 
nanoparticles. Journal of biomedical materials research. Part A 2008, 84 (3), 598-606. 
33. Thiesen, B.; Jordan, A. Clinical applications of magnetic nanoparticles for hyperthermia. 
International journal of hyperthermia : the official journal of European Society for Hyperthermic 
Oncology, North American Hyperthermia Group 2008, 24 (6), 467-474. 
34. Bothun, G.; Lelis, A.; Chen, Y.; Scully, K.; Anderson, L.; Stoner, M. Multicomponent 
folate-targeted magnetoliposomes: design, characterization, and cellular uptake. Nanomedicine: 
nanotechnology, biology, and medicine 2011, 7 (6), 797-805. 
35. Reddy, L. H.; Arias, J. L.; Nicolas, J.; Couvreur, P. Magnetic Nanoparticles: Design and 
Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications. 
Chem. Rev. (Washington, DC, U. S.) 2012, 112 (11), 5818-5878. 
36. Massart, R. Preparation of aqueous magnetic liquids in alkaline and acidic media. IEEE 
Trans. Magn. 1981, MAG-17, 1247-8. 
37. Lu, A.-H.; Salabas, E.; Schüth, F. Magnetic nanoparticles: synthesis, protection, 
functionalization, and application. Angewandte Chemie (International ed. in English) 2007, 46 
(8), 1222-1244. 
38. Laurent, S.; Forge, D.; Port, M.; Roch, A.; Robic, C.; Vander Elst, L.; Muller, R. N. Magnetic 
Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical 
Characterizations, and Biological Applications. Chem. Rev. (Washington, DC, U. S.) 2008, 108 (6), 
2064-2110. 
39. Sun, C.; Lee, J.; Zhang, M. Magnetic nanoparticles in MR imaging and drug delivery. 
Advanced drug delivery reviews 2008, 60 (11), 1252-1265. 
40. Hasany, S. F.; Ahmed, I.; Rajan, J.; Rehman, A. Systematic review of the preparation 
techniques of iron oxide magnetic nanoparticles. Nanosci. Nanotechnol. (Rosemead, CA, U. S.) 
2012, 2 (6), 148-158, 11 pp. 
41. Yang, C.; Wu, J.; Hou, Y. Fe3O4 nanostructures: synthesis, growth mechanism, 
properties and applications. Chem. Commun. (Cambridge, U. K.) 2011, 47, 5130-5141. 
42. Salabas, E.-L. Structural and magnetic investigations of magnetic nanoparticles and core-
shell colloids. 2005. 
43. Yuen, A.; Hutton, G.; Masters, A.; Maschmeyer, T. The interplay of catechol ligands with 
nanoparticulate iron oxides. Dalton transactions (Cambridge, England : 2003) 2012, 41 (9), 2545-
2559. 
44. Lin, M. M.; Kim, H.-H.; Kim, H.; Muhammed, M.; Kim, D. K. Iron oxide-based 
nanomagnets in nanomedicine: fabrication and applications. Nano Rev. 2010, 1, No pp. given. 
45. Mojica Pisciotti, M. L.; Lima, E., Jr.; Vasquez Mansilla, M.; Tognoli, V. E.; Troiani, H. E.; 
Pasa, A. A.; Creczynski-Pasa, T. B.; Silva, A. H.; Gurman, P.; Colombo, L.; Goya, G. F.; Lamagna, A.; 
Zysler, R. D. In vitro and in vivo experiments with iron oxide nanoparticles functionalized with 
DEXTRAN or polyethylene glycol for medical applications: Magnetic targeting. J. Biomed. Mater. 
Res., Part B 2014, 102B (4), 860-868. 
46. Yang, Y.; Jiang, J.-S.; Du, B.; Gan, Z.-F.; Qian, M.; Zhang, P. Preparation and properties of 
a novel drug delivery system with both magnetic and biomolecular targeting. J. Mater. Sci.: 
Mater. Med. 2009, 20 (1), 301-307. 
178 
 
47. Ma, H.-L.; Qi, X.-R.; Ding, W.-X.; Maitani, Y.; Nagai, T. Magnetic targeting after femoral 
artery administration and biocompatibility assessment of superparamagnetic iron oxide 
nanoparticles. Journal of Biomedical Materials Research Part A 2007, 598-606. 
48. Weissleder, R.; Stark, D. D.; Engelstad, B. L.; Bacon, B. R.; Compton, C. C.; White, D. L.; 
Jacobs, P.; Lewis, J. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J 
Roentgenol 1989, 152 (1), 167-73. 
49. Li, C. H.; Hodgins, P.; Peterson, G. P. Experimental study of fundamental mechanisms in 
inductive heating of ferromagnetic nanoparticles suspension (Fe3O4 Iron Oxide Ferrofluid) 
Journal of Applied Physics 2011, 110 (05). 
50. Torres-Lugo, M.; Rinaldi, C. Thermal potentiation of chemotherapy by magnetic 
nanoparticles. Nanomedicine (London, U. K.) 2013, 8, 1689-1707. 
51. Riedinger, A.; Guardia, P.; Curcio, A.; Garcia, M. A.; Cingolani, R.; Manna, L.; Pellegrino, 
T. Subnanometer local temperature probing and remotely controlled drug release based on azo-
functionalized iron oxide nanoparticles. Nano Lett. 2013, 13, 2399-2406. 
52. Müller, S. Magnetic fluid hyperthermia therapy for malignant brain tumors--an ethical 
discussion. Nanomedicine : nanotechnology, biology, and medicine 2009, 5 (4), 387-393. 
53. Johannsen, M.; Thiesen, B.; Wust, P.; Jordan, A. Magnetic nanoparticle hyperthermia for 
prostate cancer. International journal of hyperthermia : the official journal of European Society 
for Hyperthermic Oncology, North American Hyperthermia Group 2010, 26 (8), 790-795. 
54. Shultz, M.; Reveles, J.; Khanna, S.; Carpenter, E. Reactive nature of dopamine as a 
surface functionalization agent in iron oxide nanoparticles. Journal of the American Chemical 
Society 2007, 129 (9), 2482-2487. 
55. Jain, T.; Morales, M.; Sahoo, S.; Leslie-Pelecky, D.; Labhasetwar, V. Iron oxide 
nanoparticles for sustained delivery of anticancer agents. Molecular pharmaceutics 2005, 2 (3), 
194-205. 
56. Jing, J.; Zhang, Y.; Liang, J.; Zhang, Q.; Bryant, E.; Avendano, C.; Colvin, V. L.; Wang, Y.; Li, 
W.; Yu, W. W. One-step reverse precipitation synthesis of water-dispersible superparamagnetic 
magnetite nanoparticles. J. Nanopart. Res. 2012, 14 (4), 827/1-827/8. 
57. Chen, S. Polymer-coated iron oxide nanoparticles for medical imaging. 2010. 
58. Petri-Fink, A.; Steitz, B.; Finka, A.; Salaklang, J.; Hofmann, H. Effect of cell media on 
polymer coated superparamagnetic iron oxide nanoparticles (SPIONs): colloidal stability, 
cytotoxicity, and cellular uptake studies. European journal of pharmaceutics and 
biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische 
Verfahrenstechnik e.V 2008, 68 (1), 129-137. 
59. Jung, C. W. Surface properties of superparamagnet iron oxide MR contrast agents: 
Ferumoxides, Ferumoxtran, Ferumoxsil. Magnetic Resonance Imaging 1995, 13 (5), 675-691. 
60. Hidenori, O.; Yukio, N.; Kazunori, K. PEGylated nanoparticles for biological and 
pharmaceutical applications. Advanced Drug Delivery Reviews 2003, 55. 
61. Sun, Q.; Reddy, B. V.; Marquez, M.; Jena, P.; Gonzalez, C.; Wang, Q. Theoretical Study on 
Gold-Coated Iron Oxide Nanostructure: Magnetism and Bioselectivity for Amino Acids. Journal of 
Physical Chemistry C 2007, 111. 
62. Pope-Harman, A.; Cheng, M. M.-C.; Robertson, F.; Sakamoto, J.; Ferrari, M. Biomedical 
nanotechnology for cancer. Med. Clin. North Am. 2007, 91 (5), 899-927. 
63. Rahman, A. M.; Yusuf, S. W.; Ewer, M. S. Anthracycline-induced cardiotoxicity and the 




64. Gewirtz, D. A critical evaluation of the mechanisms of action proposed for the antitumor 
effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical pharmacology 
1999, 57 (7), 727-741. 
65. Fornari, F. A.; Randolph, J. K.; Yalowich, J. C.; Ritke, M. K.; Gewirtz, D. A. Interference by 
Doxorubicin with DNA Unwinding in MCF-7 Breast Tumor Cells. Molecular Pharmacology 1994, 
45, 649-656. 
66. Pastorino, F.; Marimpietri, D.; Brignole, C.; Paolo, D. D.; Pagnan, G.; Daga, A.; Piccardi, F.; 
Cilli, M.; Allen, T. M.; Ponzoni, M. Ligand-Targeted Liposomal Therapies of Neuroblastoma. 
Current Medicinal Chemistry 2007, 14, 3070-3078. 
67. Tian Hu, S.; Brändle, E.; Zbinden, G. Inhibition of Cardiotoxic, Nephrotoxic and 
Neurotoxic Effects of Doxorubicin by ICRF-159. Pharmacology 1983, 26 (4), 210-220. 
68. Carvalho, F. S.; Burgeiro, A.; Garcia, R.; Moreno, A. J.; Carvalho, R. A.; Oliveira, P. J. 
Doxorubicin-Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to 
Cardiomyopathy. Medicinal Research Reviews 2014, 34 (1), 106-135. 
69. Hua, M.-Y.; Yang, H.-W.; Liu, H.-L.; Tsai, R.-Y.; Pang, S.-T.; Chuang, K.-L.; Chang, Y.-S.; 
Hwang, T.-L.; Chang, Y.-H.; Chuang, H.-C.; Chuang, C.-K. Superhigh-magnetization nanocarrier as 
a doxorubicin delivery platform for magnetic targeting therapy. Biomaterials 2011, 32 (34), 
8999-9010. 
70. Li, S.-Z.; Ma, Y.; Yue, X.-L.; Cao, Z.; Dai, Z.-F. One-pot construction of doxorubicin 
conjugated magnetic silica nanoparticles. New J. Chem. 2009, 33 (12), 2414-2418. 
71. Tannock, I. F.; Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation. 
Cancer Res 1989, 49 (16), 4373-84. 
72. Chang, Y.-L.; Meng, X.-L.; Zhao, Y.-L.; Li, K.; Zhao, B.; Zhu, M.; Li, Y.-P.; Chen, X.-S.; Wang, 
J.-Y. Novel water-soluble and pH-responsive anticancer drug nanocarriers: Doxorubicin-PAMAM 
dendrimer conjugates attached to superparamagnetic iron oxide nanoparticles (IONPs). J. 
Colloid Interface Sci. 2011, 363 (1), 403-409. 
73. Patra, H. K.; Ul Khaliq, N.; Romu, T.; Wiechec, E.; Borga, M.; Turner, A. P. F.; Tiwari, A. 
MRI-Visual Order-Disorder Micellar Nanostructures for Smart Cancer Theranostics. Adv. 
Healthcare Mater. 2014, 3 (4), 526-535. 
74. El-Dakdouki, M. H.; Zhu, D. C.; El-Boubbou, K.; Kamat, M.; Chen, J.; Li, W.; Huang, X. 
Development of Multifunctional Hyaluronan-Coated Nanoparticles for Imaging and Drug 
Delivery to Cancer Cells. Biomacromolecules 2012, 13 (4), 1144-1151. 
75. Gautier, J.; Munnier, E.; Paillard, A.; Herve, K.; Douziech-Eyrolles, L.; Souce, M.; Dubois, 
P.; Chourpa, I. A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for 
magnetic drug targeting. Int. J. Pharm. (Amsterdam, Neth.) 2012, 423 (1), 16-25. 
76. Yolles, S.; Leafe, T. D.; Meyer, F. J. Timed-release depot for anticancer agents. J. Pharm. 
Sci. 1975, 64 (1), 115-16. 
77. Chen, J.; Shi, M.; Liu, P.; Ko, A.; Zhong, W.; Liao, W.; Xing, M. M. Q. Reducible 
polyamidoamine-magnetic iron oxide self-assembled nanoparticles for doxorubicin delivery. 
Biomaterials 2014, 35 (4), 1240-1248. 
78. Lubbe, A. S.; Bergemann, C.; Riess, H.; Schriever, F.; Reichardt, P.; Possinger, K.; 
Matthias, M.; Dorken, B.; Herrmann, F.; Gurtler, R.; Hohenberger, P.; Haas, N.; Sohr, R.; Sander, 
B.; Lemke, A. J.; Ohlendorf, D.; Huhnt, W.; Huhn, D. Clinical experiences with magnetic drug 
targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. 
Cancer Res 1996, 56 (20), 4686-93. 
79. Lee, J. E.; Lee, N.; Kim, H.; Kim, J.; Choi, S. H.; Kim, J. H.; Kim, T.; Song, I. C.; Park, S. P.; 
Moon, W. K.; Hyeon, T. Uniform Mesoporous Dye-Doped Silica Nanoparticles Decorated with 
180 
 
Multiple Magnetite Nanocrystals for Simultaneous Enhanced Magnetic Resonance Imaging, 
Fluorescence Imaging, and Drug Delivery. J. Am. Chem. Soc. 2010, 132 (2), 552-557. 
80. Li, W. M.; Chen, S. Y.; Liu, D. M. In situ doxorubicin-CaP shell formation on amphiphilic 
gelatin-iron oxide core as a multifunctional drug delivery system with improved 
cytocompatibility, pH-responsive drug release and MR imaging. Acta Biomater. 2013, 9 (2), 
5360-5368. 
81. Fan, C.-H.; Ting, C.-Y.; Lin, H.-J.; Wang, C.-H.; Liu, H.-L.; Yen, T.-C.; Yeh, C.-K. SPIO-
conjugated, doxorubicin-loaded microbubbles for concurrent MRI and focused-ultrasound 
enhanced brain-tumor drug delivery. Biomaterials 2013, 34 (14), 3706-3715. 
82. Brulé, S.; Levy, M.; Wilhelm, C.; Letourneur, D.; Gazeau, F.; Ménager, C.; Le Visage, C. 
Doxorubicin release triggered by alginate embedded magnetic nanoheaters: a combined 
therapy. Advanced materials (Deerfield Beach, Fla.) 2011, 23 (6), 787-790. 
83. Peiris, P. M.; Bauer, L.; Toy, R.; Tran, E.; Pansky, J.; Doolittle, E.; Schmidt, E.; Hayden, E.; 
Mayer, A.; Keri, R. A.; Griswold, M. A.; Karathanasis, E. Enhanced Delivery of Chemotherapy to 
Tumors Using a Multicomponent Nanochain with Radio-Frequency-Tunable Drug Release. ACS 
Nano 2012, 6 (5), 4157-4168. 
84. Grochowski, E.; Jurczak, J. A New Synthesis of O-Alkylhydroxylamines. Synthesis 1976,  
(10), 682-684. 
85. Sandler, S. R.; Karo, W. Organic Functional Group Preparations; 2 ed.; Academic Press, 
Inc.: San Diego, California, 1989; Vol. 3. 
86. Li, Z.; Tang, Y.; Liu, Y.; Li, Y. Salting effect in partially miscible systems of n-butanol-water 
and butanone-water. Fluid Phase Equilibria 1995, 103, 143-153. 
87. Yang, W.-C.; Regnier, F.; Jiang, Q.; Adamec, J. In vitro stable isotope labeling for 
discovery of novel metabolites by liquid chromatography-mass spectrometry: Confirmation of 
gamma-tocopherol metabolism in human A549 cell. Journal of chromatography. A 2010, 1217 
(5), 667-675. 
88. Bantscheff, M.; Schirle, M.; Sweetman, G.; Rick, J.; Kuster, B. Quantitative mass 
spectrometry in proteomics: a critical review. Anal. Bioanal. Chem. 2007, 389 (4), 1017-1031. 
89. Psychogios, N.; Hau, D. D.; Peng, J.; Guo, A. C.; Mandal, R.; Bouatra, S.; Sinelnikov, I.; 
Krishnamurthy, R.; Eisner, R.; Gautam, B.; Young, N.; Xia, J.; Knox, C.; Dong, E.; Huang, P.; 
Hollander, Z.; Pedersen, T. L.; Smith, S. R.; Bamforth, F.; Greiner, R.; McManus, B.; Newman, J. 
W.; Goodfriend, T.; Wishart, D. S. The Human Serum Metabolome. PLoS ONE 2011, 6 (2). 
90. Tai, L.-A.; Tsai, P.-J.; Wang, Y.-C.; Wang, Y.-J.; Lo, L.-W.; Yang, C.-S. Thermosensitive 
liposomes entrapping iron oxide nanoparticles for controllable drug release. Nanotechnology 
2009, 20 (13), 135101. 
91. Qiu, D.; An, X. Controllable release from magnetoliposomes by magnetic stimulation and 
thermal stimulation. Colloids Surf., B 2013, 104, 326-329. 
92. Bringas, E.; Koeysueren, O.; Quach, D. V.; Mahmoudi, M.; Aznar, E.; Roehling, J. D.; 
Marcos, M. D.; Martinez-Manez, R.; Stroeve, P. Triggered release in lipid bilayer-capped 
mesoporous silica nanoparticles containing SPION using an alternating magnetic field. Chem. 
Commun. (Cambridge, U. K.) 2012, 48 (45), 5647-5649. 
93. Hsu, M.-H.; Su, Y.-C. Iron-oxide embedded solid lipid nanoparticles for magnetically 
controlled heating and drug delivery. Biomedical microdevices 2008, 10 (6), 785-793. 
94. Choubey, J.; Bajpai, A. K. Investigation on magnetically controlled delivery of 
doxorubicin from superparamagnetic nanocarriers of gelatin crosslinked with genipin. J. Mater. 
Sci.: Mater. Med. 2010, 21, 1573-1586. 
95. Thomas, C. R.; Ferris, D. P.; Lee, J.-H.; Choi, E.; Cho, M. H.; Kim, E. S.; Stoddart, J. F.; Shin, 
J.-S.; Cheon, J.; Zink, J. I. Noninvasive Remote-Controlled Release of Drug Molecules in Vitro 
181 
 
Using Magnetic Actuation of Mechanized Nanoparticles. J. Am. Chem. Soc. 2010, 132, 10623-
10625. 
96. Elmore, W. C. Ferromagnetic Colloid for Studying Magnetic Structures. Physical Review 
1938, 54, 309-310. 
97. Mikhaylova, M.; Kim, D. K.; Bobrysheva, N.; Osmolowsky, M.; Semenov, V.; Tsakalakos, 
T.; Muhammed, M. Superparamagnetism of Magnetite Nanoparticles: Dependence on Surface 
Modification. Langmuir 2004, 20, 2472-2477. 
98. Mikhaylova, M.; Kim, D.; Bobrysheva, N.; Osmolowsky, M.; Semenov, V.; Tsakalakos, T.; 
Muhammed, M. Superparamagnetism of magnetite nanoparticles: dependence on surface 
modification. Langmuir : the ACS journal of surfaces and colloids 2004, 20 (6), 2472-2477. 
99. Biswas, S. Functionalized Nanoparticles for AMF-Induced Gene and Drug Delivery. 
Doctor of Philosophy in Chemistry, University of Louisville2011. 
100. Yu, S.; Chow, G. M. Carboxyl group (-CO2H) functionalized ferrimagnetic iron oxide 
nanoparticles for potential bio-applications. Journal of Materials Chemistry 2004, 14, 2781-2786. 
101. Huang, H.; Christmann, R.; Ulber, R.; Schuenemann, V. Moessbauer spectroscopy of 
protein-passivated iron oxide nanoparticles. Hyperfine Interact. 2012, 205, 121-124. 
102. Haneda, K.; Morrish, A. H. Magnetite to maghemite transformation in ultrafine particles. 
J. Phys. (Paris), Colloq. 1977, 321-3. 
103. Vargas, J. M.; Socolovsky, L. M.; Goya, G. F.; Knobel, M.; Zanchet, D. Structural, 
magnetic, and Mossbauer characterization of size-controlled iron-iron oxide nanoparticles 
obtained by chemical methods. IEEE Trans. Magn. 2003, 39, 2681-2683. 
104. Kiwada, H.; Sato, J.; Yamada, S.; Kato, Y. Feasibility of magnetic liposomes as a targeting 
device for drugs. Chem. Pharm. Bull. 1986, 34 (10), 4253-8. 
105. Amonette, J. E.; Templeton, J. C. Improvements to the quantitative assay of 
nonrefractory minerals for Fe (II) and total Fe using 1,10-phenanthroline. Clays and Clay 
Minerals 1998, 46 (1), 51-62. 
106. Hanzlik, M.; Petersen, N.; Keller, R.; Schmidbauer, E. Electron microscopy and 57Fe 
Mossbauer spectra of 10 nm particles, intermediate in composition between Fe3O4 and γ-
Fe2O3, produced by bacteria. Geophys. Res. Lett. 1996, 23 (5), 479-82. 
107. Latorre, M.; Rinaldi, C. Applications of Magnetic Nanoparticles in Medicine: Magnetic 
Fluid Hyperthermia. Puerto Rico Health Sciences Journal 2009, 28 (3), 227-238. 
108. Zhuravlev, L. T. The surface chemistry of amorphous silica. Zhuravlev model. Colloids 
Surf., A 2000, 173 (1-3), 1-38. 
109. Galeotti, F.; Bertini, F.; Scavia, G.; Bolognesi, A. A controlled approach to iron oxide 
nanoparticles functionalization for magnetic polymer brushes. Journal of Colloid and Interface 
Science 2011, 360, 540-547. 
110. Heyda, J.; Lund, M.; Oncák, M.; Slavícek, P.; Jungwirth, P. Reversal of Hofmeister 
ordering for pairing of NH4(+) vs alkylated ammonium cations with halide anions in water. The 
journal of physical chemistry. B 2010, 114 (33), 10843-10852. 
111. Biswas, S.; Huang, X.; Badger, W. R.; Nantz, M. H. Nucleophilic cationization reagents. 
Tetrahedron Letters 2010, 51 (13), 1727-1729. 
112. Feng, M.; Yang, Y.; He, P.; Fang, Y. Spectroscopic studies of copper(II) and iron(II) 
complexes of adriamycin. Spectrochim. Acta, Part A 2000, 56A (3), 581-587. 
113. Kostoryz, E. L.; Yourtee, D. M. Oxidative mutagenesis of doxorubicin-Fe(III) complex. 
Mutat. Res., Genet. Toxicol. Environ. Mutagen. 2001, 490 (2), 131-139. 
114. Ivkov, R.; DeNardo, S. J.; Daum, W. Application of High Amplitude Alternating Magnetic 




115. Heyda, J.; Lund, M.; Ončák, M.; Slavíček, P.; Jungwirth, P. Reversal of Hofmeister 
Ordering for Pairing of NH4+ vs Alkylated Ammonium Cations with 
Halide Anions in Water. J. Phys. Chem. B 2010, 114, 10843-10852. 
116. Reeve, L. Desulfurization of coke-oven gas at Appleby-Frodingham. J. Inst. Fuel 1958, 31, 
319-24. 
117. Schrodt, J. T.; Yamanis, J.; Ota, K.; Sodesawa, T. Reaction of sulfides in fuel gases with 
the iron oxide in coal ashes. Fixed-bed experiments and simulations. Ind. Eng. Chem. Process 
Des. Dev. 1982, 21 (3), 382-90. 
118. Miura, K.; Mae, K.; Inoue, T.; Yoshimi, T.; Nakagawa, H.; Hashimoto, K. Simultaneous 
removal of carbonyl sulfide and hydrogen sulfide from coke oven gas at low temperature by iron 
oxide. Ind. Eng. Chem. Res. 1992, 31 (1), 415-19. 
119. Lin Wang, F. Z., Jianmin Chen. Carbonyl Sulfide Derived from Catalytic Oxidation of 
Carbon Disulfide over Atmospheric Particles. Environmental Science & Technology 2001, 35, 
2543-2547. 
120. Chen, H.; Kong, L.; Chen, J.; Zhang, R.; Wang, L. Heterogeneous Uptake of Carbonyl 
Sulfide on Hematite and Hematite-NaCl Mixtures. Environ. Sci. Technol. 2007, 41 (18), 6484-
6490. 
121. Kwan, T.; Fujita, Y. Chemisorption of CO2 over oxide catalysts of spinel type. Journal of 
the Research Institute for Catalysis Hokkaido University 1953, 2 (2), 110-116. 
122. Parkinson, G.; Novotný, Z.; Jacobson, P.; Schmid, M.; Diebold, U. Room temperature 
water splitting at the surface of magnetite. Journal of the American Chemical Society 2011, 133 
(32), 12650-12655. 
123. Chang, Y.-S.; Savitha, S.; Sadhasivam, S.; Hsu, C.-K.; Lin, F.-H. Fabrication, 
characterization, and application of greigite nanoparticles for cancer hyperthermia. Journal of 
Colloid and Interface Science 2011, 363 (1), 314-319. 
124. McCarthy, S. A.; Davies, G.-L.; Gun'ko, Y. K. Preparation of multifunctional nanoparticles 
and their assemblies. Nat. Protoc. 2012, 7, 1677-1693. 
125. Li, C.; Ma, C.; Wang, F.; Xi, Z.; Wang, Z.; Deng, Y.; He, N. Preparation and biomedical 
applications of core-shell silica/magnetic nanoparticle composites. J. Nanosci. Nanotechnol. 
2012, 12 (4), 2964-2972. 
126. Malvindi, M. A.; De Matteis, V.; Galeone, A.; Brunetti, V.; Anyfantis, G. C.; Athanassiou, 
A.; Cingolani, R.; Pompa, P. P. Toxicity assessment of silica coated iron oxide nanoparticles and 
biocompatibility improvement by surface engineering. PLoS One 2014, 9 (1), e85835/1-
e85835/11, 11 pp. 
127. Pinho, S. L. C.; Pereira, G. A.; Voisin, P.; Kassem, J.; Bouchaud, V.; Etienne, L.; Peters, J. 
A.; Carlos, L.; Mornet, S.; Geraldes, C. F. G. C.; Rocha, J.; Delville, M.-H. Fine Tuning of the 
Relaxometry of γ-Fe2O3@SiO2 Nanoparticles by Tweaking the Silica Coating Thickness. ACS 
Nano 2010, 4, 5339-5349. 
128. Villanueva, A.; Cañete, M.; Roca, A.; Calero, M.; Veintemillas-Verdaguer, S.; Serna, C.; 
Morales, M.; Miranda, R. The influence of surface functionalization on the enhanced 
internalization of magnetic nanoparticles in cancer cells. Nanotechnology 2009, 20 (11), 115103. 
129. Zhang, Y.; Yang, M.; Portney, N.; Cui, D.; Budak, G.; Ozbay, E.; Ozkan, M.; Ozkan, C. Zeta 
potential: a surface electrical characteristic to probe the interaction of nanoparticles with 
normal and cancer human breast epithelial cells. Biomedical microdevices 2008, 10 (2), 321-328. 




131. Soenen, S.; Hodenius, M.; De Cuyper, M. Magnetoliposomes: versatile innovative 
nanocolloids for use in biotechnology and biomedicine. Nanomedicine (London, England) 2009, 
4 (2), 177-191. 
132. de Cuyper, M.; Soenen, S. J. H. Cationic magnetoliposomes. Methods Mol. Biol. (Totowa, 
NJ, U. S.) 2010, 605 (Liposomes, Volume 1), 97-111. 
133. Soenen, S. J.; De Meyer, S. F.; Dresselaers, T.; Velde, G. V.; Pareyn, I. M.; Braeckmans, K.; 
De Cuyper, M.; Himmelreich, U.; Vanhoorelbeke, K. I. MRI assessment of blood outgrowth 
endothelial cell homing using cationic magnetoliposomes. Biomaterials 2011, 32 (17), 4140-
4150. 
134. Soenen, S. J. H.; Baert, J.; De Cuyper, M. Optimal conditions for labelling of 3T3 
fibroblasts with magnetoliposomes without affecting cellular viability. ChemBioChem 2007, 8 
(17), 2067-2077. 
135. Soenen, S. J. H.; Brisson, A. R.; De Cuyper, M. Addressing the problem of cationic lipid-
mediated toxicity: The magnetoliposome model. Biomaterials 2009, 30 (22), 3691-3701. 
136. Soenen, S. J. H.; Brisson, A. R.; Jonckheere, E.; Nuytten, N.; Tan, S.; Himmelreich, U.; De 
Cuyper, M. The labeling of cationic iron oxide nanoparticle-resistant hepatocellular carcinoma 
cells using targeted magnetoliposomes. Biomaterials 2011, 32 (6), 1748-1758. 
137. Soenen, S. J. H.; De Cuyper, M. How to assess cytotoxicity of (iron oxide-based) 
nanoparticles. A technical note using cationic magnetoliposomes. Contrast Media Mol. Imaging 
2011, 6 (3), 153-164. 
138. Soenen, S. J. H.; Illyes, E.; Vercauteren, D.; Braeckmans, K.; Majer, Z.; De Smedt, S. C.; De 
Cuyper, M. The role of nanoparticle concentration-dependent induction of cellular stress in the 
internalization of non-toxic cationic magnetoliposomes. Biomaterials 2009, 30 (36), 6803-6813. 
139. Soenen, S. J. H.; Nuytten, N.; Himmelreich, U.; De Cuyper, M. The Possible Side-Effects 
Of Iron Oxide Nanoparticles On Cell Functionality. AIP Conf. Proc. 2010, 1275 (Bonsai Project 
Symposium, 2010), 106-111. 
140. Soenen, S. J. H.; Vercauteren, D.; Braeckmans, K.; Noppe, W.; De Smedt, S.; De Cuyper, 
M. Stable long-term intracellular labeling with fluorescently tagged cationic magnetoliposomes. 
ChemBioChem 2009, 10 (2), 257-267. 
141. Biswas, S.; Knipp, R. J.; Gordon, L. E.; Nandula, S. R.; Gorr, S.-U.; Clark, G. J.; Nantz, M. H. 
Hydrophobic Oxime Ethers: A Versatile Class of pDNA and siRNA Transfection Lipids. 
ChemMedChem 2011, 6, 2063-2069. 
142. Junquera, E.; Aicart, E. Cationic Lipids as Transfecting Agents of DNA in Gene Therapy. 
Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2014, 14 (5), 649-663. 
143. Pan, X.; Guan, J.; Yoo, J.-W.; Epstein, A. J.; Lee, L. J.; Lee, R. J. Cationic lipid-coated 
magnetic nanoparticles associated with transferrin for gene delivery. Int. J. Pharm. 2008, 358 (1-
2), 263-270. 
144. Jiang, S.; Eltoukhy, A.; Love, K.; Langer, R.; Anderson, D. Lipidoid-coated iron oxide 
nanoparticles for efficient DNA and siRNA delivery. Nano letters 2013, 13 (3), 1059-1064. 
145. Biswas, S.; Gordon, L. E.; Clark, G. J.; Nantz, M. H. Click assembly of magnetic 
nanovectors for gene delivery. Biomaterials 2011, 32, 2683-2688. 
146. Zhi, D.; Zhang, S.; Cui, S.; Zhao, Y.; Wang, Y.; Zhao, D. The Headgroup Evolution of 
Cationic Lipids for Gene Delivery. Bioconjugate Chem. 2013, 24 (4), 487-519. 
147. Hanson, R. M. The synthetic methodology of nonracemic glycidol and related 2,3-epoxy 
alcohols. Chem. Rev. 1991, 91 (4), 437-76. 
148. Azizi, N.; Saidi, M. Highly chemoselective addition of amines to epoxides in water. 
Organic letters 2005, 7 (17), 3649-3651. 
184 
 
149. Heydari, A. Organic synthesis in an unconventional solvent, 5.0 M lithium 
perchlorate/diethyl ether. Tetrahedron 2002. 
150. Kuwabe, S.; Torraca, K.; Buchwald, S. Palladium-catalyzed intramolecular C-O bond 
formation. Journal of the American Chemical Society 2001, 123 (49), 12202-12206. 
151. Effenberger, K.; Breyer, S.; Ocker, M.; Schobert, R. New doxorubicin N-acyl hydrazones 
with improved efficacy and cell line specificity show modes of action different from the parent 
drug. Int J Clin Pharmacol Ther 2010, 48 (7), 485-6. 
152. Effenberger, K.; Breyer, S.; Schobert, R. Modulation of doxorubicin activity in cancer cells 
by conjugation with fatty acyl and terpenyl hydrazones. European journal of medicinal chemistry 
2010, 45 (5), 1947-1954. 
153. Frézard, F.; Garnier-Suillerot, A. Permeability of lipid bilayer to anthracycline derivatives. 
Role of the bilayer composition and of the temperature. Biochimica et Biophysica Acta (BBA)-
Lipids … 1998. 
154. Krüger, M.; Beyer, U.; Schumacher, P.; Unger, C.; Zahn, H.; Kratz, F. Synthesis and 
stability of four maleimide derivatives of the anticancer drug doxorubicin for the preparation of 
chemoimmunoconjugates. Chem. Pharm. Bull. 1997, 45, 399-401. 
155. Graeser, R.; Esser, N.; Unger, H.; Fichtner, I.; Zhu, A.; Unger, C.; Kratz, F. INNO-206, the 
(6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy 
compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas 
carcinoma model. Investigational new drugs 2010, 28 (1), 14-19. 
156. Dirksen, A.; Dawson, P. Rapid oxime and hydrazone ligations with aromatic aldehydes 
for biomolecular labeling. Bioconjugate chemistry 2008, 19 (12), 2543-2548. 
157. Petralito, S.; Spera, R.; Memoli, A.; D'Inzeo, G.; Liberti, M.; Apollonio, F. Preparation and 
characterization of lipid vesicles entrapping iron oxide nanoparticles. Asia-Pac. J. Chem. Eng. 
2012, 7 (S3), S335-S341. 
158. Laouini, A.; Jaafar-Maalej, C.; Limayem-Blouza, I.; Sfar, S.; Charcosset, C.; Fessi, H. 
Preparation, Characterization and Applications of Liposomes: State of the Art. Journal of Colloid 
Science and Biotechnology 2012, 1, 147-168. 
159. Niculescu-Duvaz, D.; Heyes, J.; Springer, C. J. Structure-activity relationship in cationic 
lipid mediated gene transfection. Curr. Med. Chem. 2003, 10 (14), 1233-1261. 
160. Nantz, M. H.; Li, L.; Zhu, J.; Aho-Sharon, K. L.; Lim, D.; Erickson, K. L. Inductive Electron-
Withdrawal From Ammonium Ion Headgroups of Cationic Lipids and the Influence on DNA 
Transfection. Biochimica et Biophysica Acta 1998, 1394, 219-223. 
161. Le Corre, S. S.; Berchel, M.; Le Gall, T.; Haelters, J.-P.; Lehn, P.; Montier, T.; Jaffres, P.-A. 
Cationic Trialkylphosphates: Synthesis and Transfection Efficacies Compared to 
Phosphoramidate Analogues. Eur. J. Org. Chem. 2014, Ahead of Print. 
162. Nantz, M. H.; Dicus, C. W.; Hilliard, B.; Yellayi, S.; Zou, S.; Hecker, J. G. The benefit of 
hydrophobic domain asymmetry on the efficacy of transfection as measured by in vivo imaging. 
Mol. Pharmaceutics 2010, 7 (3), 786-794. 
163. Heyes, J. A.; Niculescu-Duvaz, D.; Cooper, R. G.; Springer, C. J. Synthesis of Novel 
Cationic Lipids: Effect of Structural Modification on the Efficiency of Gene Transfer. J. Med. 
Chem. 2002, 45 (1), 99-114. 
164. Santel, A.; Aleku, M.; Keil, O.; Endruschat, J.; Esche, V.; Fisch, G.; Dames, S.; Loeffler, K.; 
Fechtner, M.; Arnold, W.; Giese, K.; Klippel, A.; Kaufmann, J. A novel siRNA-lipoplex technology 
for RNA interference in the mouse vascular endothelium. Gene Ther. 2006, 13 (16), 1222-1234. 
165. Bennett, M. J.; Aberle, A. M.; Balasubramaniam, R. P.; Malone, J. G.; Malone, R. W.; 
Nantz, M. H. Cationic lipid-mediated gene delivery to murine lung: correlation of lipid hydration 
with in vivo transfection activity. J. Med. Chem. 1997, 40 (25), 4069-4078. 
185 
 
166. Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. NMR Chemical Shifts of Common Laboratory 
Solvents as Trace Impurities. J. Org. Chem. 1997, 62, 7512-7515. 
167. Buruiana, E. C.; Buruiana, T.; Melinte, V.; Negulescu, I. Synthesis, Structure and 
Mesogenic Properties of Some Alkylammonium Derivatives. Revue Roumaine de Chimie 2005, 50 
(6), 465-470. 
168. Tsubone, K.; Uchida, N.; Niwase, H.; Honda, K. Syntheses of Sodium 2-(N-alkyI-N-
methylamino)ethanephosphates and Their Physicochemical Properties. Journal of the American 
Oil Chemists' Society 1989, 66 (6), 829-833. 
169. Fan, T. W.-M.; Lane, A. N.; Higashi, R. M.; Yan, J. Stable isotope resolved metabolomics 
of lung cancer in a SCID mouse model. Metabolomics 2010. 
170. Kim, B.; Moon, S.; Hwang, B. Structure elucidation and antifungal activity of an 
anthracycline antibiotic, daunomycin, isolated from Actinomadura roseola. Journal of 
Agricultural and Food Chemistry 2000, 48 (5), 1875-1881. 
171. Sommer, H.; Lipp, H.; Jackson, L. Alkylation of amines. General exhaustive alkylation 
method for the synthesis of quaternary ammonium compounds. The Journal of Organic … 1971. 
172. Mancuso, A. J.; Huang, S.-L.; Swern, D. Oxidation of long-chain and related alcohols to 
carbonyls by dimethyl sulfoxide "activated" by oxalyl chloride. J. Org. Chem. 1978, 43, 2480-2. 
173. Kuwabe, S.-i.; Torraca, K. E.; Buchwald, S. L. Palladium-Catalyzed Intramolecular C-O 





A.1. NMR spectra 
A.2. Zeta potential measurements 
A.3. Excitation-emission spectra 
A.4. Dynamic light scattering measurements 
A.5. Fluorescence and bright-field microscope images 
A.6. Copyright permissions 
187 
 






































































































































































































































































































































A.2. ZETA-POTENTIAL MEASUREMENTS 





















Zeta potential of CS2-modified NPs 
 






A.3. EXCITATION-EMISSION SPECTRA 
 
Excitation-emission spectra for FITC derivatives 
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A.4. DYNAMIC LIGHT SCATTERING MEASUREMENTS 
  
3D stack plots of DLS 
measurements over 24 mixing time 
with lipid 1 (A), 2 (B), and 3 (C). 
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A.5. FLUORESCENCE AND BRIGHT-FIELD  
MICROSCOPE IMAGES 
Fluorescence (green filter) and bright-field microscope images were acquired after 
2h treatment with CML/SNP formulations on an EVOS FL Cell Imaging System at 





Fluorescence images of MCF-7 cells after 2h treatment with SNP 




Bright-field images of MCF-7 cells after 2h treatment with SNP 
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A.7. LIST OF ABBREVIATIONS 
ATR attenuated total reflectance 
CML cationic magnetoliposome 
DLS dynamic light scattering 
DMEM Dulbecco's modified eagle medium 
DOPE 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine 
Dox∙HCl Doxorubicin hydrochloride 
Dox-AH Doxorubicin acyl hydrazone 
DRIFT diffuse reflectance infrared Fourier transform 
EA elemental analysis  
EES excitation-emission spectrum 
FITC fluorescein isothiocyanate 
FT-ICR-MS Fourier-transform ion-cyclotron resonance mass spectrometry 
MS mass spectrometry 
NP iron oxide nanoparticle 
PBS phosphate buffered saline 
QAO quaternary aminooxy 




QOA quaternary octyl aminooxy 
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